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Cardiac fibroblasts are fundamental regulators of multiple aspects of cardiac 
function under both physiological and pathophysiological conditions. These cells 
contribute to cardiac inflammation, angiogenesis, fibrosis and cardiomyocyte 
hypertrophy and are therefore a potential therapeutic target for ameliorating 
adverse cardiac remodelling. Cardiac fibroblasts become activated upon 
mechanical stimulation; mechanically-activated ion channels have been 
implicated as sensors of mechanical stress in these cells. The mechanosensitive 
non-selective cation channel, Piezo1, has widespread physiological importance 
and although Piezo1 mRNA expression has been detected in the murine heart, 
its role in the myocardium is poorly understood. The hypothesis is that Piezo1 is 
important for detecting mechanical stress in cardiac fibroblasts in order to affect 
cell function and phenotype. 
 
Methods and Results 
RT-PCR analysis indicated that Piezo1 mRNA is expressed in cardiac fibroblasts 
at similar levels to endothelial cells and Fura-2 intracellular Ca2+ measurements 
using the Piezo1 agonist, Yoda1, validated Piezo1 as a functional ion channel in 
these cells. Yoda1-induced Ca2+ entry can be inhibited by non-specific Piezo1 
blockers (gadolinium, ruthenium red) and affected proportionally by alterations in 
Piezo1 activity or mRNA expression. In addition to using chemical stimulation, 
Piezo1 could be activated using mechanical force generated by cell-attached 
patch clamp electrophysiology. Investigation into the effect of Yoda1 on selected 
cardiac remodelling genes indicated that Piezo1 activation induces the  
expression of tenascin C (TNC), a mechanosensitive glycoprotein, and 
interleukin-6 (IL-6), a pro-hypertrophic and pro-fibrotic cytokine, which are both 
known to be upregulated following cardiac injury. Piezo1 was demonstrated to 
have a role in regulating basal IL-6 levels; this appeared to be dependent on 
substrate stiffness and/or composition. Multiplex kinase activity profiling, 
combined with kinase inhibitor studies and phospho-specific western blotting, 
established that Ca2+ entry instigated by Piezo1 activation by Yoda1 stimulates 
concentration-dependent phosphorylation of both p38α MAPK and ERK. It was 
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revealed that it was p38α MAPK which mediated Yoda1-induced IL-6 expression 
and secretion. Src-family kinases were subsequently discovered to be the link 
between Piezo1 activation and p38 MAPK phosphorylation; three members of the 
kinase family were found to be expressed in cardiac fibroblasts. Preliminary data 
gathered using a myofibroblast-specific Piezo1 KO murine model implied that 
Piezo1 may promote cardiac remodelling following pressure overload and that its 
deletion may be advantageous in cardiac dysfunction. 
 
Conclusion 
In summary, this study reveals that cardiac fibroblasts express functional Piezo1 
channels and that utilisation of Yoda1 to stimulate the opening of these channels 
is coupled to increased secretion of IL-6. This occurs via activation of Src-family 
kinases and p38 MAP kinase. Improved understanding of Piezo1 channels in 
cardiac fibroblasts may be necessary for achieving a greater appreciation of how 
cardiac fibroblasts sense mechanical stimuli in pathological conditions such as 
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Chapter 1 Introduction 
1.1 Cardiovascular disease 
According to the World Health Organisation, cardiovascular disease (CVD) is the 
leading cause of death worldwide, claiming the lives of 17.9 million people each 
year. The British Heart Foundation affirm that CVD is the cause of a quarter of 
deaths in the UK, with a total annual healthcare cost of a staggering £9 billion. 
Hypertension, hypercholesterolemia, cigarette smoking, inactivity, aging, 
genetics and diabetes all increase the likelihood of developing these diseases. 
CVD are a class of diseases which affect the heart, blood vessels and the 
vasculature of the brain. Some examples are: atherosclerosis, ischaemic heart 
disease, cerebrovascular disease, ischaemic stroke, haemorrhagic stroke, 
hypertensive heart disease, cardiomyopathy and myocarditis, atrial fibrillation, 
aortic aneurysm, peripheral vascular disease and endocarditis (Roth et al. 2017). 
This thesis will discuss some of the more common diseases associated with the 
myocardium. 
 
1.1.1 Myocardial infarction 
Coronary artery disease is the narrowing or blockage of the coronary arteries, 
usually caused by atherosclerosis, a thickening of the intimal and medial layers 
of arteries due to deposition of atheromatous plaques (Lahoz and Mostaza 2007). 
This restricts blood flow, which can result in inadequate supply of blood to the 
myocardium (“ischaemia”) and a myocardial infarction (MI). Following MI, there 
is a multifaceted approach to repair the myocardium (Prabhu and Frangogiannis 
2016). Ischaemia initiates the necrosis of cardiomyocytes and this rapidly triggers 
an intense inflammation response, involving the upregulation of proinflammatory 
cytokines and chemokines by cardiac and inflammatory cells, together with 
neutrophil and macrophage infiltration to clear necrotic cells and matrix debris 
(Bujak and Frangogiannis 2007; Turner 2016). Within a few days, inflammation 
is suppressed as inflammatory cells undergo apoptotic death and there is 
formation of granulation tissue comprising of newly synthesised extracellular 
matrix (ECM) and blood vessels and activated cardiac fibroblasts (Jourdan-
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LeSaux, Zhang and Lindsey 2010). The final stage encompasses the healing of 
the myocardium, characterised by the upregulation of profibrotic and anti-
inflammatory factors and scar formation (Chen and Frangogiannis 2013). As the 
infarct matures, “stress-shielding” of activated cardiac fibroblasts by the ECM 
prompts quiescence and normally triggers their apoptotic death (Chen and 
Frangogiannis 2013). However, it has been demonstrated that these cells can 
remain active in the infarct region up to 17 years post-MI (Willems et al. 1994). 
 
1.1.2 Hypertension 
Extensive growth of the left ventricle, termed left ventricular (LV) hypertrophy, is 
induced by factors such as prolonged and abnormal hemodynamic stress; this is 
known as pathological hypertrophy, but this term can also refer to the 
physiological adaptation to increased work load e.g. in athletes or during 
pregnancy (Shimizu and Minamino 2016). It is well established that persistently 
elevated blood pressure (“hypertension”) has been associated with LV 
hypertrophy and that LV hypertrophy is a risk factor for future cardiac events 
(Verdecchia et al. 1990; Vakili, Okin and Devereux 2001). Hypertrophy can be 
categorised into two subgroups: concentric hypertrophy, transpiring due to 
hypertension and subsequent sustained pressure overload, where wall thickness 
increases without chamber enlargement, or eccentric hypertrophy, occurring 
following chronic volume overload in which the volume of the chamber is 
augmented, with no increase in wall thickness (Rossi and Carillo 1991). The 
hypertrophic growth of cardiomyocytes is the leading response by which the heart 
lessens the stress on the LV wall imposed by pressure overload (González et al. 
2018). The hypertrophic growth of myocytes is an attempt to maintain cardiac 
output but the subsequent remodelling consequently lowers ventricle compliance 
and can cause cardiac dysfunction. In addition to during pressure overload, 
myocardial hypertrophy is also part of the remodelling process following MI 
(Kahan and Bergfeldt 2005). 
 
1.1.3 Heart failure  
Adverse cardiac remodelling following MI or pressure overload can lead to heart 
failure (Schirone et al. 2017). Improved medical care following cardiac events 
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such as MI has resulted in increased patient survival and, therefore, the 
frequency of secondary complications such as heart failure has intensified. It is 
approximated that 1-2 % of adults in Western populations have heart failure 
(Mosterd and Hoes 2007), with the most common symptoms being 
breathlessness, fatigue and swollen lower limbs. The economic burden on the 
National Health Service is second only to stroke in the UK (Stewart et al. 2002) 
and the severity of the disease is most commonly assessed using the New York 
Heart Association Class guidelines. The classes range from I (mild), 
characterised as patients without limitation of physical activity to IV (severe),  
described as patients with the inability to carry out any physical activity without 
discomfort; symptoms may even be present at rest in this population. 
Heart failure is a broad term described by the American Heart Association as “a 
complex clinical syndrome that results from any structural or functional 
impairment of ventricular filling or ejection of blood” (Yancy et al. 2013) and can 
occur due to dysfunction during systole and/or diastole. Systolic dysfunction is 
characterised by compromised contraction and ejection of blood, resulting in 
reduced ejection fraction, principally due to increased collagen deposition 
(Murtha et al. 2017). It has been suggested that this increased deposition may 
result in impairment of systolic function through disturbed coordination of 
myocardial excitation-contraction coupling (Janicki and Brower 2002). In contrast, 
in diastolic dysfunction, ejection fraction is preserved; however, there is impaired 
filling of the LV ventricle (Murtha et al. 2017). This is largely due to compromised 
ventricular relaxation or increased myocardial stiffness triggered by excessive 
ECM deposition which reduces the compliance of the ventricles (Federmann and 
Hess 1994). 
 
1.2 Cardiac fibrosis 
Nearly all aetiologies of heart disease, including MI and heart failure, involve 
pathological remodelling characterised by the excessive deposition of ECM 
proteins (“fibrosis”) (Travers et al. 2016). Fibrosis presents as interstitial (reactive) 
or replacement (reparative) fibrosis. Interstitial fibrosis is described as chronic 
expansion of the interstitium in order to maintain organ function (e.g. during 
pressure overload) without the initial loss of cardiomyocytes (Murtha et al. 2017). 
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This is accompanied by adaptive cardiomyocyte hypertrophy, in an attempt to 
preserve cardiac output while normalising wall stress (Biernacka and 
Frangogiannis 2011). Subsequently there may be necrosis and apoptosis of 
cardiomyocytes, possibly due to the augmented ECM surrounding hypertrophied 
cardiomyocytes giving rise to an inadequate supply of nutrients (Biernacka and 
Frangogiannis 2011). In contrast, replacement fibrosis involves necrotic cells 
being replaced with a collagen-rich scar, as occurs following MI (Murtha et al. 
2017). Myocardial deposition of collagen has also been revealed in patients with 
diabetes (Heerebeek et al. 2008; Patil et al. 2011). Patil et al. (2011) 
demonstrated that the incidence of diastolic dysfunction is high in patients with 
type 2 diabetes mellitus, in the absence of coronary artery disease; the level of 
dysfunction correlated with the duration of diabetes and diabetic 
microangiopathies. Excessive diastolic left ventricular stiffness has been reported 
to be an important contributor to heart failure in these patients; this is presumed 
to be due to the deposition of collagen and advanced glycation end products 
(Heerebeek et al. 2008). Using a genetically-induced mouse model of type 2 
diabetes mellitus generated by a point mutation in the leptin receptor, it was 
demonstrated that cardiac fibroblasts derived from diabetic hearts had elevated 
expression of several pro-fibrotic markers, including type I collagen and 
transforming growth factor-β (TGF-β), compared with those from non-diabetic 
hearts (Hutchinson et al. 2013). This pattern of protein expression was associated 
with myocardial stiffness and LV diastolic dysfunction (Hutchinson et al. 2013). 
This correlates with the finding that cardiac fibroblasts from type 2 diabetic 
patients possess a pro-fibrotic phenotype (Sedgwick et al. 2014). 
Progressive cardiac fibrosis in heart failure is principally facilitated by the tissue-
resident cardiac fibroblast, which becomes activated and differentiates into a 
myofibroblast (Khalil et al. 2017), these cells will be discussed in more detail 
below. Initially, fibrosis is an adaptive, protective mechanism required to avoid a 
loss of integrity in the mechanical strength of the ventricle following injury, which 
could lead to rupture due to LV wall thinning (Ma et al. 2014). For example, post-
MI, an appropriate degree of fibrosis in the infarct zone is essential to replace 
necrotic cardiomyocytes (Talman and Ruskoaho 2016). However, over time, 
irreversible, adverse ventricular remodelling can contribute to the contractile 
demise of the organ (Porrello and Olson 2014). Fibrosis results in stiffening of the 
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heart, impairment of electrical conductivity and reduced contraction capacity and 
oxygen diffusion, thus exacerbating deleterious remodelling (Piek, de Boer and 
Silljé 2016). 
 
1.3 Cardiac Remodelling 
1.3.1 Extracellular matrix deposition 
In physiology, the ECM provides structural support, acts as reservoir for cytokines 
and growth factors and enables communication of extracellular cues between 
cells (Valiente-Alandi, Schafer and Blaxall 2016). Following cardiac injury, the 
ECM undergoes remodelling and it is cardiac fibroblasts which are chiefly 
responsible for this regulation of the ECM. Cardiac fibroblasts secrete ECM 
proteins including proteins serving a structural role such as collagens, adhesive 
glycoproteins such as fibronectin and proteases named matrix 
metalloproteinases (MMPs) which degrade the ECM, along with their native 
inhibitors, tissue inhibitors of metalloproteinases (TIMPs) (Valiente-Alandi, 
Schafer and Blaxall 2016). Production of these proteins leads to cardiac 
remodelling (Dobaczewski, Gonzalez-Quesada and Frangogiannis 2010). 
Cardiac fibroblasts are known to secrete MMP-1,-2,-3,-9,-13,-14 and TIMP-1,-2,-
3 and -4 in response to cardiac injury (Vanhoutte et al. 2006; Turner and Porter 
2012); macrophages present in granulation tissue also contribute to the 
generation of MMPs (Iyer, Jung and Lindsey 2016). MMPs and TIMPs are 
important for ECM homeostasis in physiology but have also been demonstrated 
to participate in the development and progression of heart failure (Barton et al. 
2003). Evidence suggests that MMP-1,-2,-3,-9 and TIMP-1 activity is associated 
with adverse pathophysiology and clinical outcomes in MI patients 
(Phatharajaree, Phrommintikul and Chattipakorn 2007); the correlation with 
MMP-9 expression is so strong that it has been suggested this molecule could be 
used as a predictor for cardiovascular mortality in patients with coronary artery 
disease (Blankenberg et al. 2003). 
Cardiac fibroblasts also secrete matricellular proteins, which have regulatory, 
rather than structural, roles in the ECM; examples are periostin and tenascin-C 
(TNC). Periostin is scarcely expressed in the developed myocardium but can be 
more readily detected following myocardial injury or pressure overload 
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stimulation (Shimazaki et al. 2008; Stansfield et al. 2009). Mice deficient in 
periostin showed attenuated fibrosis following pressure overload and displayed 
improved ventricular performance after MI; however, animals were more 
susceptible to cardiac rupture (Oka et al. 2007; Shimazaki et al. 2008). As might 
be anticipated, inducible overexpression of myocardial periostin protected mice 
from rupture following MI and induced spontaneous hypertrophy with aging (Oka 
et al. 2007). TNC is highly expressed in development and repressed in the adult 
myocardium but, similarly to periostin, its levels soar following MI or pressure 
overload (Imanaka-Yoshida et al. 2001; Xia et al. 2009). It has been suggested 
that TNC loosens the adhesion of cardiomyocytes to connective tissue; this may 
aid in releasing surviving cardiomyocytes to reorganise their arrangement 
following cardiac injury (Imanaka-Yoshida et al. 2001). 
Cardiac fibroblasts are the principal producers of TGF-β, a pleiotropic 
cytokine/growth factor. TGF-β stimulation of cardiac fibroblasts causes increased 
synthesis of collagen, fibronectin, proteoglycans, expression of contractile genes 
and triggers their subsequent differentiation into myofibroblasts (Eghbali et al. 
1991; Villarreal et al. 1996). TGF-β signals via heterotetrameric complexes of 
type I and type II receptors in the plasma membrane (Heldin and Moustakas 
2016). Of the three TGF-β isoforms (1-3), TGF-β1 is the predominant isoform and 
is found almost ubiquitously (Dobaczewski, Chen and Frangogiannis 2011). TGF-
β receptor activation generates downstream intracellular signals through the 
Smad proteins (Shi and Massagué 2003) and alternative non-canonical pathways 
(Derynck and Zhang 2003). The overexpression of TGF-β in the mouse heart is 
associated with cardiac fibrosis and hypertrophy (Dobaczewski, Chen and 
Frangogiannis 2011). Incisional rat wounds treated with anti-TGF-β antibodies 
displayed an evident reduction in ECM deposition and scarring (Shah, Foreman 
and Ferguson 1995). Moreover, TGFβ1-deficient mice had an overt reduction in 
collagen deposition, accompanied by a pronounced inflammatory response 
which was ultimately lethal (Kulkarni et al. 1993). This is presumably due to the 
anti-inflammatory effects of TGF-β (Werner et al. 2000) which have been 





1.3.2 Cardiomyocyte hypertrophy 
In addition to being primarily responsible for the deposition of excessive ECM, 
cardiac fibroblasts are now recognised as being important direct regulators of 
cardiac hypertrophy via paracrine mechanisms (Gray et al. 1998; Fujiu and Nagai 
2014; Kamo, Akazawa and Komuro 2015). Pathological hypertrophy gives rise to 
ventricular remodelling associated with systolic and diastolic dysfunction, 
inflammation and interstitial fibrosis, which can result in adverse outcomes, such 
as congestive heart failure, arrhythmia, and sudden death (Kamo, Akazawa and 
Komuro 2015). Cardiac hypertrophy triggers multiple molecular modifications, 
including genetic reprogramming (re-induction of various foetal genes and 
diminished adult genes) (Izumo, Nadal-Ginard and Mahdavi 1988). In fact, the re-
expression of foetal genes, including β-myosin heavy chain (β-MHC) and atrial 
natriuretic factor (ANF) is an indicator of pathological hypertrophy (Pandya and 
Smithies 2011). 
Fibroblasts synthesise a range of paracrine signalling molecules including growth 
factors, cytokines and microRNAs that can act to stimulate hypertrophy of 
cardiomyocytes (Fujiu and Nagai 2014; Kamo, Akazawa and Komuro 2015). 
Conditioned medium from cardiac fibroblasts isolated from pressure-overloaded 
rat hearts caused hypertrophy of cardiomyocytes; this could be inhibited by a 
TGF-β1 receptor antagonist, indicating that TGF-β is important in mediating 
cardiomyocyte hypertrophy (Cartledge et al. 2015). Interleukin-6 (IL-6), a 
pleiotropic cytokine which participates in cell growth, apoptosis, differentiation 
and survival, is produced by and can stimulate both cardiac fibroblasts and 
cardiomyocytes (Banerjee et al. 2009). The activity of IL-6 is modulated by 
binding to the IL-6Rα/gp130 signal transduction complex (Coles et al. 2007). 
Importantly, high levels of IL-6 are detected in patients with heart failure (Nian et 
al. 2004). It has since been reported that IL-6 is cardioprotective during acute 
injury to the myocardium but becomes pathogenic when elevated persistently 
(Fontes, Rose and Čiháková 2015). Initially, IL-6 protects myocytes from 
apoptosis (Smart et al. 2006); however, continuous activation of gp130 has been 
revealed to instigate pathological cardiac hypertrophy (Hirota et al. 1995; 
Kunisada et al. 1998). Cardiac hypertrophy is accompanied by increased IL-6 
after 1 week of isoproterenol infusion (Cha et al. 2010) and genetic deletion of IL-
6 has been shown to attenuate thoracic aortic constriction (TAC)- and 
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norepinephrine-induced LV hypertrophy in mice (Zhao et al. 2016a; Meier et al. 
2009). IL-6 also directly induces cardiomyocyte hypertrophy in cultures of primary 
human cardiomyocytes and cardiac fibroblasts (Ancey et al. 2003). Bageghni et 
al. (2018) observed that IL-6 secretion from cardiac fibroblasts following 
isoproterenol infusion was dependent on the activity of p38α mitogen-activated 
protein kinase (MAPK). Fibroblasts can also modulate cardiomyocyte 
hypertrophy through signalling molecules such as fibroblast growth factor 2 
(Bogoyevitch et al. 1994; Pellieux et al. 2001), insulin-like growth factor 1 
(McMullen et al. 2004) and miR-21*, which is delivered to cardiomyocytes through 
fibroblast-derived exosomes (Duygu and Da Costa Martins 2015). The processes 
involved in cardiac remodelling which can lead to the development of heart failure 
are summarised in Figure 1.1. 
 
Figure 1.1 Mechanisms of pathological cardiac remodelling leading to heart 
failure. In response to pathophysiological stimuli such as ischemia or excessive 
mechanical load, various processes occur which contribute to cardiac 
remodelling. These include: cardiomyocyte loss, cardiomyocyte hypertrophy and 
the accumulation of excess ECM leading to fibrosis. These structural changes 
induce ventricular dysfunction, which can culminate in heart failure. 
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1.4 Cardiac fibroblasts 
1.4.1 Characterisation of cardiac fibroblasts 
During embryonic development, cardiac fibroblasts evolve from multiple sources; 
the epicardium was believed to be the chief source of cardiac fibroblasts found in 
the ventricular myocardium, with epicardial cells undergoing epithelial-to-
mesenchymal transition (Dettman et al. 1998). This has been a source of debate 
as lineage tracing with the epicardial marker, Tbx18, revealed only one third of 
cardiac fibroblasts were Tbx18-expressing (Cai et al. 2008). However, more 
recent evidence demonstrated that 80 % of cardiac fibroblasts in the adult heart 
were derived from the epicardium (Moore-Morris et al. 2014). It has been reported 
that endothelial-to-mesenchymal transition and the recruitment of bone marrow-
derived cells also contribute to the source of cardiac fibroblasts during cardiac 
fibrosis (Zeisberg et al. 2007; Fan et al. 2012). 
It is recognised that cardiomyocytes constitute approximately 25-35% of total 
cardiac cells (Nag 1980) but the composition of the non-myocyte cardiac cell 
population has been disputed. It was originally suggested that fibroblasts 
accounted for the majority of the non-myocyte portion (Banerjee et al. 2007). 
However, with the availability of genetic tracers and enhanced flow cytometry 
techniques, it was verified by Pinto et al. (2016) that cardiac fibroblasts in fact 
represent a more minor population (<20 %) in the myocardium than endothelial 
cells, which are the most abundant cell type (>60 %). 
Cardiac fibroblasts lack a basement membrane, display a cytoplasm with multiple 
processes and, in vitro, appear flat and spindle-shaped (Camelliti, Borg and Kohl 
2005). The interconnected network of cardiac fibroblasts forms the fibrous, 
supportive skeleton of the myocardium, where they are spatially intermingled with 
cardiomyocytes (Fountoulaki, Dagres and Iliodromitis 2015). Cardiac fibroblasts 
are a highly heterogeneous cell population, depending on their origin or 
physiological state (Zeisberg and Kalluri 2010). For an extensive period, these 
cells were poorly characterised as the majority of markers were either non-
specific or lacked sensitivity and this hindered investigation into this cell type 
(Camelliti, Borg and Kohl 2005). Early markers of cardiac fibroblasts, such as 
thymocyte differentiation antigen 1 (Thy1) and fibroblast specific protein 1 
(FSP1), also identify endothelial cells, immune cells and pericytes (Kong et al. 
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2013; Hudon-David et al. 2007) and vimentin also labels other mesoderm-derived 
cells in the heart (Bursac 2014). More recently, lineage-tracing experiments 
relying on platelet-derived growth factor receptor-α (PDGFRα) and the 
collagen1a1-GFP reporter line being coexpressed successfully identified the 
majority of cardiac fibroblasts in the heart (Moore-Morris et al. 2014). 
It was previously assumed that cardiac fibroblasts exclusively regulated ECM 
remodelling but it is now acknowledged that these cells have vital roles in several 
aspects of cardiac function in both physiological and pathophysiological 
circumstances (Porter and Turner 2009; Dostal, Glaser and Baudino 2015). Their 
functions include proliferation, migration, differentiation into a myofibroblast 
phenotype, ECM generation and degradation and secretion of cytokines and 
growth factors (Souders, Bowers and Baudino 2009; Fan et al. 2012). These roles 
grant cardiac fibroblasts the ability to contribute to cardiac disease and they have 
been considered as potential therapeutic targets. However, inadequate 
understanding of the regulatory mechanisms governing this cell type has so far 
been a hindrance. 
 
1.4.2 Differentiation of cardiac fibroblasts 
Cardiac fibroblasts are highly plastic cells with the ability to adjust their phenotype 
and function to meet the challenges of the mechanical load relentlessly inflicted 
upon the heart. In response to injury, stretch or cytokines such as TGF-β, 
fibroblasts become activated and differentiate (Souders, Bowers and Baudino 
2009; Kendall and Feghali-Bostwick 2014; Herum et al. 2017a). The 
differentiated cells, which are absent in healthy myocardium and only appear after 
cardiac injury (Willems et al. 1994), are termed ‘myofibroblasts’. Myofibroblasts 
were first described in skin wounds, where they were suggested to be responsible 
for wound contraction (Gabbiani, Ryan and Majno 1971) by imparting mechanical 
tension on the surrounding ECM. They were named myofibroblasts due to 
features similar to smooth muscle cells such as cytoplasmic stress fibres 
containing alpha smooth muscle actin (α-SMA) (Ehrlich, Allison and Leggett 
2006). 
Following cardiac injury, profuse proliferation of myofibroblasts occurs to satisfy 
the temporarily high demand during cardiac remodelling. Historically, it was 
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presumed myofibroblasts were sourced from resident cardiac fibroblasts. This 
was challenged and it was established that cellular sources including endothelial 
cells, epithelial cells, mesenchymal stem cells, pericytes, smooth muscle cells 
and bone marrow-derived fibrocytes also participate in increasing myofibroblast 
numbers (van den Borne et al. 2009; Turner and Porter 2013). More recent 
studies using lineage-tracing have confirmed earlier thoughts that in fact the 
majority of myofibroblasts arise from tissue-resident cardiac fibroblasts 
(Kanisicak et al. 2016). The more contractile myofibroblasts increase collagen 
turnover, migrate towards chemokines released at the site of injury and secrete 
a number of cytokines, thus maintaining the inflammatory response to injury 
(Gabbiani 2003; Baum and Duffy 2011; Dostal, Glaser and Baudino 2015). The 
majority of myofibroblasts are thought to undergo apoptosis when ECM tension 
is restored, after the healing process (Kis, Liu and Hagood 2011). 
Knowledge of the importance of myofibroblast differentiation following cardiac 
injury is well established but, more recently, it has been suggested that cardiac 
fibroblasts exhibit distinct phenotypes at different time points post-cardiac injury 
(Ma et al. 2017). Ma et al. (2017) suggested that, at day 1 post-MI, fibroblasts are 
pro-inflammatory, secreting pro-inflammatory mediators and MMPs. At day 7, 
fibroblasts are pro-reparative, secreting anti-inflammatory mediators and 
producing ECM and, at day 28, fibroblasts resume to a homeostatic-like 
phenotype. Recent in-depth molecular analyses and lineage-tracing experiments 
have supported the idea of a continuum of differentiation states in cardiac 
fibroblasts following MI (Fu et al. 2018; Mouton et al. 2019). The final 
differentiation state is referred to by Fu et al. (2018) as a “matrifibrocyte”, a 
specialised cell highly adapted to collagenous environments, which reinforces the 
mature scar. A schematic illustrating the process of myofibroblast differentiation 




Figure 1.2 Model of cardiac fibroblast differentiation. In vivo, fibroblasts 
display neither stress fibres nor do they form adhesion complexes with the ECM. 
Under mechanical stress or when transforming growth factor (TGF)-β1 is present, 
fibroblasts differentiate into proto-myofibroblasts, which form cytoplasmic actin-
containing stress fibres that terminate in focal adhesion complexes. Further 
exposure to TGF-β1 and mechanical stress promotes the modulation of proto-
myofibroblasts into differentiated myofibroblasts, characterised by expression of 
α-smooth muscle actin in more extensively developed stress fibres. Functionally, 
differentiated myofibroblasts display an increase in proliferation, matrix synthesis 
and generate greater contractile force, which all enable cardiac remodelling. 
Figure is adapted from Tomasek et al. (2002). 
  
1.4.3 Mechanical signalling in cardiac fibroblasts 
It is obligatory that there is a balance in the heart between tissue being sufficiently 
resilient to endure the constant mechanical load but also compliant enough to 
allow contraction. Following cardiac injury, enhanced ECM synthesis leads to 
compliant ECM and cardiomyocytes being replaced by stiffer collagenous scar 
tissue, resulting in ECM stiffening (van Putten, Shafieyan and Hinz 2016). 
Young's Modulus (in Pa) can be used to determine the stiffness of tissue; this is 
the force per area (stress) needed to strain an elastic material (Solon et al. 2007). 
Healthy heart tissue has a Young's modulus of 10-15 kPa whereas fibrotic tissue 
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is on average 2-10-times stiffer (20-100 kPa) (van Putten, Shafieyan and Hinz 
2016). 
The impact of mechanical strain on cardiac fibroblast phenotype can be observed 
in fibroblasts cultured on compliant substrates such as soft collagen gels, which 
show little development of stress fibres, compared to fibroblasts grown on stiffer 
substrates which form stress fibres and are therefore characterised as 
myofibroblasts (Darby et al. 2014). Driesen et al. (2014) observed that a reduction 
in mechanical strain can promote the dedifferentiation of myofibroblasts. 
Mechanical stimulation of fibroblasts gives rise to a pronounced upregulation of 
ECM components and cytokine and growth factor expression, creating a pro-
fibrotic environment (Chapman, Weber and Eghbali 1990; Hsieh et al. 2000; 
Yokoyama et al. 1999; Ruwhof et al. 2000). Moreover, the release of endothelin-
1 and  TGF-β from stretched cardiac fibroblasts act as paracrine mediators in 
cardiomyocyte hypertrophy (van Wamel et al. 2001). These studies indicate that 
mechanical load is important in the regulation of cardiac fibroblast gene 
expression. 
 
1.5 Mechanotransduction in cardiac fibroblasts 
Cells are able to sense mechanical cues from their surrounding environment 
(mechanosensing) and respond by transducing this information into biochemical 
signals (mechanotransduction) (Martino et al. 2018). Mechanotransduction is 
initiated at the interface between the plasma membrane and the ECM (Rustad, 
W Wong and Gurtner 2013). Mechanisms by which cardiac fibroblasts sense and 
respond to mechanical inputs remain enigmatic. In this section, a brief overview 
will be offered on the most prominent molecular mechanisms implicated in 
cardiac fibroblast mechanotransduction. 
 
1.5.1 Integrins 
Integrins are heterodimeric proteins consisting of one α and one β subunit which 
span the plasma membrane and participate in bi-direction signalling (Liu, 
Calderwood and Ginsberg 2000). There are at least 18 α and 8 β subunits known 
in humans; through different combinations of these subunits, 24 integrin 
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heterodimers can be generated (Takada, Ye and Simon 2007). Early studies 
established that integrins were fundamental for cell adhesion to the ECM but it 
has since been determined that they have a diverse range of functions including 
cell survival and migration, in addition to remodelling of the cellular cytoskeleton 
and focal adhesion (Manso, Kang and Ross 2009). Integrin-mediated signalling 
involves the binding of ECM proteins, such as fibronectin, vitronectin and laminin 
(Schlaepfer and Hunter 1998). Integrins are viewed as mechanosensitive as they 
provide a link between the contractile cytoskeleton and the ECM and permit 
fibroblasts to probe the mechanical state of the environment (van Putten, 
Shafieyan and Hinz 2016). Cardiac fibroblasts express at least 8 of the α subunits 
and 3 β subunits (Manso, Kang and Ross 2009); several of these are upregulated 
during cardiac fibrosis (Schroer and Merryman 2015). 
 
1.5.1.1 TGF-β receptor type 1 
The importance of TGF-β1 in fibrosis and cardiac hypertrophy has previously 
been discussed. TGF-β is secreted in an inactive protein complex consisting of 
TGF-β and latency-associated propeptide, which links to latent TGF-β binding 
protein 1 (Robertson et al. 2015). Upon integrin-binding caused by cell traction 
forces, such as during myofibroblast contraction, TGF-β is released from its 
complex in the ECM and subsequently activated to allow receptor binding (Wipff 
et al. 2007). Blocking of αvβ3 and αvβ5 integrins led to diminished TGF-β1 
activation and α-SMA expression upon cardiac fibroblast contraction; the 
appearance of myofibroblasts was re-established upon addition of active TGF-β1 
(Sarrazy et al. 2014). The activation of latent TGF-β1 is directly influenced by 
ECM compliance (Hinz 2015); on substrates of increased stiffness, cell 
contraction-mediated release of TGF-β1 from the ECM is augmented (Wipff et al. 
2007). The mechanical properties of the ECM thereby modulate TGF-β1 activity 
and thus, TGF-β1-evoked induction of myofibroblasts. 
 
1.5.1.2 Focal adhesions 
Focal complexes are the first contacts that develop when a fibroblast interacts 
with the ECM during cell adhesion and migration; once a mechanically stable 
contact can be established between an activated integrin and ECM ligand, focal 
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complexes mature into larger focal adhesions, located at the termini of 
cytoskeletal actin stress fibres (Chiquet et al. 2009). This initiates the attachment 
of the cytoplasmic domain of the integrin to the cytoskeleton, which involves the 
recruitment of paxillin, phosphoproteins and vinculin, and is reliant on the 
presence of cytoskeletal tension (Katsumi et al. 2004). The transformation of focal 
complexes into focal adhesions is dependent upon the activation of Rho, a small 
GTPase, and its downstream target, Rho-associated kinase (ROCK) (Matthews 
et al. 2006). ROCK aids focal adhesion formation and increases cell contractility 
(Matthews et al. 2006). The Rho/ROCK pathway leads to actin cytoskeletal 
reorganisation, which facilitates myofibroblast differentiation and collagen 
synthesis (Ni et al. 2013). Fittingly, ROCK inhibitors have been suggested as 
promising anti-fibrotic agents in models of cardiac fibrosis in vivo (Li et al. 2012). 
 
1.5.1.3 Talin 
The adaptor protein talin can form a connection between integrins and the 
cytoskeleton upon mechanical stimulation (Critchley 2009). Talin-deficient mice 
displayed lessened pressure overload-induced cardiac fibrosis and improved 
cardiac function; this was linked to reduced MAPK signalling (Manso et al. 2013). 
Talin has also been reported to sense substrate stiffness; a rigid matrix caused 
talin to stimulate focal adhesion formation and nuclear translocation of Yes-
associated protein (YAP) (Elosegui-Artola et al. 2017). The transcription factors, 
YAP and transcriptional coactivator with PDZ-binding motif (TAZ), have been 
discovered to be vital in mechanosensing. Mechanical inputs trigger nuclear 
translocation of the YAP/TAZ complex where it regulates gene expression 
(Dupont et al. 2011). Jin et al. (2018) demonstrated that inhibition of the YAP 
signalling pathway contributed to improved cardiac function in mice with dilated 
cardiomyopathy, in part due to a reduction in myofibroblast differentiation. 
 
1.5.2 Syndecan-4 
The syndecans are a family of four transmembrane proteins which each consist 
of an extracellular polysaccharide glycosaminoglycan chain that binds molecules 
in the ECM (Couchman 2010). Syndecan-4 has been reported to play a role in 
mechanotransduction (Bellin et al. 2009). Mice deficient in syndecan-4 expressed 
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reduced collagen I and III and markers of myofibroblast differentiation following 
aortic banding-evoked pressure overload (Herum et al. 2013). There is a lack of 
knowledge on how syndecan-4 transduces mechanical stress into intracellular 
signals but Herum et al. (2013) found that, upon cyclic stretch, the 
calcineurin/nuclear factor of activated T-cell (NFAT) pathway was activated in a 
syndecan-4-dependent manner in murine cardiac fibroblasts.  
 
1.5.3 Angiotensin II receptor type 1 
The Angiotensin II receptor type 1 (AT1) receptor is a well-established G-protein 
coupled receptor (GPCR) proven to have substantial importance in the 
development of cardiac hypertrophy (Yasuda et al. 2008). Angiotensin II (Ang II) 
is known to act through the AT1 receptor to induce collagen production and 
secretion from cardiac fibroblasts (Lijnen, Petrov and Fagard 2001). In addition, 
Yasuda et al. (2008) determined that mechanical stress could induce cardiac 
hypertrophy in vivo through the AT1 receptor in mice deficient in angiotensinogen. 
It has been stated that the AT1 receptor can be activated by mechanical stretch 
in cardiac fibroblasts in the absence of G-protein activation, through the 
scaffolding protein β-arrestin-2; this couples to activation of the c-Jun N-terminal 
kinase (JNK) signalling cascade (Dostal, Glaser and Baudino 2015). This has 
been suggested to be due to mechanical stretch triggering an AT1 receptor-
mediated conformational change in β-arrestin (Rakesh et al. 2010). Cardiac 
hypertrophy can also be induced by the activation of other GPCRs, such as the 
receptors for endothelin 1 and adrenoceptors; however, it has been reported that 
mechanical stretch does not induce activation in cells overexpressing these 
receptors so this effect appears to be specific to only some GPCRs (Yasuda et 
al. 2008). 
 
1.5.4 Tenascin C 
As previously discussed, TNC is an ECM glycoprotein, rather than being present 
in the plasma membrane, but has also been reported to be directly modulated by 
mechanical stress. Following MI, TNC is localised at the border zone between 
the intact and infarcted lesion; this is where the majority of tissue remodelling 
takes place and is a region that must withstand strong mechanical stress 
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(Imanaka-Yoshida et al. 2001). Correlating with this, inducing aortic stiffness and 
hypertension in mice with a deficiency in TNC evoked acute aortic dissection 
(Kimura et al. 2014). TNC expression was amplified in chick embryo fibroblasts 
subjected to cyclic strain within 3-6 h (Chiquet, Sarasa-Renedo and Tunç-Civelek 
2004); this was independent of protein synthesis (i.e. a transcription factor) or any 
paracrine factor but found to be dependent on Rho/ROCK signalling factors 
(Chiquet, Sarasa-Renedo and Tunç-Civelek 2004). TNC has been shown to 
interfere with the action of fibronectin (Chiquet-Ehrismann et al. 1988). It has 
been speculated that, under high mechanical load, this is required to loosen 
matrix adhesion contacts and prevent overstretching (Chiquet et al. 2009). 
 
1.5.5 Protein kinases 
Integrins associate with or activate numerous non-receptor protein tyrosine 
kinases (PTKs) in response to tension; it is believed this triggers much of their 
downstream signalling (Schlaepfer and Hunter 1998; Seong et al. 2013). These 
include focal adhesion kinase (FAK), Src-family kinases (SFKs) and MAPKs. It 
has been demonstrated that FAK promotes cyclic stretch-induced, integrin-
mediated proliferation and differentiation of cardiac fibroblasts (Dalla Costa et al. 
2009) and FAK knockdown reduced fibrosis in response to chronic pressure 
overload in mice (Clemente et al. 2007). Integrins have been shown to play a vital 
role in mechanical stress-induced p38 MAPK activation and cardiac hypertrophy, 
through a FAK-Src-Ras pathway in the myocardium (Aikawa et al. 2002). 
 
1.5.5.1 Src-family kinases 
The SFKs are a group of membrane-associated intracellular proteins (Blk, Fgr, 
Fyn, Hck, Lck, Lyn, Src, and Yes) which act as important signalling mediators, 
playing key roles in cell morphology, motility, proliferation, and survival (Roskoski 
2004). All SFKs have a C-terminal domain preceded by Src 2 and 3 homology 
domains (SH2 and SH3, respectively), a membrane-anchoring SH4 N-terminal 
region and a unique domain (a short sequence which varies between the family 
members) (Amata, Maffei and Pons 2014). 
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SFKs are regulated by phosphorylation which, at certain sites, induces activation, 
and at other sites initiates inhibition, due to the generation of a closed inactive 
conformation (Roskoski 2005). For example, phosphorylation of Y527 in c-Src, 
the prototype of the family, leads to an interaction between the phospho-residue 
and the SH2 domain, causing inactivity; dephosphorylation of phospho-Y527 by 
phosphatases permits opening of the structure and subsequent phosphorylation 
and activation (Anguita and Villalobo 2017). Activated SFKs can then modulate 
other proteins; Src and Fyn have been demonstrated to enable the activation of 
Rho GTPases in response to tension (Guilluy et al. 2011; Herum et al. 2017b). 
 
1.5.5.2 p38 mitogen-activated protein kinases 
The MAPKs are a family of kinases which participate in essential cell functions, 
such as gene regulation, proliferation, differentiation and mobility (Krishna and 
Narang 2008). p38 MAPKs are one of the four classical MAPK signalling 
cascades, the others being the extracellular signal-regulated kinases (ERK1/2), 
c-Jun N-terminal kinases (JNK1-3) and ERK5 (Figure 1.3) Stimulation of these 
cascades leads to sequential phosphorylation events; a MAP kinase kinase 
kinase (MAPKKK) phosphorylates a MAP kinase kinase (MAPKK) on specific 
serine/threonine residues and this subsequently triggers dual phosphorylation of 
the MAPK on specific threonine and tyrosine residues, as shown in Figure 1.3. 
Activated MAPKs influence cell function by phosphorylating downstream 













Figure 1.3 Canonical MAPK signalling.  Schematic simplified representation of 
the classical MAP kinase (MAPK) pathways. These comprise a cascade of three 
kinases which phosphorylate (denoted by P) and activate each other 
consecutively. Mitogens, cytokines, and cellular stresses stimulate the MAPK 
pathways. MAPKs subsequently phosphorylate downstream substrates in the 
nucleus (e.g., transcription factors), cytosol, cytoskeleton, mitochondria and 
plasma membrane to affect cellular function. MAPK: Mitogen-activated protein 
kinase; MAPKK: Mitogen-activated protein kinase kinase; MAPKKK: Mitogen-
activated protein kinase kinase kinase. Image taken from Turner and Blythe 
(2019). 
 
The JNKs and p38 MAPKs are together termed stress-activated protein kinases 
(SAPKs) due to factors such as stresses and inflammation (e.g. ultraviolet light, 
oxidant stress, osmotic shock, infection and cytokines) triggering their activation 
(Kyriakis and Avruch 2001). These kinases are capable of regulating cell death, 
differentiation and inflammatory responses (Kyriakis and Avruch 2001). There are 
several upstream kinases capable of initiating the p38 phosphorylation cascade, 
including the MAPKKKs, TAK1, MEKK1-4, MLK3 and ASK1, and the MAPKKs, 
MKK3/6 (Figure 1.3). The p38 MAPK family is comprised of four isoforms, 
p38α/β/γ and δ; p38α and β are approximately 70% identical and p38γ and δ also 
show structural similarity. The α isoform is the most well-established of the four 
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and, unlike the other family members which demonstrate variances in expression 
between tissues and cell types, is ubiquitously expressed (Turner and Blythe 
2019). It is known that the phosphorylation of transcription factors triggered by 
p38 MAPK activation can induce the reprogramming of cardiac gene expression 
(Heineke and Molkentin 2006). p38 can regulate both gene and protein 
expression via several mechanisms, including modulation of chromatin structure, 
transcription, mRNA stability and translation (de Nadal and Posas 2010; Turner 
and Blythe 2019). The MAPK-activated protein kinase, MK2, is reported to be 
important for regulation of mRNA stability (Turner and Blythe 2019). 
MAPK signalling, as previously discussed, has been implicated in stimulating 
cardiac hypertrophy and fibrosis (Molkentin et al. 2017; Bageghni et al. 2018). 
This tallies with reports that the MAPK signalling cascade is initiated by stretch 
(Sugden and Clerk 1998). Cyclic mechanical load for 10-20 min has been 
revealed to activate the p38 MAPK signalling pathway, in addition to the JNK and 
ERK pathways, in foetal rat cardiac fibroblasts; p38 and ERK1/2 activation were 
found to be important for the regulation of collagen I expression following cyclic 
stress (Papakrivopoulou et al. 2004). The p38 pathway has been reported to be 
central for the induction of IL-6 secretion, a key molecule through which cardiac 
fibroblasts can modulate cardiomyocyte hypertrophy (Meléndez et al. 2010). p38 
activation has been demonstrated to occur in response to various factors 
upregulated in cardiac remodelling, such as α and β-adrenergic receptor 
agonists, interleukin-1 (IL-1), interleukin-33 (IL-33), tumour necrosis factor (TNF)-
α, Ang II and adenosine (Perez, Papay and Shi 2009; Bageghni et al. 2018; 
Turner 2011; Zhu and Carver 2012). 
 
1.5.6 Ion channels 
In addition to integrins, syndecans and the AT1 receptor, another method of cell 
surface mechanotransduction is via the passage of current through 
mechanosensitive ion channels (Figure 1.4) . Mechanical forces applied to the 
cell membrane have been revealed to induce calcium ion (Ca2+) influx across the 
plasma membrane in cardiac fibroblasts (Kiseleva et al. 1996); this influx of Ca2+ 
ions into the cell leads to downstream signalling and changes in cardiac fibroblast 
function in normal physiology and disease states (Castella et al. 2010; Reed, Kohl 
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and Peyronnet 2014). In the next section, cellular Ca2+  handing mechanisms will 
be discussed, with a particular emphasis on mechanically-activated ion channels. 
 
 
Figure 1.4 Cardiac fibroblast mechanotransduction at the plasma 
membrane. Simplified schematic of proteins participating in 
mechanotransduction at the plasma membrane of the cardiac fibroblast. These 
include: angiotensin II receptor type 1 (AT1), integrins, ion channels and 
syndecans.  
 
1.6 Ca2+ handling mechanisms 
The cytosolic free calcium ion (Ca2+i) operates as a highly versatile second 
messenger in virtually all types of eukaryotic cells. Ca2+i regulates an extensive 
array of cellular processes including excitation-contraction coupling, gene 
transcription, cell growth, differentiation and apoptosis (Berridge, Lipp and 
Bootman 2000). In cardiac fibroblasts, intracellular Ca2+ is known to control 
various functions including ECM synthesis and cell proliferation (Zhang et al. 
2014) and is a feature of many intracellular signalling pathways (Chen et al., 
2010). However, Ca2+ signals in cardiac fibroblasts are not as well characterised 
as those in cardiac myocytes (Bers and Guo 2005). 
Prolonged cytoplasmic Ca2+ overload can lead to cell death, and irregular Ca2+ 
signalling is defined as a key element of numerous diseases (Clapham 1995). It 
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has become apparent that abnormalities in calcium transport and signalling are 
associated with both cardiac hypertrophy and heart failure (Bers, Eisner and 
Valdivia 2003; Cartwright et al. 2011; Ritter and Neyses 2003). Therefore, 
mechanisms by which cells control cytosolic Ca2+ levels are carefully regulated. 
The standard intracellular Ca2+ concentration is 100 nM; this is 20,000-fold lower 
than the concentration found extracellularly (Clapham 1995). It is ion channels 
located within cell membranes which are depended upon to regulate Ca2+ ions in 
a controlled manner (Kondratskyi et al. 2015). An overview of the mechanisms 






Figure 1.5 Overview of cellular Ca2+ handling. The intracellular Ca2+ 
concentration is carefully maintained by various membrane pumps and 
exchangers; these ensure a 20,000 fold gradient is kept constant. Ca2+ can enter 
the cell through Ca2+-permeable ion channels in response to particular stimuli and 
is able to leave the cell through exchangers (Na+/Ca2+ exchanger; NCX) and 
pumps (Plasma membrane Ca2+ ATPase; PMCA). Inside the cell, the majority of 
Ca2+ is stored in the endoplasmic reticulum (ER) where it is released through 
inositol-1,4,5-trisphosphate receptors (IP3R) and ryanodine receptors (RyR) and 
recycled via the sarcoplasmic reticulum Ca2+ ATPase (SERCA) extrusion pump. 
Mitochondrial Ca2+ homeostasis is accomplished through Ca2+ uniporters and  




1.6.1 Ca2+ extrusion 
Pumps and exchangers present in the plasma membrane and endoplasmic 
reticulum membrane are responsible for the extrusion of Ca2+ from the cytosol to 
achieve Ca2+ homeostasis. The Na+/Ca2+ Exchanger (NCX) is located in the 
plasma membrane, exists in three isoforms (NCX1-3) and predominantly exports 
one Ca2+ ion for the uptake of three Na+ ions (Hilge 2012). This exchanger uses 
the electrochemical gradient of Na+ and has a high capacity for Ca2+ which 
enables the transport of many Ca2+ ions at a fast rate (Clapham 2007). The 
plasma membrane Ca2+-ATPase (PMCA) pumps are high-affinity Ca2+ extruders, 
binding a single intracellular Ca2+ ion which is deposited to the extracellular space 
following conformational changes; this occurs in conjunction with the import of 
protons (Stafford et al. 2017). There are four known PMCA isoforms (PMCA1-4)  
(Strehler and Zacharias 2001). Notably, total PMCA4 knockout (KO) specifically 
from cardiac fibroblasts protected mice against pressure overload-induced 
cardiac hypertrophy by regulating Ca2+ signalling (Mohamed et al. 2016). The 
related ATPase of the sarco(endo)plasmic reticulum (SERCA), which has 3 
isoforms, instead pumps Ca2+ from the cytosol into the endoplasmic reticulum 
(ER). It has a higher capacity for Ca2+ clearance than PMCA, removing two Ca2+ 
ions per ATP molecule hydrolysed (Stafford et al. 2017). RT-PCR analysis 
revealed NCX3, PMCA1,3,4 and SERCA1-3 were detected in human cardiac 
fibroblasts (Chen et al. 2010). Mitochondria also accumulate significant amounts 
of Ca2+ from the cytosol (Kirichok, Krapivinsky and Clapham 2004). The balance 
is mainly achieved by Ca2+ influx through the mitochondrial Ca2+ uniporter and 
efflux by the mitochondrial version of the Na+/Ca2+ exchanger (NCLX) (Boyman 
et al. 2013). 
 
1.6.2 Ca2+ release from stores 
Intracellular Ca2+-release channels on the sarcoplasmic reticulum of striated 
muscle (ryanodine receptors, RyRs) and on the endoplasmic reticulum of virtually 
all cell types (inositol 1,4,5-trisphosphate receptors, IP3Rs) play crucial roles in 
Ca2+-mediated signalling (Marks 1997). Three isoforms of RyR have been 
characterised (1-3) with RyR2 being expressed predominantly in cardiac muscle. 
RyR2 is activated during excitation-contraction coupling by Ca2+ influx via the 
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dihydropyridine receptor, a phenomenon referred to as Ca2+-induced Ca2+ 
release (Marks 1997). IP3R function is regulated by a classic second messenger 
cellular signalling pathway mediated by inositol 1,4,5‐trisphosphate (IP3), 
generated primarily by phospholipase C (PLC) metabolism of phosphoinositol‐
4,5‐bisphosphate (PIP2), in response to the stimulation of GPCRs by extracellular 
agonists (Santulli et al. 2017). This results in Ca2+ release from the ER. Chen et 
al. (2010) detected IP3R1-3 mRNA expression, but not that of RyR, in human 
cardiac fibroblasts. 
 
1.6.3 Ca2+ entry 
Ion channels are transmembrane proteins which permit the passage of ions in 
response to a stimulus. There are two important properties which distinguish ion 
channels from simple aqueous pores. Firstly, they show ion selectivity, permitting 
only certain ions to pass; some ion channels are selective to specific ions 
whereas others discriminate ions only by charge. The second distinction is that 
ion channels are not continuously open, they are gated. The most common stimuli 
known to cause the opening of ion channels are: a change in voltage across the 
membrane (voltage-gated channels), the binding of a ligand (ligand-gated 
channels) and mechanical stress (mechanically-activated channels). Ion 
channels are extremely efficient; up to 100 million ions can pass through one 
open channel each second, a rate 105 times higher than the fastest rate of 
transport mediated by any known carrier protein (Alberts 2002). However, 
channels are not coupled to an energy source so are only able to mediate passive 
movement of ions down their electrochemical gradients across the lipid bilayer. 
Voltage-gated Ca2+ channels are activated upon membrane potential changes 
and are able to transduce this into intracellular Ca2+ transients which orchestrate 
many physiological events in excitable cells (Catterall 2011). These events 
include rapid contraction in skeletal muscle cells, secretion of hormones in 
endocrine cells and initiation of synaptic transmission in neurons (Catterall 2011). 
The channels have been classified into three subfamilies named Cav1 (L-type), 
Cav2 and Cav3 (T-type) (Ertel et al. 2000). Despite the detection of mRNA 
expression of L-type and T-type Ca2+ channels in neonatal rat cardiac fibroblasts, 
their significance in fibroblast function is not clear (Ross and Jahangir 2016). 
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Ligand-gated ion channels are directly activated by the binding of an agonist to 
their extracellular domain and are sometimes referred to as ionotropic receptors; 
P2X receptors are examples of ligand-gated Ca2+ channels and their particular 
agonist is ATP (Mahaut-Smith, Taylor and Evans 2016). Chen et al. (2012) found 
that ATP activation of P2X receptors leads to proliferation and migration of human 
cardiac fibroblasts. 
Store-operated Ca2+ entry (SOCE) is another Ca2+ influx mechanism in non-
excitable cells, including fibroblasts. Orai proteins have been identified as store-
operated channels and stromal interaction molecule 1 (STIM1) proteins as ER 
Ca2+ sensors in SOCE. Depletion of Ca2+ from the ER causes STIM to cluster at 
ER-plasma membrane junctions where it is able to activate Orai channels to allow 
Ca2+ entry into the cytosol. ER Ca2+ stores are refilled via SERCA. RT-PCR 
analysis has revealed expression of STIM1 and Orai1-3 in human cardiac 
fibroblasts (Chen et al. 2010). Human ventricular fibroblasts from patients with 
heart failure secrete increased collagen in comparison with those from non-failing 
hearts; this was shown to be related to an increase in Ca2+ entry via SOCE and 
enhanced expression of Orai1 (Ross et al. 2017). Another study unravelled 
SOCE as a key modulator in Ang II-induced cardiac fibrosis (Zhang et al. 2016). 
 
1.7 Mechanically-activated ion channels 
Detecting and responding to mechanical stimuli is an obligatory part of any living 
system. The plasma membrane is a target of external mechanical stimuli and 
mechanically-activated ion channels play a vital role in the physiology of 
mechanotransduction (Martinac 2004). They detect and transduce external 
mechanical cues into electrical and/or chemical intracellular signals in a diverse 
range of cell types. Mechanically-activated ion channels are implicated in a 
myriad of physiological processes, for example touch and pain sensation, 







1.7.1 Selective cation stretch-activated channels 
Kim (1993) first described whole-cell potassium-selective stretch-activated 
channel currents in cardiac cells. These channels are outwardly rectifying and 
lead to potassium exit from the cytoplasm. Two-pore domain potassium (K2P) 
channels have been revealed to be expressed in human cardiac tissue (Schmidt 
et al. 2017) and involved in cardiac arrhythmogenesis (Gurney and Manoury 
2008). One of these, TWIK-related potassium channel (TREK)-1 is activated by 
numerous stimuli including pH, temperature, fatty acids, anaesthetics, membrane 
deformation or stretch (Patel and Honoré 2001). TREK-1 contributes to the ‘leak’ 
potassium conductance in cardiomyocytes which aids normal repolarisation 
(Goonetilleke and Quayle 2012). While cardiomyocyte-specific deletion of TREK-
1 in mice resulted in cardiac dysfunction in response to pressure overload, TREK-
1 deletion in fibroblasts prevented deterioration in cardiac function (Abraham et 
al. 2018). The authors confirmed this was associated with diminished cardiac 
fibrosis and reduced activation of JNK in cardiomyocytes and fibroblasts. 
Although conventionally considered to be ligand-gated, Van Wagoner and 
Lamorgese (1994) obtained single-channel inside-out patch clamp recordings 
from neonatal rat atrial myocytes which demonstrated that patch pipette negative 
pressure increased KATP channel sensitivity. In normal metabolic conditions, KATP 
channels are inactivated. If ATP levels fall, KATP open probability increases. In the 
presence of stretch, this increase occurs at less reduced ATP levels (Peyronnet, 
Nerbonne and Kohl 2016). Stretch-preconditioning has been reported to reduce 
ischaemia-reperfusion injury but this is abolished when KATP channels are 
blocked (Kristiansen et al. 2005). Benamer et al. (2013) reported that MI in rats 
induced expression of functional KATP channels in scar and border zone cardiac 
fibroblasts. 
The mechanosensitivity of voltage-gated sodium channels has been reported in 
heterologous expression studies (Beyder et al. 2010) and they are stated to be 
expressed in cultured ventricular fibroblasts (Li et al. 2009). Chatelier et al. (2012) 
showed that human atrial myofibroblasts display a fast inward voltage-gated 
sodium current, whereas no current was detectable in non-differentiated 
fibroblasts. Quantitative RT-PCR revealed 4-fold expression of the Nav1.5 α-
subunit in myofibroblasts when compared to fibroblasts, indicating that sodium 
current may be important in the fibrogenesis cascade. 
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1.7.2 Non-selective cation stretch-activated channels 
Transient receptor potential (TRP) channels are a large superfamily consisting of 
28 members which can be classified into 6 subfamilies according to sequence 
homology: TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPP 
(polycystin), TRPML (mucolipin) and TRPA (ankyrin). The proteins are Ca2+-
permeable non-selective cation channels that detect a wide variety of 
environmental stimuli. Stimuli range from vision to taste, smell, touch, hearing, 
proprioception and thermosensation (Liu and Montell 2015). Several of the 
channels have also been demonstrated to be involved in mechanosensation; 
TRPC6 and TRPV4 have been implicated in osmosensing (Wilson and Dryer 
2014; Feetham et al. 2015). It has been reported that TRPC1/3/4/5/6/7 are all 
involved in cardiac hypertrophy but most of the studies demonstrate the 
involvement of TRPC channels in Ca2+ signalling in cardiomyocytes (Eder and 
Molkentin 2011; Nishida and Kurose 2008; Satoh et al. 2007). More recent 
studies have focussed on cardiac fibroblast TRP channels and imply that TRP 
channels may serve as a potential therapeutic target for cardiac fibrosis. 
Numerous TRP channels are highly expressed in cardiac fibroblasts from various 
sources; these are primarily TRPs from the TRPC (1-7), TRPV (2/4) and TRPM 
(6/7) subfamilies (Yue et al. 2013). Harada et al. (2012) demonstrated that 
TRPC3 expression was upregulated in atria from patients with atrial fibrillation 
(AF), goats with electrically maintained AF and dogs with tachypacing-induced 
heart failure. They found that TRPC3 channels in canine atrial fibroblasts were 
responsible for cardiac fibroblast proliferation and differentiation, through 
controlling Ca2+ influx that subsequently activates ERK signalling. TRPC6 has 
been proposed to promote TGF-β1- and Ang II-induced myofibroblast 
differentiation which aided wound healing in mice (Davis et al. 2012). In addition, 
Adapala et al. (2013) discovered that TRPV4 was important for TGFβ1-induced 
differentiation in rat cardiac fibroblasts in vitro; this effect was dependent on ECM 
stiffness. Although these TRP channels have been suggested to be 
mechanically-activated, there is ambiguity as to whether these channels sense 
force and act as primary transducers, or whether they have an indirect, supporting 
role as part of a downstream signalling pathway (Christensen and Corey 2007). 
Peyronnet, Nerbonne and Kohl (2016) stated in a review on cardiac 
mechanically-activated ion channels that the two main molecular candidates for 
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non-selective cation stretch-activated channels were TRP channels and Piezo 
channels. Piezo proteins are a more recent discovery in this field (Coste et al. 
2010) and their identification has significantly expanded understanding of 
mammalian, mechanically-activated currents and their functions. This family of 
proteins will be discussed in more depth below. 
 
1.8 The Piezo family  
Molecules responsible for many mechanically-activated cation channel activities 
remained elusive until 2010, when a novel family of ion channels was identified. 
Using RNA interference, Coste et al. (2010) discovered that Piezo1 (encoded for 
by the Fam38a gene) was responsible for a rapidly-activating current initiated in 
response to pressure stimulation in a mouse neuroblastoma cell line. The channel 
was named Piezo1 based on the Greek word for pressure, ‘πίεση’. Piezo1 and 
Piezo2 (encoded by Fam38b) make up the Piezo family (Coste et al. 2010). Both 
proteins assemble to form functional channels which independently confer 
mechanically-activated non-selective cationic current (Coste et al. 2010). Piezo1 
expression was observed to be highest in bladder, colon, kidney, lung and skin 
whereas strong expression of Piezo2 was revealed in bladder, lung and dorsal 
root ganglion sensory neurons (Coste et al. 2010). This correlates with more 
recent data published disclosing the role of Piezo2 in somatosensory 
mechanotransduction; the channel has been revealed to be important for light 
touch, pain and proprioception (Woo et al. 2014; Woo et al. 2015; Dubin et al. 
2012). 
 
1.8.1 Structure and activation of Piezo1 
Mouse Piezo1 heterologously expressed in HEK-293 cells and purified was able 
to mediate mechanosensitive cationic currents when reconstituted into lipid 
bilayers (Coste et al. 2012; Syeda et al. 2016). This confirmed its ability to form 
an intrinsically mechanosensitive channel, without a requirement for other 
cofactors. Gnanasambandam et al. (2015) discovered that Piezo1 is permeable 
to monovalent ions (K+, Na+, Cs+, Li+) and most divalent ions (Ba2+, Ca2+ and 
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Mg2+, not to Mn2+). Therefore, Piezo1 is a non-selective cation channel; however, 
Coste et al. (2010) suggested that Piezo1 displays a slight preference for Ca2+. 
The Piezo proteins were revealed not to possess sequence homology with any 
known class of ion channels (Zhao et al. 2016b). Piezo1 is a relatively large 
protein estimated to be 286 kDa in humans and 292 kDa in mouse (Soattin et al. 
2016). Initial structural analysis suggested that Piezo1 formed a tetramer (Coste 
et al. 2012) but, in recent years, cryo-electron microscopy has enabled the full-
length structure (2547 amino acids) of mouse Piezo1 to be resolved at a 
resolution of 4.8A˚ and this revealed the protein formed a trimeric propeller-like 
structure (Ge et al. 2015). Coste et al. (2012) first ascertained Piezo1 to be a 
multipass transmembrane protein and the protein is now suggested to possess 
an unprecedented 38 transmembrane domains, meaning a total of 114 
transmembrane helices are present in the trimeric channel complex (Zhao et al. 
2018). 
Zhao et al. (2018) confirmed the findings of Ge et al. (2015) that mouse Piezo1 
possesses a three-bladed, propeller-shaped architecture comprising of a central 
cap, three peripheral blades and three long intracellular beams (Figure 1.6). It is 
hypothesised that Piezo1 may use its peripheral blade regions to detect 
mechanical force (Ge et al. 2015). This was validated by the use of whole-cell 
electrophysiology on mutated and chimeric Piezo1 channels, which revealed the 
N-terminal blade structures are important for sensing force and mechanical 
activation, whereas the C-terminal cap region is important for efficient ion 
conduction and cation selectivity (Zhao et al. 2016b). Zhao et al. (2018) proposed 
that Piezo1 utilises its curved blades and long beams as a pivot to form a lever-
like apparatus. The lever-like mechanism may enable Piezo1 channels to create 
a slight opening of the central pore, allowing cation-selective permeation. 
In vitro, Piezo1 is able to respond to differing forms of mechanical stimulation 
including poking, suction, stretch, cell swelling and flow-induced shear stress 
(Coste et al. 2010; Li et al. 2014; Ranade et al. 2014; Miyamoto et al. 2014; 
Gudipaty et al. 2017). Membrane tension has also been shown to activate the 





Figure 1.6 Cryogenic electron microscopy structure of the Piezo1 trimer. 
Intracellular view of the structure of the Piezo1 trimer, the three Piezo1 subunits 
are illustrated in different colours. On the right is the image rotated 90° to present 
the beam, blade and extracellular structures. Image adapted from Zhao et al. 
(2018). 
 
1.8.2 Modulation of Piezo1 activity 
1.8.2.1 Piezo1 activators 
Syeda et al. (2015) developed a high-throughput screen in which over 3 million 
compounds were assessed for their ability to activate Piezo1 and Piezo2 in 
transfected HEK-293 cells using Ca2+ imaging. They identified and characterised 
a synthetic small molecule, Yoda1, which was able to activate human and mouse 
Piezo1 channels to cause Ca2+ influx, with no effect on Piezo2 channels.  
Lipid bilayer experiments suggested that Yoda1 does not require other proteins 
or specific lipid domains to activate Piezo1, indicating that Yoda1 is acting directly 
on the channel or through alterations in membrane tension or curvature. Lacroix, 
Botello-Smith and Luo (2018) engineered chimeras of mouse Piezo1 and its 
Yoda1-insensitive paralog Piezo2 and identified a minimal region in Piezo1 
located between the blade and pore (residues 1961-2063) required for Yoda1 
sensitivity. The group suggest that the C-terminal part of this region has an 
important role in mediating the effects of Yoda1. Syeda et al. (2015) proposed 
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that Yoda1 stabilises the open state of Piezo1, rather than destabilising the 
closed state; this would explain why Yoda1 increases the sensitivity and slows 
inactivation kinetics of mechanically-induced responses. Prominent Yoda1-
dependent calcium responses are also seen in the absence of externally applied 
forces. Yoda1 is the first known agonist of Piezo1 and has already been 
instrumental in facilitating studies aimed at clarifying the gating mechanism of 
Piezo1 and exploring its functional roles in various biological processes, without 
the need for mechanical stimulation. Yoda1 causes Ca2+ influx and subsequent 
dehydration of red blood cells (RBCs) in a similar manner to mechanical stretch 
(Cahalan et al. 2015). The compound can also mimic shear stress by activating 
endothelial nitric oxide synthase (eNOS) in human umbilical artery endothelial 
cells (HUAECs) and causing relaxation of murine mesenteric arteries (Wang et 
al. 2016). One disadvantage is that Yoda1 displays poor aqueous solubility above 
20-30 μM (Syeda et al. 2015); therefore, improved agonists of the Piezo1 channel 
are necessary for any future translational research.  
A subsequent high-throughput screen identified a set of two alternative chemical 
activators of Piezo1, named Jedi1 and Jedi2; both compounds specifically elicit 
concentration-dependent Ca2+ responses in cells transfected with mouse Piezo1, 
but not with mouse Piezo2 (Wang et al. 2018). Jedi was shown to activate Piezo1 
through the extracellular side of the blade and activation required key 
mechanotransduction components, including two extracellular loops in the distal 
blade and two leucine residues in the proximal end of the beam (Wang et al. 
2018). 
 
1.8.2.2 Piezo1 inhibitors 
Current antagonists of the Piezo1 channel, such as ruthenium red and 
gadolinium, are generic inhibitors of many cationic mechanically-activated 
currents (Coste et al. 2010). Ruthenium red has been revealed to act via the 
extracellular side of the channel, perhaps directly blocking the pore (Coste et al. 
2012). A peptide toxin isolated from the venom of the Chilean rose tarantula 
spider, Grammostola spatulata mechanotoxin 4 (GsMTx4), has been shown to 
inhibit Piezo1 responses (Bae, Sachs and Gottlieb 2011) but also inhibits a range 
of endogenous cationic mechanosensitive channels (Suchyna et al. 2000).  
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GsMTx4 inhibits the channel only when applied from the extracellular side (Bae, 
Sachs and Gottlieb 2011) and is believed to function indirectly through 
interactions with plasma membrane lipids (Suchyna et al. 2004). 
Our group at the University of Leeds generated analogues of Yoda1 using 
synthetic chemistry and tested them against the Piezo1 channel, with the aim of 
developing improved Piezo1 modulators and increasing knowledge on the 
structure-activity relationship for Yoda1 activation of Piezo1 (Evans et al. 2018). 
This led to the identification of Dooku1, an inhibitor of Yoda1‐induced Piezo1 
channel activity that blocks Yoda1‐induced relaxation of aorta (Evans et al. 2018). 
Dooku1 only has activity against Yoda1‐induced, rather than constitutive, Piezo1 
channel activity, suggesting the compound may compete with Yoda1 or act 
allosterically at another site to reduce the binding or efficacy of Yoda1 (Evans et 
al. 2018). The discovery of a small molecule specific inhibitor of constitutive 
Piezo1 activity would be invaluable for future studies. 
 
1.8.3 Expression and functional roles of Piezo1 
Since the discovery of the Piezo1 channel as a molecular carrier of a 
mechanically-activated current in 2010, there has been a surge of activity to study 
this ion channel. Over the past 10 years, ground-breaking research has identified 
that Piezo1 is important for sensing pressure in numerous tissues throughout the 
body. 
1.8.3.1 Cardiovascular functions 
The physiological force of shear stress is vital for vascular development and 
function; Piezo1 has been verified as a direct sensor of shear stress (Li et al. 
2014; Ranade et al. 2014). Li et al. (2014) found that global Piezo1 KO results in 
embryonic lethality in mice at day E9.5-11.5; growth retardation and less 
prominent vasculature in the yolk sac was observed in these animals, compared 
to wild-type (WT) animals. Endothelial-specific Piezo1 KO caused similar 
vascular defects during development, whereas heterozygote Piezo1 KO mice 
had no major phenotype. In vitro, the diminution of Piezo1 supressed tube 
formation and attenuated the migration of human umbilical vein endothelial cells 
(HUVECs) towards vascular endothelial growth factor (VEGF), a key stimulant of 
angiogenesis. Piezo1-/- embryonic endothelial cells had reduced shear stress-
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evoked Ca2+ entry and showed directionless alignment, whereas endothelial cells 
isolated from Piezo+/+ littermates exhibited cell alignment in the direction of blood 
flow. This study highlights the role of Piezo1 in vascular function. 
Rode et al. (2017) addressed the role of Piezo1 in the adult vasculature, this 
required conditional disruption in mature mice. The group found that the channel 
was important for elevation of blood pressure during whole body physical activity 
by redistributing blood flow. Mice with conditional endothelial KO of Piezo1 had 
no obvious phenotype until performing exercise, when they displayed an 
attenuated increase in blood pressure in the mesenteric artery, compared to WT 
mice. Investigation into the mechanism revealed that Piezo1 opposed the 
relaxation mechanism, endothelium-dependent hyperpolarisation (EDH). Piezo1 
channels depolarise endothelial cells, this then depolarises adjacent vascular 
smooth muscle cells, triggering contraction and thus vasoconstriction. During 
exercise, mesenteric arteries constrict to allow the redistribution of blood flow to 
skeletal muscles. Mice lacking endothelial Piezo1 had compromised physical 
performance, thought to be due to their inability to advantageously redistribute 
blood flow from the gut to skeletal muscles upon physical exercise. Wang et al. 
(2016) found that mice with induced endothelium-specific deletion of Piezo1 lost 
the ability to form nitric oxide and therefore induce vasodilation in response to 
flow and consequently mice developed hypertension. 
Retailleau et al. (2015) established that smooth muscle Piezo1 plays a key role 
in the structural remodelling of resistance arteries upon Ang II-induced 
hypertension or when mechanoprotection was removed due to the deletion of 
filamin A, the actin crosslinking element which exerts a tonic repression on the 
opening of stretch-activated channels (Kainulainen et al. 2002). Deletion of 
smooth muscle filamin A stimulated Piezo1 opening; its increased activity 
induced structural remodelling of small-diameter arteries, even in the absence of 
hypertension. When Piezo1 was also deleted, hypertension-induced remodelling 
of caudal arteries was eradicated, suggesting that Piezo1 plays a role in the 






1.8.3.2 Non-cardiovascular functions 
McHugh et al. (2010) were the first to discover a functional role of the still 
uncharacterised FAM38A gene; they showed that siRNA knockdown of FAM38A 
in epithelial cells inactivates endogenous β1 integrin, reducing cell adhesion. Two 
years later, the same group demonstrated that knockdown of Piezo1 increased 
cell migration in lung epithelial cells and, as Piezo1 expression was depleted in 
small cell lung cancer lines, proposed that the loss of Piezo1 expression may 
cause increased cell migration and metastasis in lung tumours (McHugh et al. 
2012). Data from Yang et al. (2014) differed; they demonstrated that the 
knockdown of Piezo1 attenuated cell mobility of gastric cancer cells. Contrasting 
roles for Piezo1 may imply that Piezo1 mediates differential signalling pathways 
in specialised cells. 
Piezo1 has been associated with RBC volume homeostasis (Cahalan et al. 
2015). When Yoda1 was used to activate Piezo1, Ca2+ influx was triggered which 
led to activation of a Ca2+-activated K+ channel; this activation caused osmotic 
loss of water and subsequent dehydration of RBCs. As expected, RBCs from 
blood cell-specific Piezo1 conditional KO mice were overhydrated and exhibited 
increased fragility (Cahalan et al. 2015). 
Murine urothelial cells exhibited a Piezo1-dependent increase in cytosolic Ca2+ 
concentrations in response to mechanical stretch, which led to ATP release 
(Miyamoto et al. 2014). GsMTx4 inhibited the stretch-induced Ca2+ influx and 
subsequent ATP release in urothelial cells, suggesting a role for Piezo1 in 
sensing extension of the bladder urothelium. Piezo1 has been revealed to 
influence urinary concentration following dehydration or fasting, correlating with 
its prominent expression in the inner medulla (Martins et al. 2016). Urinary dilution 
and the decrease in urea concentration following rehydration are both 
significantly delayed in the absence of Piezo1 in collecting duct epithelial cells of 
adult mice, indicating that Piezo1 plays a functional role in the regulation of 
urinary osmolarity. 
Romac et al. (2018) applied high pressure to pancreatic acinar cells using 
buffered saline solution, causing pancreatitis. GsMTx4 and acinar cell-specific 
genetic deletion of Piezo1 protected mice against pressure-induced pancreatitis, 
indicating a potential role for Piezo1 in pancreatitis development following 
abdominal trauma or pancreatic duct obstruction. Consistent with Piezo1 
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promoting pancreatitis, Yoda1 application into the pancreatic duct also induced 
pancreatitis (Romac et al. 2018). 
 
1.8.4 Piezo1 in human disease 
1.8.4.1 Dehydrated hereditary stomatocytosis 
Mutations in the Piezo1 channel have been associated with an autosomal 
dominant hereditary haemolytic anaemia named dehydrated hereditary 
stomatocytosis (DHS), which is also referred to as hereditary xerocytosis 
(Albuisson et al. 2013; Andolfo et al. 2013; Zarychanski et al. 2012); the M2225R 
mutation was one of the first mutations discovered to be responsible for this 
disease (Zarychanski et al. 2012). The group confirmed that 3 members of the 
same family were homozygous for this particular mutation. The mutation caused 
an imbalance in intracellular cation concentrations which led to defective RBC 
membrane properties. Patients suffer from severe haemolytic anaemia with 
reticulocytosis, shortened RBC survival, stomatocytosis, hyperbilirubinemia and 
markedly altered erythrocyte sodium and potassium levels. This was the first 
report of human disease associated with a mutation in a mammalian 
mechanosensory transduction ion channel. Those investigating the properties of 
the mutated channel found that the DHS-associated mutation was a gain-of-
function mutation which caused Piezo1 to exhibit delayed inactivation kinetics i.e. 
the channel remained open for longer, leading to increased Ca2+ influx (Albuisson 
et al. 2013; Bae et al. 2013). 
Ma et al. (2018) engineered a mouse model of DHS and revealed that 
Plasmodium infection failed to cause cerebral malaria in these mice due to the 
action of Piezo1 in RBCs and T cells. The group subsequently found that a novel 
human gain-of-function PIEZO1 allele, E756del, was present in a third of the 
African population. The RBCs of patients were dehydrated and exhibited 
attenuated Plasmodium infection in vitro, suggesting this particular gain-of-






1.8.4.2 Lymphatic dysplasia 
Lymphatic endothelial cells are known to regulate the frequency and strength of 
lymphatic contraction in response to shear stress; intracellular Ca2+ is an 
important factor regulating lymphatic contraction (Jafarnejad et al. 2015). Failure 
of the lymphatic system to effectively drain interstitial fluid back to the blood 
results in lymphoedema. Loss-of-function mutations in Piezo1 have been 
associated with generalised lymphatic dysplasia, an autosomal recessive 
disease (Fotiou et al. 2015; Lukacs et al. 2015). Generalised lymphatic dysplasia 
is a rare form of primary lymphoedema affecting the whole body. High-throughput 
sequencing of a family with congenital lymphatic dysplasia identified 
heterozygosity for a splicing variant and a missense variant in Piezo1 (Lukacs et 
al. 2015). RBCs from affected individuals revealed severely diminished Piezo1 
responses in response to Yoda1 and mechanical stimuli. The authors suggested 
that decreased function of the mutated Piezo1 may be due to reduced channel 
abundance in the plasma membrane. 
 
1.8.4.3 Bicuspid aortic valve  
Piezo1 has also been revealed to participate in cardiac development. It was found 
to be required for outflow tract and aortic valve development in zebrafish 
(Faucherre et al. 2019). Mechanical forces generated during the cardiac cycle 
were found to activate Piezo1 which initiates nitric oxide release in the outflow 
tract. Bicuspid aortic valve is a common congenital heart defect with increased 
prevalence of aortic dilatation and dissection (Giusti et al. 2017). Faucherre et al. 
(2019) followed up their results and investigated a cohort of bicuspid aortic valve 
patients; they found that novel variants of Piezo1 were detected in 3 probands; 
these were subsequently revealed to lead to inhibition of normal Piezo1 
mechanosensory activity. 
 
1.8.5 Piezo1 in the heart 
Messenger RNA expression profiles of Piezo1 in various adult mouse tissues 
revealed its expression in the murine heart, whereas Piezo2 mRNA was barely 
detectable (Coste et al. 2010). Piezo1 has been demonstrated to be upregulated 
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following MI; expression was regulated by the Ang II-AT1 receptor-ERK1/2 
signalling pathway in neonatal rat ventricular myocytes (Liang et al. 2017), 
whereas Piezo1 was shown to be downregulated in a human cardiomyocyte cell 
line subjected to mechanical stretch (Wong et al. 2018). However, there are 
currently no reports on the role of Piezo1 in cardiac fibroblasts. Piezo1 is 
important for converting mechanical signals into changes in cell function, such as 
migration and differentiation (McHugh et al. 2012; Pathak et al. 2014). Mechanical 
stress is a mediator of the differentiation of cardiac fibroblasts into myofibroblasts 
and of cardiac hypertrophy (Wang et al. 2003; Ruwhof and van der Laarse 2000), 
which can both cause cardiac remodelling. It is possible that the 
mechanosensitive ion channel Piezo1 plays a role in transducing mechanical 
stress into cellular changes in cardiac fibroblasts. Unravelling specific roles of 
Piezo1 in cardiac fibroblasts may further our understanding of adverse cardiac 
remodelling and provide the foundation for the development of novel therapeutics 
to help patients suffering from heart failure. 
 
1.9 Summary 
Cardiac fibroblasts execute a wide array of physiological functions and are 
additionally implicated in numerous pathological circumstances, such as cardiac 
hypertrophy and fibrosis. A governing factor affecting fibroblast function during 
disease is mechanical stress. The molecular mechanisms by which cardiac 
fibroblasts sense mechanical stress remain largely elusive but mechanically-
activated ion channels have been suggested to be important. The ability of Yoda1 
to activate the mechanosensitive cation channel, Piezo1, without the need for 
mechanical stimulation has enabled a more practical and targeted approach to 
investigate Piezo1 channel functions. Recent reports of the importance of Piezo1 
in the cardiovascular system and the fact that Piezo1 mutations have been 
implicated in human disease raises further interest regarding this channel in other 
cell types. Increased understanding of Piezo1 channel function may be beneficial 
in the quest to unravel the intricate mechanisms underlying cardiac fibroblast 
signalling in order to develop effective therapies for the treatment of diseases 
involving cardiac remodelling. Interventions targeting this pathologic remodelling 
would inevitably lead to significant advancements in the treatment of heart failure.  
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1.10 Aims and objectives 
Overall aim 
The overall aim of the project was to characterise Piezo1 expression, activity, 
function and downstream signalling pathways in cardiac fibroblasts in vitro and to 
determine the functional relevance of fibroblast Piezo1 in the normal and 
mechanically stressed heart in vivo. 
 
Hypothesis 
Piezo1 is important for detecting mechanical stress in cardiac fibroblasts, and 
activation of Piezo1 affects cardiac fibroblast function. 
 
Objectives 
1. To detect the expression of Piezo1 in murine and human cardiac fibroblasts. 
2. To determine the effect of Yoda1 on intracellular Ca2+ entry levels in cardiac 
fibroblasts expressing endogenous Piezo1. 
3. To use pharmacological tools and genetic methods to modulate Piezo1 
expression in cardiac fibroblasts to examine whether Yoda1-induced Ca2+ entry 
is dependent on Piezo1. 
4. To investigate the effects of Piezo1 activation on gene expression in cardiac 
fibroblasts using chemical and mechanical stimulation. 
5. To characterise the downstream signalling pathways modulated by Piezo1 
activation in cardiac fibroblasts. 
6. To generate and validate a conditional fibroblast-specific Piezo1 KO mouse 
model. 





Chapter 2 Materials and Methods 
2.1 Chemicals and Reagents 















Synthesised by the 
University of Leeds 
11R-VIVIT -20°C, 1 mM 10 μM Merck 
Adenosine triphosphate 
(ATP) 
H2O -20°C, 20 mM 5-20 μM Sigma-Aldrich 
Fura-2 AM DMSO -20°C, 1 mM 2 μM Invitrogen 
Gadolinium H2O r.t., 100 mM 10 μM Sigma-Aldrich 
Recombinant Human 
Interleukin 1α (IL1-α) 













Pluronic acid F-127 r.t., 10% 0.01% 
PD98059 -20°C , 18.7 mM 30 μM Merck 
PP1 -20°C, 10 mM 10 µM Cayman Chemical 
Probenecid NaOH r.t., made fresh 2.5 mM Sigma-Aldrich 








SP600125 Cambridge Bioscience 
Staurosporine (SSP) -20°C, 1 mM 1 μM Sigma-Aldrich 
Transforming growth 
factor (TGF)-β1 
4 mM HCl & 1 
mg/ml BSA in 
PBS 
-20°C, 20 µg/mL 10 ng/mL R&D Systems 
Vascular endothelial 
growth factor (VEGF) 
H2O -20°C, 30 μg/mL 30 ng/mL Sigma-Aldrich 
Yoda1 DMSO -20°C, 10 mM 0.01-10 μM Tocris 
Table 2.1 Table of reagents. List of chemicals and reagents used throughout 






Analogues of Yoda1 used in this study were synthesised by Kevin Cuthbertson 
in the School of Chemistry at The University of Leeds. All synthesised chemicals 
were purified by column chromatography or trituration and determined as >97% 
pure by 1H NMR (proton nuclear magnetic resonance) and 13C NMR (carbon-13 
nuclear magnetic resonance). These were prepared as stock solutions of 10mM 
in dimethyl sulfoxide (DMSO) and used at a final concentration of 0.01-10 µM. 2e 
was utilised as a negative control throughout the study, 2k/Dooku1 as a Yoda1 
antagonist and compound 159 as a potential Piezo1 agonist. The structure of 
Yoda1 and its analogues are displayed in Figure 3.15 and Figure 3.25. The 
screening of Yoda1 analogues was carried out alongside Elizabeth Evans. 
 
Ionic solutions 
Standard Bath Solution (SBS), mM: NaCl 134, KCl 5, MgCl2 1.2, CaCl2 1.5, 
HEPES 10, D-Glucose 8; pH was titrated to 7.4 with NaOH. Ca2+-free SBS was 
prepared by omitting CaCl2 and addition of 0.4 mM EGTA. 
Phosphate Buffered Saline (PBS), mM: KCl 2.68, KH2PO4 1.47, NaCl 136.89 and 
Na2HPO4-7H2O 8.06. 
 
2.2 Cell culture 
2.2.1 Mouse cell isolation and culture 
2.2.1.1 Mouse cardiac fibroblast culture 
Adult C57BL/6J mice were euthanised according to guidelines of The UK Animals 
(Scientific Procedures) Act 1986. Hearts were extracted and digested in 1.5 
mg/mL collagenase solution (Worthington) at 37°C for 90 min, with occasional 
agitation. The supernatant was collected, washed and resuspended in 
Dulbecco’s Modified Eagle’s medium (DMEM) with high glucose, pyruvate, no 
glutamine (#21969035, Invitrogen) supplemented with 10% foetal bovine serum 
(FBS) (Biosera), 1% L-glutamine (Gibco) and 1% penicillin/streptomycin (Sigma-
Aldrich) and plated in a 25 cm3 tissue culture flask for 30 min, which allowed for 




medium was changed. The next day, cells were washed and medium replaced; 
cells were grown until confluence was reached and subsequently passaged. 
Cells were studied at passages 1-2 to minimise phenotypic changes induced by 
prolonged culturing. Cells were kept in serum-free DMEM for 16 h prior to 
treatment in order to collect RNA, lysates and conditioned media. 
 
2.2.1.2 Mouse pulmonary endothelial cell culture 
CD146+ pulmonary endothelial cells (PECs) from WT mice were isolated with 
immunomagnetic microbeads (Miltenyi) and cultured in MV2 medium 
(Promocell), supplemented with 10% FBS and 1% penicillin/streptomycin. Cells 
were studied at passage 1. These cells were obtained by Dr Katy Paradine; RNA 
was extracted and qRT-PCR used to quantify Piezo1 mRNA expression. 
 
2.2.1.3 Mouse cardiomyocyte isolation 
Adult mouse cardiomyocytes (CM) were isolated from ventricles of 8 week old 
WT mice. Hearts were cannulated through the aorta and perfused with perfusion 
buffer (124.5 mM NaCl, 10 mM HEPES, 11.1 mM glucose, 1.2 mM NaH2PO4, 1.2 
mM MgSO4, 4mM KCl, 25 mM Taurine; pH 7.34) containing 10 mM butanedione 
monoxime for 5 min followed by perfusion buffer containing 1 mg/mL type 2 
collagenase, 0.05 mg/mL protease and 12.5 μM CaCl2 for 7-15 min until suitable 
digestion was observed. Ventricles were gently cut in perfusion solution 
containing 10% FBS and 12.5 μM CaCl2 and filtered. This step was repeated in 
perfusion solution containing 5% FBS and 12.5 μM CaCl2 and, finally, perfusion 
solution containing only 12.5 μM CaCl2. The filtrate was pelleted by gravity for 5 
min before resuspension in perfusion buffer containing 0.5 mM CaCl2. This step 
was repeated with increasing concentrations of CaCl2 (1.5 mM, 3.5 mM, 8 mM 
and 18 mM). Finally, the cell pellet was resuspended in 1 ml Trizol. These cells 
were obtained from David Eisner’s group at The University of Manchester by 







2.2.1.4 Cardiac cell fractionation 
Non-myocyte cardiac cell fractions were prepared as described previously 
(Bageghni et al, 2018). Briefly, collagenase-digested mouse heart tissue was 
filtered through a 30 μm MACS smart strainer (Miltenyi) to remove 
cardiomyocytes. Non-myocytes were then separated into two fractions using a 
cardiac fibroblast magnetic antibody cell separation kit, according to the 
manufacturer’s instructions (MACS; Miltenyi). ‘Non-fibroblasts’ (endothelial cells 
and leukocytes which were Pecam1-positive) were collected in fraction 1 and 
‘fibroblasts’ (Col1a1/Col1a2/Ddr2/Pdgfra-positive) were collected in fraction 2, as 
previously characterised (Bageghni et al. 2018). RNA was extracted and qRT-
PCR used to quantify specific cellular markers and Piezo1 mRNA expression in 
the different fractions. 
 
2.2.2 Human cell culture 
2.2.2.1 Human cardiac fibroblasts 
Biopsies of human atrial appendage were obtained from patients undergoing 
elective coronary artery bypass grafting at the Leeds General Infirmary. Biopsies 
from patients were obtained following local ethical committee approval (reference 
01/040) and informed patient consent. Cardiac fibroblasts were harvested, 
cultured and characterised as described previously (Turner et al. 2003). Cells 
were taken from liquid nitrogen storage and maintained in DMEM, supplemented 
with 10% FBS, 1% L-glutamine and 1% penicillin/streptomycin. Experiments 
were performed on human cardiac fibroblasts from passages 2-5. Serum-free 
DMEM was used for 1 h prior to treatments and subsequent collection of RNA, 
lysates and conditioned media. 
 
2.2.2.2 Human saphenous vein endothelial cells (SVECs) 
Samples of undistended saphenous vein were collected from patients undergoing 
coronary artery bypass grafting at the Leeds General Infirmary. Local ethical 
committee approval (reference CA01/040) and informed patient consent were 
obtained. SVECs were isolated as has been described previously (Bauer et al. 




from liquid nitrogen storage and maintained in Endothelial Cell Basal Medium 
(EGM™-2, Lonza), supplemented with 2% FBS and the following growth factors 
supplied as a bullet kit (EGM™-2 SingleQuots™ Kit, Lonza): 10 ng/mL VEGF, 5 
ng/mL human basic fibroblast growth factor, 1 µg/ml hydrocortisone, 50 ng/ml 
gentamicin, 50 ng/ml amphotericin B, 10 µg/ml heparin and 10 µg/ml ascorbic 
acid. Experiments were performed on human SVECs from passages 3-7. 
 
2.2.2.3 Human umbilical vein endothelial cells 
HUVECs from pooled donors were purchased from Lonza and cultured in 
EGM™-2 medium, supplemented as described above for SVECs. Cells were 
utilised at passage 2-3. 
 
2.2.3 HEK-293 cell culture 
All HEK-293 cells were maintained in DMEM supplemented with 10% FBS and 
1% penicillin/streptomycin. Non-transfected HEK T-Rex™-293 cells were used 
as control cells. 
2.2.3.1 HEK-T-REx-hPiezo1 cells 
Cells which overexpress human Piezo1 upon induction with tetracycline were 
created by Dr Baptiste Rode as described in Rode et al. (2017) using HEK T‐
REx™-293 cells (Invitrogen). To induce expression, cells were incubated with 1 
μg/mL tetracycline (Sigma) for 24 h prior to experiments. qRT-PCR and western 
blotting were used to validate the cell line. 
 
2.2.3.2 HEK-T-REx-mPiezo1 cells 
Cells which overexpress mouse Piezo1 were created by Dr Melanie Ludlow. 
pcDNA3_mouse Piezo1_IRES_GFP, a kind gift from Ardem Patapoutian (Coste 
et al. 2010), was used as a template to clone the mouse Piezo1 coding sequence 
into pcDNA4/TO. Overlapping mouse Piezo1 (Fwd: 
GTAACAACTCCGCCCCATTG, Rev: GCTTCTACTCCCTCTCACGTGTC) and 
pcDNA4/TO (Fwd: GACACGTGAGAGGGAGTAGAAGCCGCTGATCAGCCTC-




using Gibson Assembly (New England Biolabs) (Gibson et al. 2009). This 
construct does not contain tetracycline operator sequences. HEK T-REx™-293 
cells were transfected with pcDNA4/TO-mPiezo1 using Lipofectamine 2000 
(Invitrogen) and treated with 200 μg/mL zeocin (InvivoGen) to select for stably 
transfected cells. Individual clones were isolated and analysed for expression 
using intracellular Ca2+ measurements and Yoda1. 
All cells were maintained in a humidified incubator with 5% CO2, 95% air at 37°C. 
Once cells reached 90% confluence, cells were washed with PBS and passaged 
into cell culture flasks or seeded into tissue culture plates using Trypsin-EDTA 
(Gibco), or Detachin (Genlantis) for HUVECs, at 37°C for 5 min. 
 
2.3 Intracellular Ca2+ measurements 
Changes in intracellular Ca2+ (Ca2+i) concentration upon agonist-evoked channel 
activation were measured using Fura-2 (Invitrogen) and the FlexStationII384 
fluorescence plate reader (Molecular Devices). 
2.3.1 Fura-2 acetoxymethyl ester (Fura-2 AM) 
Fura-2 AM is a high affinity, ratiometric intracellular Ca2+ indicator dye which 
permits the measurement of intracellular Ca2+ concentration (Ca2+i). Ratiometric 
dyes allow for the accurate measurement of intracellular Ca2+ concentrations 
whilst minimising the effects of unequal dye loading, unequal cell number and 
leakage, therefore leading to more reproducible results (Grynkiewicz, Poenie and 
Tsien 1985). The acetoxymethyl ester (AM) form is membrane permeable and 
once inside the cell, the AM group is cleaved by non-specific esterases to 
produce the charged and active form (Fura-2) which is able to bind Ca2+ with high 
affinity.  Fura-2 is excited at 340 nm and 380 nm and has an emission wavelength 
of 510 nm; the excitation spectra is shown in Figure 2.1. Once bound to Ca2+, 
there is a spectral shift in Fura-2 absorption which is proportional to the 
intracellular concentration of Ca2+, increasing emission from excitation at 340 nm 
and decreasing emission from excitation at 380 nm. A change in intracellular Ca2+ 
concentration (ΔCa2+i) causes a change in the ratio (ΔF340/380). An increase in 





Figure 2.1 Fluorescence excitation spectra of Fura-2. The fluorescence 
excitation spectra of Fura-2 in various free calcium concentrations. An increase 
in intracellular Ca2+ causes the Fura-2 fluorescence emission intensity at 510 nm 
to increase at excitation wavelength 340 nm and decrease at 380 nm. The two 
excitation wavelengths are indicated on the image. Image adapted from Life 
Technologies. 
 
2.3.2 High throughput Ca2+ measurements using the FlexStation III384 
Intracellular Ca2+ measurements were made using the FlexStationIII384, a bench-
top high-throughput fluorescence plate reader that can be utilised for kinetic 
fluorescence experiments using either a 96 or 384 well-based assay. The 
automated device has 3 drawers which are able to hold the tips, the assay plate 
and the compound plate. A built-in 8-head dispenser is programmed to add 
compounds from the compound plate into the assay plate containing cells. 
SOFTmax PRO 4.7.1 software (Molecular Devices) is able to select the desired 
excitation wavelengths (340 nm and 380 nm), the emission wavelength (510 nm), 
the time course of the experiment and amount of compound addition. 
Experiments were performed at r.t. (21 ± 2°C). 
 
2.3.3 Experimental Protocol 
HEK T-REx™-293 were seeded onto Bio-One™ CELLCOAT™ Poly-D-Lysine 





cells throughout the assay. A seeding density of 50,000 cells per well was used 
for HEK cells. Cardiac fibroblasts and HUVECs were seeded onto clear non-
coated 96 well plates (Corning) at a seeding density of 20,000 and 25,000 cells 
per well, respectively.  All cells were grown to confluence overnight at 37°C in a 
5% CO2 incubator. 
On the day of experimentation, cells were incubated for 1 h at 37°C in 1.5 mM 
Ca2+ SBS containing 2 μM Fura-2 AM and 0.01% pluronic acid. Pluronic acid is 
a mild detergent that has been found to facilitate the solubilisation of water-
insoluble dyes. During all Fura-2 assays involving cardiac fibroblasts, probenecid 
(Sigma-Aldrich) was present throughout all stages of the experiment; this is an 
inhibitor of non-specific plasma membrane anion transport and is used to reduce 
leakage of Fura-2 AM.  It was freshly prepared in 1 M NaOH and diluted to a final 
concentration of 2.5 mM. After 1 h, cells were washed with 1.5 mM Ca2+ SBS and 
incubated for 30 min at r.t. prior to recordings to allow for de-esterification of Fura-
2 AM. During this time, if applicable, inhibitors were added. These steps were 
performed with all solutions and cells protected from light. 
After the wash or pre-incubation stage, the assay plate, compound plate and 
FlexStation tips were loaded into the FlexStation. The FlexStation transferred 
solution from the compound plate into the assay plate wells, at a 1:2 dilution. For 
experiments involving the addition of a compound to the assay plate where there 
was no prior incubation with the compound, the compound was prepared at 2x 
the desired final concentration so that the further 1:2 dilution ensured the 
compound was the desired concentration. For  pre-incubation, the drug was 
added to the compound plate at 1x to maintain its concentration. Baseline 
fluorescence ratios were recorded at 60 seconds; these were subtracted from 
values taken at the peak Ca2+ entry. Recordings were taken every 5 seconds for 
a total of 150 or 300 seconds. ‘Zero baseline’ traces are displayed in figures when 
baseline Ca2+ levels remain consistent.  The DMSO concentration was kept 
constant throughout the experiment (< 0.1%). 
 
2.3.4 Hypotonic assay 
Following loading with Fura-2 AM, cells were kept in SBS for 30 min at r.t. If an 




contained solutions of varying hypotonicity. Na+ was replaced in the SBS with N-
methyl-D-glucamine chloride (NMDG-Cl) (Sigma) to allow us to control the 
osmolarity of the solution. 135 mM NMDG-Cl was used as an isotonic control and 
NMDG-Cl was used at decreasing concentrations (135-55 mM), with solutions 
becoming increasingly hypotonic. More hypotonic solutions induce increasing 
movement of water into the cells by osmosis, causing cell swelling and increased 
membrane tension, this was done in an attempt to activate the Piezo1 channel. 
This assay was developed by Dr Melanie Ludlow. 
 
2.4 Transfection with small interfering RNA (siRNA)  
2.4.1 Murine cardiac fibroblasts 
The knockdown of Piezo1 was conducted using small interfering RNA (siRNA). 
These double stranded sequences of mRNA are complementary to the gene of 
interest (Piezo1). The siRNA transfection results in inhibition of mRNA which 
therefore reduces the expression of the target protein. Murine cardiac fibroblasts 
were grown to 80% confluence. A final concentration of 10 nM Piezo1-specific 
Silencer Select Pre-Designed siRNA (#4390771, siRNA ID: s107968, Ambion, 
Life Technologies) or Silencer Select Negative Control No. 1 siRNA (#4390843, 
Ambion, Life Technologies) was added to 250 μL OptiMEM (Gibco) with 7.5 μL 
Lipofectamine RNAiMAX Reagent (Life Technologies) in OptiMEM (Gibco), as 
per the manufacturer’s instructions. This was incubated at r.t. for 20 min and then 
added to one well of a 6-well plate holding 2.25 mL 0.4 % FBS-containing DMEM 
(without antibiotics). Medium was replaced with full-growth DMEM 24 h later and 
cells were used for experimentation after 48-72 h. The negative control was a 
non-targeting siRNA control with no significant homology to sequences in the 
human genome and was transfected into adjacent wells. During optimisation of 
murine Piezo1-specific siRNAs, cells were also transfected with 10 or 20 nM 
Piezo1-specific Smartpool siRNA (#L-061455-00-0005, Dharmacon) or negative 
control siRNA (#D-001810-10-05, Dharamcon), using 1.35% Lipofectamine 2000 
in OptiMEM. However, siRNAs from Ambion were used throughout 
experimentation. Sequences of control and Piezo1-specific siRNAs can be found 





2.4.2 Human cardiac fibroblasts 
Human cardiac fibroblasts were grown to 90% confluence. 20 nM Piezo1-specific 
Silencer Select Pre-designed siRNA (#4392422, siRNA ID: s18891, Ambion) or 
ON-TARGETplus Non-targeting Pool siRNA (#001810, Dharmacon) was added 
to 200 μL Opti-MEM (Gibco) with 3 μL Lipofectamine 2000. This was incubated 
at r.t. for 20 min and then added to one well of a 6-well plate holding 800 μL 0.4% 
FBS-containing DMEM media (without antibiotics). Fresh full-growth DMEM 
media was added after 4.5 h and cells were used for experimentation 48-72 h 
after transfection. 20 nM Piezo2-specific Smartpool siRNA (Dharmacon cat. #L-
013925-02-005) was also employed, alongside the control siRNA stated above, 
using the same protocol. Sequences of control and Piezo1/Piezo2-specific 
siRNAs can be found in Table 2.2. 
 
Gene Species Control sequence 
(5’ to 3’) 
Specific sequence 





























Table 2.2 Sequences of control and siRNAs specific for Piezo1 and Piezo2. 
Small interfering RNAs with 4 sequences are Dharmacon ON-TARGET plus 





2.5 RNA isolation, cDNA preparation and real time quantitative 
polymerase chain reaction (RT-qPCR)  
2.5.1 RNA isolation from cultured cells 
To collect RNA from a fully confluent 6 well plate, media was removed, cells were 
washed with 1 mL PBS, applied with 250 µL trypsin and incubated for 5 min. It 
was confirmed that cells were detached and then 3 mL ice-cold PBS was applied 
to cells and transferred into a 15 mL falcon tube. This step was repeated and the 
falcon tube was centrifuged at 600 g for 6 min. The supernatant was discarded 
and the falcon tube was left upside down to air-dry. Pellets were stored at -80°C 
until RNA isolation. 
All subsequent steps were performed in a designated RNA preparation area 
using dedicated pipettes, sterile filter tips and autoclaved plastics. RNA was 
isolated using the Aurum™ Total RNA Mini Kit (Bio-Rad), according to the 
manufacturer’s instructions. Briefly, this involved utilising a stringent reagent 
composed of guanidine isothiocyanate and β-mercaptoethanol for efficient 
sample lysis, followed by purification on silica membrane in a spin-column format. 
A DNase digestion stage was used to remove any contaminating genomic DNA. 
At the final stage, RNA was eluted in 80 µL (6 well plate) or 60 µL (12 well plate) 
elution solution. RNA was quantified using the Nanodrop (ThermoScientific); 
RNA concentrations obtained were in the range of 20-100 ng/µl. The ratio of 
absorbance at 260 nm and 280 nm was used to assess RNA purity and a ratio of 
~2.0 was generally accepted as pure; lower values indicate the presence of 
proteins that absorb strongly at or near 280 nm. The ratio at 260/230 was used 
as a secondary measure of nucleic acid purity; expected values were 2.0-2.2. 
Lower ratios indicated the presence of organic contaminants, such as phenol, 
which absorb at 230 nm. RNA was stored at -80°C until RT-PCR was carried out. 
 
2.5.2 RNA isolation from whole heart tissue 
RNA was isolated from whole heart using a phase-separation technique. The 
apex of the heart was lysed using 1 mL ice-cold TriZol (Sigma) in a 2 mL tube, 
with a 5mm stainless steel bead present (Qiagen). This was then homogenised 




performed 4 times to ensure thorough tissue lysing. The solution was transferred 
to a sterile 1.5 mL Eppendorf tube and 200 μL phenol-chloroform (Sigma-Aldrich) 
was added. The solution was shaken vigorously for 15 seconds and subsequently 
left for 2 min at r.t. before undergoing centrifugation (12,000g, 15 min, 4°C) to 
separate the phases – RNA in the superior aqueous layer, DNA at the interface 
and protein in the inferior organic phase. The RNA-containing phase was 
transferred to a new Eppendorf and RNA was precipitated with an equal volume 
of ice-cold isopropanol, inverted and incubated at r.t. for 10 min. The sample was 
then centrifuged (12,000g, 15 min, 4°C) to pellet the RNA, followed by a wash 
step with 75% ethanol. The sample was vortexed to wash the pellet, left for 5 min 
and then spun (12,000g, 5 min, 4°C). The pellet was resuspended in 75% ethanol 
once more and spun down a final time (12,000g, 5 min, 4°C). Ethanol was 
carefully removed and the pellet was air-dried for 5 min at r.t. RNA was dissolved 
in 30 µL nuclease-free water on ice and stored at -80°C. 
 
2.5.3 qRT-PCR using TaqMan Gene Expression Assays 
2.5.3.1 Reverse transcription  
The reverse transcription stage is used to convert mRNA to cDNA prior to real-
time PCR. 5 µL RNA was incubated at 70°C for 10 min and then left to cool on 
ice. cDNA was synthesised using the Reverse Transcription System (Promega) 
based on the manufacturer’s instructions. Based on a total of 20 µL reaction mix, 
2 µL RNA was added to a tube containing: 4 µL MgCl2 (25 mM),  2 µL 10x reverse 
transcriptase buffer,  2 µL dNTP (10 mM), 1 µL random primers, 0.5 µL RNasin, 
0.6 µL AMV reverse transcriptase and made up with 7.9 µL nuclease-free water. 
The solutions were mixed and centrifuged and cDNA was synthesised at 25°C 
for 10 min, 42°C for 15 min and then incubated at 95°C for 5 min to terminate the 
reaction in a T100™ Thermal Cycler (Bio-Rad). The cDNA was then used for 







2.5.3.2 Quantitative reverse transcription polymerase chain reaction (qRT-
PCR) 
PCR relies on rounds of DNA synthesis (cycles) via the action of DNA polymerase 
and is used to exponentially amplify specific regions of DNA. A positive reaction 
in qRT-PCR is detected by a fluorescent signal. The Ct (cycle threshold) is the 
intersection between an amplification curve and a threshold line (this was set at 
0.2) (Figure 2.2). This number of cycles is a relative measure of the concentration 
of target in the PCR reaction. Ct levels are inversely proportional to the amount 
of target in the sample, e.g. the lower the Ct value, the larger the amount of target 
nucleic acid in the sample. 
A master mix was made ensuring a solution containing 10 µL Taqman Universal 
PCR Master Mix and 0.5 µL Taqman primer/probe sets (both Applied Biosytems), 
made up to 18 µL with nuclease-free water, could be added into each well of a 
96-well semi-skirted with raised rim PCR plate (Starlab). After cDNA preparation, 
2 µL of sample was added into each well containing Taqman Universal PCR 
Master Mix with primer/probe set. Subsequently, the plate was spun to ensure 
solution was collected at the bottom of the well.  
qRT-PCR was performed in duplicate using an Applied Biosystems™ 7500 PCR 
System. DNA was amplified for 2 min at 50°C, 10 min at 95°C, followed by 50 
amplification cycles (15 seconds at 95°C and 60 seconds at 60°C). Mouse and 
human primers utilised are shown in Table 2.3 and Table 2.4, respectively. The 
expression of the target in a sample is compared to that of a housekeeping gene, 
typically a constitutive gene which is uniformly expressed with low variance under 
both control and experimental conditions. Data are expressed as a percentage of 
housekeeping gene mRNA expression: mouse Gapdh (Mm99999915_g1) or 
human GAPDH (Hs99999905_m1), using the formula 2−ΔCt x 100. When multiple 
housekeeping genes were utilised, the geometrical average of the reference 
gene Ct values were calculated (Vandesompele et al. 2002). Data were analysed 






Figure 2.2 qRT-PCR amplification curve. An illustration of an amplification 
curve of a qRT-PCR reaction. The first few cycles represent the initiation phase, 
where the number of amplicons present is too low to produce a fluorescent signal. 
As the amount of fluorescence increases, the threshold line is exceeded; the 
number of cycles at this point is known as the cycle threshold (Ct). Image taken 

















Protein Primer code 
Acta2 Alpha-smooth muscle actin Mm00725412_s1 
Actb Beta-actin Mm00607939_s1 
Col1a1 Collagen 1 Mm01302043_g1 
Col3a1 Collagen 3 Mm01254476_m1 
Ddr2 Discoidin domain-containing receptor 2 Mm00445615_m1 
Fam38a Piezo1 Mm01241545_g1 
Gapdh Glyceraldehyde 3-phosphate dehydrogenase Mm99999915_g1 
Hprt Hypoxanthine guanine phosphoribosyltransferase Mm03024075_m1 
Il1β Interleukin-1β Mm00434228_m1 
Il6 Interleukin-6 Mm00446190_m1 
Mmp3 Matrix metalloproteinase 3 Mm00440295_m1 
Mmp9 Matrix metalloproteinase 9 Mm00442991_m1 
Myh6 Alpha myosin heavy chain Mm00440354_m1 
Myh7 Beta myosin heavy chain Mm01319006_g1 
Nppa Atrial natriuretic factor Mm01255747_g1 
Pdgfra Platelet Derived Growth Factor Receptor Alpha Mm00440701_m1 
Pecam-1 Platelet And Endothelial Cell Adhesion Molecule 1 Mm01242584_m1 
Postn Periostin Mm01284919_m1 
Tgf-β1 Transforming growth factor beta1 Mm01178820_m1 
Tnc Tenascin-C Mm00495662_m1 
Table 2.3 Mouse primers used for qRT-PCR using Taqman primers. Table 
includes the catalogue numbers for mouse primers used to amplify genes of 
interest in qRT-PCR experiments; all are supplied by Applied Biosystems 











Protein Primer code 
FAM38A Piezo1 Hs00207230_m1 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase Hs99999905_m1 
IL6 Interleukin-6 Hs00174131_m1 
TNC Tenascin-C Hs01115665_m1 
Table 2.4 Human primers used for qRT-PCR using Taqman primers. Table 
includes the catalogue numbers for human primers used to amplify genes of 
interest in qRT-PCR experiments; all are supplied by Applied Biosystems. 
 
2.5.4 qRT-PCR using SYBR™ Green 
2.5.4.1 Reverse transcription 
Reverse transcription of mRNA was performed using Superscript™ III Reverse 
Transcriptase (Invitrogen). Complementary DNA (cDNA) was synthesised by 
mixing 300 ng of RNA with 2 µL random primers (Promega), made up with 
nuclease-free water; this was heated for 7 min at 75ºC. Subsequently, the 
following were added to each sample: 4 μL 5x RT buffer, 0.5 μL M-MLV 
transcriptase, 1 µL dNTP, 0.5 µL RNase OUT™, 0.2 µL DTT (all Invitrogen) and 
nuclease-free water. Non-reverse transcribed (-RT) control solutions were 
prepared and tested in parallel. The solutions were mixed, centrifuged and 
incubated for 10 min at r.t., 1 h at 37°C followed by 5 min at 95°C. Complementary 
DNA was then used for qRT-PCR. 
 
2.5.4.2 Quantitative reverse transcription polymerase chain reaction (qRT-
PCR) 
qRT-PCR was carried out using SYBR Green I (Bio-Rad) on a LightCycler 
(Roche). SYBR Green I binds to double stranded DNA and fluoresces when 
excited at 470 nm. The emission of light at 530 nm is significantly enhanced in 
the DNA bound, compared to the unbound, state. Each reaction contained the 
following: 5 μL of iTaq™ Universal SYBR® Green Supermix (containing antibody-




enhancers and stabilizers), 0.75 μL of both forward and reverse primers (2 μM) 
and 2.5 μL nuclease-free water. This was made as a master mix and 9 μL was 
added into each well of a 96-well plate, before the addition of 1 μL cDNA. The 
plate was spun to ensure solution was collected at the bottom of the well. Primer 
sequences are displayed in Table 2.5. Reactions were run with a standard 2-step 
cycling program, 95 °C for 10 s and 60 °C for 40 s, for 40 cycles. The relative 
abundance of target genes amplified by RT-PCR were calculated relative to a 
housekeeping gene (β-ACTIN/GAPDH) using the 2−ΔCt analysis method. Primer 
efficiencies were also tested; the efficiencies of primers for Piezo1 and Piezo2 
are shown in Figure 3.4 as an example. Efficiencies were calculated by 
performing a serial dilution of RNA and calculating Ct values. Ct values were 
plotted and efficiencies calculated using the slope of the line. Piezo1 and Piezo2 
primer efficiencies were 97 % and 83 %, respectively. As these were both over 
80 %, they were judged to be accurate enough to be used for analysis. However, 
due to a 14 % difference in efficiency between the two primer sets, mean data of 
Piezo1 and Piezo2 mRNA expression relative to housekeeper were adjusted to 

















Gene of interest Primer sequence (5’ to 3’) 
Human β-ACTIN Fwd: TCGAGCAAGAGATGGC 
Rv: CATCCAACGAAACTACCTTCA 
Human BLK Fwd: CTCTCAGGCTGGTCAGGAAA 
Rv: CAGAGCCTTCATCACGTTGG 
Human FGR Fwd: TGGCTTCCTTGATAGTGGCA 
Rv: CTGGGAATGCAGCCAGTTTT 
Human GAPDH Fwd: AGATCATCAGCAATGCCTCC 
Rv: CATGAGTCCTCCCACGATAC 
Human FAM38A Fwd: AGATCTCGCACTCCAT 
Rv: CTCCTTCTCACGAGTCC 
Human FAM38B Fwd: ATGGCCTCAGAAGTGGTGTG 
Rv: ATGTCCTTGCATCGTCGTTTT 
Human FYN Fwd: TCACCAAAGGAAGAGTGCCA 
Rv: CAAAAGTGGGGCGTTCTTCA 
Mouse Gapdh Fwd: AGGTCGGTGTGAACGGATTTG 
Rv: TGTAGACCATGTAGTTGAGGTCA 
Human HCK Fwd: CCACAGAGAGCCAGTACCAA 
Rv: TTCCAGTCCAACCTACCCAC 
Human LCK Fwd: CAACCTGGTTATCGCTCTGC 
Rv: TGGCCACAAAATTGAAGGGG 
Human LYN Fwd: CCACTATAGCTGGGAGGGTG 
Rv: GGCAAGAGAAGGCGGTATTG 
Mouse Fam38A Fwd: AGGACTTCCCCACCTATTGG 
Rv: CCAGGGATGAGGATACTGGAAAA 
Mouse Fam38B Fwd: ATGTGCGTTCCGGTACAATGG 
Rv: TGTGTCCTTGCATCGTTGCT 
Human SRC Fwd: AAACCCTGCCCTCCTTAGAC 
Rv: TCCTGAGGATGACAGAGGGA 
Human YES Fwd: GCTGGTTGATATGGCTGCTC 
Rv: CGACCATACAGTGCAGCTTC 
Table 2.5 Primers used for qRT-PCR using SYBR™ Green. Table includes the 
sequences for forward and reverse primers (Sigma-Aldrich) used to amplify 
genes of interest in qRT-PCR experiments. 
 
2.5.4.3 Agarose gel electrophoresis 
PCR products were loaded onto a 1 % agarose gel containing SYBR™ Safe DNA 
Gel Stain (1:10,000) (Invitrogen), which binds DNA and allows visualisation of 




to confirm product size. Agarose gels were prepared by boiling 1 g molecular 
biology grade agarose (Eurogentec) in 100 mL Tris-acetate-EDTA (TAE) buffer 
(Fisher Scientific). PCR reaction solutions were mixed with 6 x loading buffer 
containing the following: 2.5% Ficoll-400, 11 mM EDTA, 3.3 mM Tris-HCl (pH 
8.0), 0.017% SDS and 0.015% bromophenol blue (New England Biolabs) and 
loaded on to the gel. The size of the product was compared to 100 bp DNA Ladder 
(New England Biolabs). Human brain RNA was purchased from Ambion (ref: 
AM7962) as a positive control. Electrophoresis was performed at a constant 
voltage of 85 V for 50 min. DNA was visualised by illumination using Syngene’s 
G:BOX Chemi XT4 and GeneSys image acquisition software. 
 
2.6 Western blotting 
2.6.1 Solutions 
Lysis buffer, used to lyse cells and make up samples to the required volume 
10 mM Tris, pH 7.4, 150 mM NaCl, 0.5 mM EDTA, 0.5% NP-40. Minutes 
iComplete protease inhibitors (Roche 1:500) and PhosSTOP phosphatase 
inhibitors (Roche 1:500) were added prior to lysing. 
Sample (loading) buffer (4x), used to dilute samples prior to loading on the gel 
200 mM Tris pH 6.8, 8% SDS, 40% glycerol, 8% mercaptoethanol, 0.1% 
bromophenol blue. 
Separating gel buffer, used to prepare separating gel 
45.42 g Tris-base in 250 mL of distilled water, pH 8.8. 
Stacking gel buffer, used to prepare stacking gel 
6 g Tris-base in 100 mL of distilled water, pH 6.8. 
Running (electrophoresis) buffer, used to run the samples 
190 mM glycine, 25 mM Tris-base, 1% SDS. 
Transfer buffer, used for the transfer stage 
190 mM glycine, 25 mM Tris-base, 20% methanol. 




150 mM NaCl, 20 mM Tris-base, pH 7.4. 
Tris-buffered saline-Tween (TBS-T), used to make 5 % milk which antibodies 
were diluted in and also used to wash membranes following incubation with 
antibodies 
150 mM NaCl, 20 mM Tris-base, 0.1% Tween-20, pH 7.4. 
 
2.6.2 Cell treatment and lysis 
Cells were grown to confluence in a 6 well plate; prior to treatment, cells were 
serum-starved overnight to dampen basal activation/phosphorylation of signalling 
proteins. Pretreatment of cells with inhibitors was carried out prior to treatment 
with an agonist where appropriate. Cells were treated with vehicle (DMSO) or 
compound in serum-free medium, at the appropriate time-points prior to lysing. 
Medium was removed and cells were immediately washed with 1 mL ice-cold 
PBS to halt all phosphorylation/dephosphorylation events. Cells were put on ice 
and PBS was removed and replaced with 65 µL ice-cold lysis buffer per well for 
5 min. Cells were harvested using a cell scraper and samples were kept on ice 
for 30 min. Samples were spun for 10 min at 14,000 g at 4ºC and supernatant 
was taken into a new Eppendorf tube to remove unsolubilised cell debris. 
 
2.6.3 Protein quantification 
Protein quantification was performed on the supernatant using DC™ Protein 
Assay (BioRad). This is a dye-binding assay in which a differential colour change 
occurs which indicates protein concentration. Absorbance was measured using 
a plate reader at a wavelength of 750 nm. Comparison was made to a BSA 
standard curve (0-1333.3 µg/mL) and protein concentrations were derived from 








2.6.4 Preparation of gels 
 Separating gel Stacking gel 
Distilled H2O 4.3 mL 2.81 mL 
Ultra Pure ProtoGel® 30% acrylamide (National 
Diagnostics) 
3 mL 0.83 mL 
Separating/stacking gel buffer 2.5 mL 1.25 mL 
10% sodium dodecyl sulphate (SDS) 
(VWR™) 
100 μL 50 μL 
10% ammonium persulphate (APS) 
(Sigma-Aldrich) 
100 μL 50 μL 
N,N,N′,N′-Tetramethylethylenediamine (Temed) 
(Sigma-Aldrich) 
4 μL 5 μL 
Table 2.6 Recipe for polyacrylamide gels. Quantities needed for producing two 
10% SDS polyacrylamide gels. 
 
2.6.5 Western blotting 
10-30 μg of protein sample (depending on protein being analysed) was mixed 
with one-quarter volume of SDS-reducing sample buffer and heated at 90°C for 
5 min to ensure complete denaturation of the proteins. Samples were loaded 
alongside 4 μL Precision Plus Protein™ Dual Colour ladder (Bio-Rad) or 10 µL 
HiMark™ Pre-Stained High Molecular Weight Protein Standard (Invitrogen), 
depending on the size of the protein of interest. Separation occurred on either 7.5 
or 10% gels, depending on the size of the target protein. Electrophoresis was 
carried out for approximately 90 min at a constant current of 20 mA per gel in 
SDS-containing running buffer using PowerPac Basic™ (Bio-Rad). SDS is an 
anionic detergent which disrupts the secondary structures of proteins to create 
linear, negatively charged structures. An electrical charge across the gel leads to 
movement of negatively charged proteins towards the positively charged 
electrode. The distance each protein travels is inversely proportional to its size 
and molecular weight. 
Polyvinylidene fluoride (PVDF) membrane (Immobilon-P, Merck) was soaked in 




membrane were soaked in transfer buffer for approximately 10 min. After 
resolution by electrophoresis, protein samples were transferred to the PVDF 
membrane using Bio-Rad wet transfer system at a constant current of 350 mA 
for 2 h in transfer buffer. After completion of the transfer, the membrane was 
rinsed once for 5 min in Tris-buffered saline (TBS) and incubated for 1 h in TBS 
containing Tween (TBS-T) containing 5% non-fat dried milk to block non-specific 
background binding. Membranes were then labelled overnight with primary 
antibodies diluted in TBS-T containing 5% milk and placed on a roller at 4°C. 
Table 2.7 contains a list of primary antibodies and dilutions used. The next 
morning, after 6 x 5 min washes in TBS-T on a rocker, the membrane was 
incubated with secondary horseradish-peroxidase (HRP) donkey anti-mouse, 
rabbit or rat secondary antibodies (1:5000/10000, Jackson ImmunoResearch) in 
TBS-T containing 5% milk for 1 h at r.t. on a roller, before another 6 x 5 min 
washes with TBS-T on a rocker. Membranes were probed with phosphorylation 
antibodies and then reprobed with total expression antibodies from different 
species. In the case of phospho-ERK, blots were placed in stripping buffer 
(Thermo-Scientific) for 15 min, washed and blocked in 5% milk after probing for 
p-ERK before probing for total ERK. This was necessary due to prior phospho-
ERK antibody binding impairing total ERK antibody binding. 
 
2.6.6 Protein visualisation 
SuperSignal Femto detection reagents (Pierce Science) were used to detect 
immunolabelled protein bands. Membranes were imaged using Syngene’s 
G:BOX Chemi XT4 and GeneSys image acquisition software. Data were 
analysed using Image J software (NIH) by calculating the mean intensity of each 









Protein Antibody Dilution Vendor 










phospho-p38α MAPK (Thr180Tyr182) (3D7) Rabbit mAb 1:250 Cell Signalling 
Technology #9215 




phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) (E10) Mouse 
mAb 
1:5000 Cell Signalling 
Technology #9106 
p44/42 MAPK (Erk1/2) p44/42 MAPK (Erk1/2) (137F5) 
Rabbit mAb 
1:4000 Cell Signalling 
Technology #4695 
TNC (EGF Like Domain) (4F10TT) 
Mouse mAb 
1:200 Tecan #JP10337 
Table 2.7 Primary antibodies used for Western Blotting. Summary of primary 
antibodies used along with their dilution factor, vendor and catalogue number, 
mAb: monoclonal antibody. 
 
2.7 Mechanical stimuli experiments 
2.7.1 Patch clamp electrophysiology 
Human cardiac fibroblasts were seeded and grown to 80% confluence on glass 
coverslips (Thermo Scientific, thickness 0.15 mm) in 24 well plates. Cells were 
transfected with control or Piezo1-specific siRNA, where applicable. After 72 h of 
transfection, ionic currents were recorded through cell-attached patches using 
standard patch-clamp technique in voltage-clamp mode. Patch pipettes had 
resistance of 4–6 MΩ when filled with pipette solution. Ionic solution of 
composition (mM): CsCl 145, MgCl2 2, HEPES 10, ATP 5, GTP 0.1, EGTA 1 
(titrated to pH 7.2 using CsOH) was used in the pipette. The bath solution was 




patch pipette). 200 ms pressure steps were applied to the patch pipette with an 
interval of 10 s using High Speed Pressure Clamp HSPC-1 System (ALA 
Scientific Instruments, USA). All recordings were made with an Axopatch-200B 
amplifier (Axon Instruments, Inc., USA) equipped with Digidata 1550B and 
pClamp 10.6 software (Molecular Devices, USA) at room temperature. Currents 
were filtered at 2 kHz and digitally sampled at 20 kHz. Data were analysed using 
pClamp 10.6, MicroCal Origin 2018 (OriginLab Corporation, USA) software 
package. Patch clamp experiments were performed by Katsuhiko Muraki. 
 
2.7.2 Application of shear stress 
To generate shear stress, fibroblasts were plated in a 6-well plate, grown to 
confluence and placed on an orbital shaker (SSM1, Stuart) rotating at 153 rpm 
with an orbit of 16 mm for 24 h. Cells were cultured in 2 mL of media; meaning 
shear stress at the edge of the wells was ~10 dyn/cm2 (Dardik et al. 2005). RNA 
was extracted from cells and used for RT-PCR. 
 
2.7.3 Mechanical stretch 
Human cardiac fibroblasts were seeded at 1x105 cells/well on collagen-coated 
silicon membranes (BioFlex® 6-well culture plates, Dunn Labortechnik, 
Germany). 72 h after transfection, cells were stretched in serum-free medium 
using an FX-4000 or FX-5000 Flexercell® Tension™ System (Flexcell 
International) to equibiaxially elongate the cell-seeded elastic membrane against 
a cylindrical loading post using a vacuum (Figure 2.3). These experiments were 
performed at either The University of Maastricht (Dr Frans van Nieuwenhoven’s 
laboratory) or The University of Manchester (Dr Joe Swift’s laboratory). This 
apparatus has been used previously to stretch cardiac fibroblasts (Fu et al., 
2016). Elongation of 10% in surface area at 1 Hz was applied to the cells for 6 or 
24 h. A 6-well stretching plate was housed inside the incubator (37°C, 5% CO2) 
alongside unstimulated cells adhered to Bioflex® plates which served as controls. 
RNA was extracted and RT-PCR was used to quantify gene expression or lysates 






Figure 2.3 Mechanism utilised for stretching cardiac fibroblasts. Mechanism 
of the Flexercell® Tension™ System (Flexcell International) which equibiaxially 
elongates the elastic membrane against a cylindrical loading post using a vacuum 
in order to stretch cells. Image taken from Flexcell® International Corporation. 
 
2.7.4 Substrate stiffness experiments 
ExCellness® PrimeCoat 35 mm dishes and 24-well plates were used to assess 
the impact of substrate stiffness on gene expression. Dishes and plates were 
coated with fibronectin in serum-free media (10 µg/mL) and kept at 37⁰C for at 
least 1 h prior to plating of cells. Murine cardiac fibroblasts were isolated and 
plated in one well of a 6-well plate. When confluent, these cells were seeded into 
a 24-well plate. The following day, cells were transfected with control and Piezo1-
specific siRNA and left for 48 h. At this point, cells transfected with both control 
and Piezo1-specific siRNA were seeded into wells of three 24-well plates: one of 
10 kPa stiffness, one of 30 kPa stiffness and a tissue culture plate and left to grow 
for 24 h. After 24 h, RNA was collected to perform RT-PCR to measure gene 
expression. 
These levels of stiffness were chosen as a study using atomic force microscopy 
to evaluate the elastic modulus of healthy and ischemic tissue in a rat heart found 
that the elastic modulus of healthy heart tissue was in the range of 10-15 kPa, 
while the respective value of ischemic tissue was around 50 kPa (Berry et al. 





Murine cardiac fibroblasts were seeded and grown to 80% confluence on glass 
coverslips (Thermo Scientific, thickness 0.15 mm) in 24 well plates. Cells were 
treated for 24 h with vehicle or 10 µM Yoda1 in the presence or absence of TGF-
β1 (10 ng/ml), where applicable. Cells were washed in PBS, fixed in 4% 
paraformaldehyde (PFA) for 10 min at r.t. and washed with Tris-saline to quench 
PFA. Cells were permeabilised with 0.1% Triton™ X-100 (Sigma-Aldrich) in PBS 
for 10 min, before blocking with 1% BSA in PBS for 30 min to prevent non-specific 
antibody binding. Primary antibodies were diluted in 1% BSA in PBS solution and 
incubated with cells for 60 min at r.t. Cells were stained for vimentin (C-20, #sc-
7557, Santa Cruz Biotechnology), α-SMA (clone 1A4, #A2547, Sigma-Aldrich) or 
CD-31 (#ab28364, Abcam). Primary antibodies were used at 1:100 (vimentin and 
α-SMA) or 1:50 (CD-31). After washing with PBS, cells were incubated with the 
relevant species-specific fluorescent dye-conjugated secondary antibodies 
(Jackson ImmunoResearch) in the dark for 30 min at r.t. Secondary antibodies 
were used at 1:300 in 1% BSA solution. Following this, coverslips were mounted 
onto glass slides using Prolong Gold Antifade Reagent (Invitrogen) containing 
DAPI (4',6-diamidino-2-phenylindole) to label the nuclei. Slides were kept at r.t. 
overnight to allow mounting media to set and imaged using a LSM 880 confocal 
microscope (Zeiss). 
 
2.9 LIVE/DEAD cell viability assay 
The LIVE/DEAD™ Viability/Cytotoxicity Kit (ThermoFisher Scientific) enables 
dual colour discrimination of a population of live cells from a dead cell population, 
based on plasma membrane integrity and esterase activity. Live cells are 
determined by the presence of intracellular esterase activity, determined by the 
enzymatic conversion of the non-fluorescent, cell-permeant calcein-AM to the 
fluorescent calcein. Calcein is retained within live cells, producing a uniform green 
fluorescence (excitation/emission ~495 nm/~515 nm).  Ethidium homodimer 
enters cells with compromised cell membranes and displays an increase in 
fluorescence upon binding nucleic acids, producing a red fluorescence in dead 
cells (excitation/emission ~495 nm/~635 nm). Ethidium homodimer however 




Murine cardiac fibroblasts were plated in 12 well plates (Corning) at 80% 
confluency and incubated overnight (37°C, 5% CO2). Vehicle (DMSO), Yoda1 (10 
µM) or Staurosporine (SSP; 1 μM) were applied the following day and cells were 
incubated for an additional 24 h prior to commencing the assay. SSP isolated 
from Streptomyces sp. (Sigma-Aldrich), a non-specific protein kinase inhibitor, 
was utilised as a positive control to induce cell death (Bombeli et al. 1997). A 
working solution was prepared containing 2 µM calcein AM and 4 µM ethidium 
homodimer in 10 mL sterile PBS; 500 µL was applied to each well following 
removal of media and PBS wash. Cells were left for 30 min at r.t., protected from 
light. Cells were imaged using the IncuCyte® ZOOM Live Imaging System (Essen 
Bioscience, Michigan). The total number of fluorescent cells in each well was 
calculated using inbuilt algorithms, using an average from 9 images per well. The 




Conditioned media were collected after treatment with stimuli, centrifuged to 
remove cellular debris and stored at -20 °C for analysis. Supernatants were 
thawed and enzyme linked immuno-sorbent assay (ELISA) performed to 
determine the levels of IL-6. Commercially available ELISA kits were utilised. The 
concentration of mouse IL-6 in medium was measured using Mouse IL-6 
Quantikine ELISA Kit (M6000, R & D Systems), according to the manufacturer's 
instructions. The concentration of human IL-6 in medium was measured using 
Human IL-6 DuoSet ELISA (DY206-05, R & D Systems) which was used 
alongside DuoSet ELISA Ancillary Reagent Kit 2 (DY008, R & D Systems), 
according to the manufacturer's instructions.  
Briefly, a 96-well plate was coated overnight at r.t. with IL-6 capture antibody in 
coating buffer. The following day, wells were blocked with BSA in PBS for 1 h at 
r.t. and then washed (these stages were only necessary for the Human IL-6 
DuoSet ELISA). Conditioned media and IL-6 standards were added to the plate 
for 2 h at r.t; samples were diluted 1:5-1:30 depending on the experiment. This 
was followed by a wash stage and addition of IL-6 detection antibody for 2 h at 




substrate solution (equal volume of H2O2 and Tetramethylbenzidine) for 20 min, 
both stages were performed in the dark. The reaction was terminated using stop 
solution (2N H2SO4) and the plate was gently tapped to mix the colour before 
absorbances were read at 450 nm; readings at 570 nm were subtracted to correct 
for optical imperfections in the plate. 
 
2.11 Collagen gel contraction assay 
The collagen gel contraction assay was performed as described previously in 24-
well plates (Van Nieuwenhoven et al., 2013). Wells were coated with 1% bovine 
serum albumin (Sigma) in PBS at 37 °C for 1 h. Collagen gels were prepared by 
mixing type I rat tail collagen solution (Merck) with 2 x concentrated DMEM 
(Merck), supplemented with 88 mM NaHCO3, and then immediately mixing with 
50,000 freshly trypsinised murine cardiac fibroblasts per gel. Gels were allowed 
to solidify at 37 °C for 1 h. Following solidification, gels were released from the 
sides of the well by addition of 0.5 mL DMEM with 0.4 % FBS containing either 
vehicle, Yoda1, compound 159 (both 10 µM) or 10 ng/ml TGF-β1. In RNA 
interference experiments, murine cardiac fibroblasts were transfected using 
control or Piezo1-specific siRNA 48 h prior to the commencement of the gel 
contraction assay. When PD98059 was tested, either vehicle or 30 µM PD98059 
were applied in DMEM after 1 h of solidification, then Yoda1 or vehicle was added 
after another 1 h. Gels were photographed and weighed 24 h later to assess their 
relative contraction. Collagen gel area was calculated using ImageJ and 
displayed as gel area relative to the total area of the well. 
 
2.12 Multiplex kinase activity profiling 
PamGene Serine-Threonine Kinase (STK) and Tyrosine Kinase (PTK) multiplex 
activity assays were used to investigate STK and PTK activity, respectively. 
Confluent murine cardiac fibroblasts (n=6) in a 6-well plate were treated for 10 
min with vehicle (DMSO) or Yoda1. Cells were washed with ice-cold PBS and 
lysed by addition of 100 µL M-PER mammalian extraction buffer (Thermo Fisher 
Scientific), containing 1:100 Halt phosphatase and Halt protease inhibitor 




for 10 min at 14,000 g at 4°C and protein concentrations were determined using 
the DC™ Protein Assay (BioRad). Aliquots were prepared and snap-frozen in 
liquid nitrogen. 
6 and 1.2 μg of protein was loaded onto each PamChip (shown in Figure 2.4) for 
the Protein Tyrosine Kinase (PTK) array protocol and the Serine-Threonine 
Kinase (STK) array protocol, respectively. The phosphorylation of PamChip 
peptides were monitored using the PamStation 12 from PamGene 
(Hertogenbosch, Netherlands). Kinase(s) in the sample actively phosphorylate 
substrates on the PamChip, in the presence of ATP. Images are taken every 5 
minutes to generate real time kinetics data (Figure 2.4). The PTK array was a 
single-step reaction. Cell extracts, ATP, and fluorescein isothiocyanate (FITC)-
labelled pY20 antibody were incubated on the chip, and the phosphorylation of 
the individual tyrosine peptides was viewed by fluorescence detection in real time. 
The STK array was a two-step reaction. First, the cell extracts, ATP, and the 
primary antibody mixture were incubated with the chip for 110 min. Then, the 
secondary FITC-labelled antibody was added. 
The STK Array consists of 140 serine/threonine containing peptides and 4 
positive control phosphorylated peptides, resulting in 144 peptides per array. 
Each peptide represents a 15-amino-acid sequence, of which 13 residues are 
derived from a putative phosphorylation site in human proteins. The PTK Array 
consists of 196 peptides with known phosphorylation sites. Peptide sequences 
are derived from the literature or computational predictions and are correlated 
with one or multiple upstream kinases. Signal intensities were analysed in the 
BioNavigator software (PamGene) as Yoda1-treated versus DMSO treatment 
after 10 min. Permutation analysis gave a specificity score (mapping of peptides 
to kinases) and a significance score (difference between treatment groups) for 
each kinase. The median total of these two scores was used to rank kinase hits. 





Figure 2.4 A PamChip and the phosphorylation signals generated. The 
PamChip contains 4 peptide arrays, composed of aluminum oxide. This material 
is approximately 60 μm thick and has a porous structure which maximises binding 
kinetics. The sample and labelled antibodies are dispensed onto a PamChip, 
which is then placed in the PamStation12. Below are some images of example 
phosphorylation signals; real time kinetics data are taken every 5 minutes. 
Images taken from PamGene. 
 
2.13 Transgenic mice 
2.13.1 Animal husbandry and ethics 
All animal use was authorised by the University of Leeds Animal Ethics 
Committee and The Home Office, UK under project licenses 40/3523, 
P144DD0D6 and P65AC17DB. Animals were housed in Optimice individually 
ventilated cages (Animal Care Systems) with bedding of Pure‘o Cell (Datesand) 
at 21°C, 50-70% humidity with light/dark cycle 12/12 h in a sterile animal unit. 
RM1 diet (SpecialDiet Services, Witham, UK) was available ad libitum and mice 
were allowed free access to triple filtered Hydropac water. Mice were housed with 
their littermates with a maximum of 5 mice per cage. Breeding pairs or trios (1 
male with up to 2 females) were established when necessary; mating 
programmes required mice of at least 6 weeks of age and ideally less than 6 
months of age. Offspring were weaned at 21 days of age. All animals were treated 





Progeny resulting from breeding cages were genotyped ~14-21 days post-
partum. Ear notches (2 mm) were taken from each mouse and this also enabled 
identification of individual animals. Tissue digestion was achieved with 0.5 mg/mL 
proteinase K (Ambion) in 0.5 mL lysis buffer (50 mM EDTA, 10 mM Tris-HCl (pH 
8.0), 1% SDS) for 24 h at 37°C. After incubation, the tubes were mixed vigorously 
to break up any remaining tissue. 0.4 mL phenol/chloroform/isoamyl alcohol 
(Sigma-Aldrich) was added. Samples were kept for 15 min at r.t. and agitated 
frequently. Samples were then centrifuged at 13,200 rpm for 15 min to separate 
the phases. The upper (DNA-containing) phase was transferred to a fresh tube 
with an equal volume of isopropanol (Fisher-Scientific) and 0.1 volume of 3 M 
NaCl. Tubes were inverted gently before being left to stand for 30 min at r.t., while 
the DNA precipitated. After a 45 minute centrifugation step at 13,200 rpm, DNA 
pellets were washed with 0.5 mL 70% ethanol, air dried and re-suspended in 65 
µL TE buffer (10 mM Tris, 1 mM EDTA buffer, pH 8.0) before being left to stand 
for 30 min before PCR was performed. 
The presence of Cre, lacZ, loxP and a deletion of Piezo1 were detected by PCR. 
Each reaction contained the following: 2.5 µL 10x ThermoPol Reaction Buffer, 
0.5 µL Deoxynucleotide (dNTP) Solution Mix, 0.25 µL Taq DNA Polymerase (all 
New England Biolabs), 1 µL each of forward and reverse primers (25 µM), 0.5 µL 
DNA and nuclease-free water to give a final volume of 25 µL. Reactions were 
carried out using the T100™ Thermal Cycler. Reaction conditions were as 
follows: 1 minute 93°C; 29 cycles x 20 seconds 93°C, 3 min 68°C; followed by a 
hold step at 4°C. Sequences of primers and expected product sizes are shown 
in Table 2.8.  
PCR products were subjected to gel electrophoresis on agarose gels and 
visualised as described in 2.5.4.3. Example genotyping results are shown below 









Primer sequence (5’ to 3’) Vendor Product 
size (bp) 
























Table 2.8 Genotyping primers. Table includes sequences of forward and 
reverse primers used to amplify genes of interest for PCR genotyping 
experiments, along with their predicted product size. 
 
2.13.3 Piezo1-modified transgenic mice 
2.13.3.1 Piezo1-HA murine model 
CRISPR-Cas9 technology was used to develop a transgenic C57BL/6 mouse 
globally expressing a mutated hemagglutinin (HA)-tagged version of Piezo1 
(Piezo1-HA). This was done as current anti-Piezo1 antibodies are non-specific. 
The HA sequence was introduced between amino acids A2439 and D2440. 2 day 
embryos were electroplated using AltR crRNA:tracrRNA:Cas9 complex. Zygotes 
were implanted into 0,5-post coitum pseudopregant mice. Genotypes were 
determined using real-time PCR with specific probes designed for each gene 
(Transnetyx, Cordova, TN). Cardiac fibroblasts were isolated from WT, 
heterozygote (HA-Het) and homozygote (HA-Hom) mice and lysed. Cardiac 
fibroblasts from HA-Hom mice were isolated and transfected with control or 
Piezo1-specific siRNA and lysed. These samples were used for western blotting. 
 
2.13.3.2 Global Piezo1+/- murine model 
C57BL/6 mice carrying global disruption of the Piezo1 gene with a lacZ insertion 




generates WT mice and mice globally heterozygous for Piezo1 (Piezo1+/-); these 
mice are referred to as Het mice throughout. Analysis of Piezo1 disruption was 
performed by genotyping using primers for lacZ (primer sequences shown in 
Table 2.8). An example gel imaged to identify genotypes can be seen in Figure 
2.5. Mice of varying ages and sexes were used for culturing cells for experiments.
 
Figure 2.5 An example gel used to identify genotypes of mice from the 
Piezo1+/- line. PCR genotyping for presence of the lacZ site (225 bp) in DNA 
extracted from ear notches from 12 mice. Gels indicate positive and negative 
controls and L=100 bp ladder. 
 
2.13.3.3 Piezo1 M2240R murine model 
The Piezo1 M2240R gain of function mice (referred to as M-R mice), which have 
a mutation equivalent to the human mutation M2225R (Zarychanski et al. 2012), 
were generated using CRISPR/Cas9 by the Manchester Transgenic Facility, Dr 
Melanie Ludlow and Elizabeth Evans (University of Leeds). The gRNA was 
designed to direct Cas9-mediated cleavage of Piezo1 6 bp upstream of the target 
methionine codon and possesses no off-target sites with less than 3 mismatches 
elsewhere in the genome (binding sequence 5’ GGGCGCUCAUGGUGAACAG 
3’). A 120 nucleotide single-stranded homology directed repair (ssHDR) template 
was designed to incorporate the methionine to arginine missense mutation, in 
addition to silent mutations introducing a Mlu1 restriction enzyme recognition site 
to facilitate genotyping (5’ccacccgtcccctgagcctgaggggctccatgctgagcgtgcttccatcc-
ccagccaTTAttTacGCGTagcgcccagcagccatccattgtgccattcacaccccaggcctacgagga
g 3’; capital letters denote the mutated bases) (Sigma Aldrich). 
The gRNA, delivered as an alt-R crRNA combined with tracrRNA (Integrated DNA 
Technologies, Illnois, USA), Cas9 protein (Thermo Fisher check) and ssHDR 




females (by Manchester Transgenic Animal Facility). Successful gene editing of 
pups was identified by Mlu1 digestion of PCR amplicons (Fwd: 5’ 
TCTGGTTCCCTCTGCTCTTC 3’, Rv: 5’ TGCCTTCGTGCCGTACTG 3’) and 
confirmed by DNA sequencing following subcloning into pCRTM-Blunt 
(Invitrogen). Further genotypes were determined by RT-PCR with specific probes 
designed for each gene (Transnetyx). Cardiac fibroblasts were isolated from 8-
12 week-old male mice and used for experiments. 
 
2.13.4 Piezo1 knockout murine models 
2.13.4.1 Cre-loxP technology 
Genetic manipulation to generate Piezo1 KO mice was performed using the Cre-
loxP system. Cre-loxP reactions are affected by the orientation and location of 
two loxP sites. When loxP sequences are orientated in the same direction, Cre 
recombinase mediates removal of the DNA segment between the two sites. 
Usually, Cre and loxP strains are developed independently and then crossed. 
Cre recombinase can be linked to a form of mutated oestrogen receptor 
(CreER(T)) to enable conditional deletion. 4-hydroxytamoxifen (4OH-TM), the 
active metabolite of tamoxifen, binds to the mutated oestrogen receptor, which 
allows CreER(T) to move to the nucleus and here, recombination occurs, causing 
targeted deletion of the gene between two loxP sites. Without 4OH-TM exposure, 
gene excision does not occur. 
 
2.13.4.2 Tamoxifen administration 
Tamoxifen free base (Sigma-Aldrich) was dissolved in corn oil at 20 mg/mL and 
shaken overnight at 200 rpm, 37°C to aid dissolution. 100 mg/kg tamoxifen was 
administered intraperitoneally (i.p.), daily, for 5 consecutive days using a 0.5 mL 
U-100 insulin syringe and 29G 13mm needle. This protocol induces Cre activity 
(and hence floxed gene deletion) that is restricted to the cell type which express 
the particular promoter utilised. Therefore, only Cre+ mice will have a deletion of 





2.13.4.3 Fibroblast-specific Piezo1 knockout murine model 
Two murine models were generated in order to obtain an inducible 
(myo)fibroblast-specific Piezo1 KO mouse and both will be discussed. The first 
was an inducible fibroblast-specific Piezo1 KO mouse line established by 
crossing C57BL/6 mice expressing tamoxifen-inducible Cre recombinase under 
a fibroblast-specific promoter (obtained from Chris Denton, UCL) with C57BL/6 
mice expressing a modified Piezo1 gene where exons 19-23 are flanked by loxP 
sites (Li et al. 2014). Fibroblast specificity of the Piezo1 deletion was determined 
by a 6 kb transcriptional enhancer sub-cloned from the far-upstream region of the 
mouse collagen I gene (Col1a2), linked to an endogenous minimal promoter 
(Zheng et al. 2002). This generated a Col1a2-Cre-ER(T)-Piezo1flx/flx mouse line. 
Strains homozygous for floxed Piezo1 alleles but heterozygous for Cre were 
obtained. Therefore, subsequent breedings yielded exclusively Cre+ Piezo1-
floxed mice (experimental) and Cre- Piezo1-floxed mice (control). This is 
illustrated in Figure 2.6. Col1a2, is expressed in all fibroblasts, therefore the 
Col1a2-Cre-ER(T) line induces gene deletion in cardiac (and other) fibroblasts; it 
has previously been confirmed that there is no effect on other type I collagen-
producing cells (Denton et al. 2001; Denton et al. 2005). Col1a2-Cre-ER(T)-
Piezo1flx/flx KO mice (i.e. Cre+ Piezo1flx/flx) were compared alongside control 
littermates (i.e. Cre- Piezo1flx/flx). Identification of correct genotype was performed 
by using genotyping primers for loxP and Cre (primer sequences are shown in 
Table 2.8). Male and female mice were injected at 3 weeks of age with tamoxifen 
for five consecutive days to induce Cre activity and facilitate loxP-directed 
deletion of exons 19-23 of Piezo1 in fibroblasts; this is illustrated in Figure 2.7. 
Hearts were harvested 7 days after the last injection of tamoxifen and cardiac 






Figure 2.6 Breeding strategy for generation of Piezo1 knockout mice. 
Breeding strategy for generation of both the Col1a2-Cre-Piezo1flx/flx and Postn-
Cre-Piezo1flx/flx murine models. 
 
 
Figure 2.7 Gene deletion using the Cre-loxP system. The tamoxifen inducible 
Cre enzyme is linked to a mutant oestrogen receptor (ER), under the control of a 
fibroblast-specific transcriptional enhancer from the Col1a2 gene or the 
myofibroblast specific promoter Postn, depending on the murine model. When 
Cre and a floxed Piezo1 allele are present, exposure to 4OH-TM causes 
CreER(T) to excise exons 19-23 of Piezo1 as a circular piece of DNA. 
 
2.13.4.4 Myofibroblast-specific Piezo1 knockout murine model  
The second model was a tamoxifen-inducible, myofibroblast-specific Piezo1 KO 
mouse line. This was established by crossing C57BL/6 mice expressing 
myofibroblast-specific, tamoxifen-inducible Cre recombinase under the Postn 






Piezo1 gene with exons 19-23 flanked by loxP sites (Li et al. 2014) to generate a 
Postn-Cre-Piezo1flx/flx mouse line (shown in Figure 2.6). The method for deletion 
of exons 19-23 in shown in Figure 2.7. The Postn-Cre line is a Mer-Cre-Mer 
(MCM) model; the tamoxifen inducible Cre recombinase is flanked by two 
modified estrogen receptor ligand binding domains and is more potent than the 
ER(T) Cre used in the Col1a2-promotor mice (shown in Figure 2.6). This was 
purchased from The Jackson Laboratory (JAX stock #029645). Strains 
homozygous for floxed Piezo1 alleles but heterozygous for Cre were obtained 
(i.e. Cre+/Piezo1flx/flx). Therefore, subsequent breedings yielded exclusively Cre+ 
Piezo1-floxed mice (experimental) and Cre- Piezo1-floxed mice (control). 
Periostin is expressed almost exclusively in myofibroblasts in areas of tissue 
injury (Kanisicak et al. 2016), therefore this line induces gene deletion in cardiac 
(and other) myofibroblasts without effect on other cells types. Experimental mice 
(i.e. Cre+ Piezo1flx/flx) were compared to control mice (i.e. Cre- Piezo1flx/flx). 
Identification of correct genotypes was performed using genotyping primers for 
loxP and Cre (primer sequences are shown in Table 2.8). 
 
2.13.5 Cardiac injury models 
2.13.5.1 Experimental myocardial infarction model 
A permanent left anterior descending (LAD) coronary artery ligation model of 
experimental MI was performed on 5% isoflurane-anaesthetised male mice (10-
12 weeks of age) by Dr Mark Drinkhill. Following intubation, mice were ventilated 
at a tidal volume of 140 µL and a respiratory rate of 120/min with 1.5% isoflurane 
and 100% oxygen. The LAD was ligated at the edge of the left atrium using 8-0 
prolene suture and occlusion confirmed by observing pallor of the anterior LV 
wall. Experimental mice were compared to sham-operated animals, which 
underwent a similar surgical procedure without tying the ligature. Data from sham 
animals are from a previous study (Bageghni et al. 2019), where Millar pressure-
volume conductance catheter data were obtained by Dr Mark Drinkhill and RT-






2.13.5.2 Experimental thoracic aortic constriction model 
Female mice aged 10-12 weeks were utilised for TAC surgery performed by Dr 
Mark Drinkhill. The TAC model results in pressure overload due to partial 
occlusion of the transverse aorta. This procedure often leads to cardiac 
hypertrophy, a common compensatory mechanism in the pressure overloaded 
heart and, in some animals, will result in heart failure over time. TAC was 
performed as described by deAlmeida, van Oort and Wehrens (2010). Briefly, 
mice were anaesthetised with 5% isoflurane. Following intubation, mice were 
ventilated at a tidal volume of 140 µL and a respiratory rate of 120/min with 1.5% 
isoflurane and 100% oxygen. Under a dissecting microscope, a sternal split of 
the cranial 1/3 of the sternum allowed an 8-0 silk ligature to be tied around the 
ascending aorta and a 26G blunted needle, which was subsequently removed. 
Experimental mice were compared to animals undergoing a sham procedure 
(surgery without banding of the aorta). 
 
2.13.5.3 Analysis following cardiac injury 
Mice were injected with tamoxifen for 5 consecutive days the week after surgery 
in order to induce Cre activity and facilitate loxP-directed deletion. Tamoxifen 
injections were carried out by Dr Simon Futers. Physiological measurements of 
cardiac function were obtained at the end of the experimental period (4 weeks 
after surgery) by Millar conductance pressure-volume (PV) catheter analysis as 
previously described by Frentzou et al. (2015). Briefly, mice were anesthetised 
with isoflurane, and body temperature was maintained with a heating pad before 
inserting a 1.4 F miniature PV catheter (ADInstruments) into the left ventricle via 
the right carotid artery and ascending aorta. Data were collected using the MPVS-
300 PV system (ADInstruments) and PV loop analysis was performed with Chart 
8 Pro software (ADInstruments). Dr Mark Drinkhill carried out the PV 
measurements and was blinded to the genotype of the animals. Stroke volume, 
ejection fraction, cardiac output, end systolic/diastolic pressure, end 
systolic/diastolic volume, heart rate, blood pressure  and myocardial contractility 
were calculated. The heart was removed and washed; ventricles were cleaned of 
blood, blotted, and weighed. Heart weight/body weight ratio (mg/g) was recorded 
prior to further processing of cardiac tissue. Left tibias were also harvested and 




indicator of cardiac weight index (mg/mm). RNA was prepared from the apex of 
the heart to evaluate cardiac gene expression, as was DNA to check for a deletion 
of Piezo1. 
 
2.14 Data analysis 
OriginPro 2015 (OriginLab, Northampton, MA, USA) was used for data analysis 
and presentation. Averaged data are presented as mean ± SEM, where “n” 
represents the number of independent experiments and “N” indicates the total 
number of replicates within the independent experiments (multiwall assays). For 
comparisons between two sets of data, a Student’s t-test was used. For multiple 
comparisons, a one-way ANOVA was used with Tukey’s post-hoc test. P<0.05 
was considered statistically significant; *P<0.05, **P<0.01 and ***P<0.001. No 
significant difference is indicated by NS (P>0.05). For EC50 and IC50 









Chapter 3 Piezo1 is expressed and functional in cardiac 
fibroblasts across species 
3.1 Introduction 
Cardiac fibroblasts respond to a wide range of mechanical signals in physiology 
and pathophysiology. It is known that increased mechanical stimulation of 
fibroblasts results in enhanced ECM synthesis and expression of various 
cytokines and growth factors (Carver et al. 1991; Yokoyama et al. 1999). This 
implies that mechanical stress plays an important role in the regulation of cardiac 
fibroblast function but there are still many unknowns in this field. Mechanically-
activated ion channels have been implicated as sensors of mechanical stress in 
cardiac fibroblasts (Reed, Kohl and Peyronnet 2014). Over the past 10 years, 
since Coste et al. (2010) discovered the Piezo1 family of proteins, there has been 
a vast amount of literature published discussing Piezo1 and its roles of sensing 
mechanical activation in a broad range of tissues. In a review by Herum et al. 
(2017b), it was suggested that the most solid data for a stretch-activated channel 
in cardiac fibroblasts would be Piezo1, as the electrophysiological properties of 
this channel are similar to that of endogenous cardiac non-selective cation 
stretch-activated channels. The objective of this study was to consider the role of 
Piezo1 in cardiac fibroblasts. 
 
3.2 Aims 
The main aims of this chapter were to investigate whether Piezo1 was present in 
murine and human cardiac fibroblasts, to ascertain if the Piezo1 agonist, Yoda1, 
could activate endogenous cardiac fibroblast Piezo1 channels to cause Ca2+ 
entry and to ascertain that this response was dependent on Piezo1. It was also 
explored whether mechanical stimuli could be used to activate the Piezo1 








Immunocytochemistry (Section 2.7), RT-PCR (Section 2.5) and Ca2+ 
measurements calculated using the FlexStation and the Ca2+ indicator, Fura-2 
(Section 2.3) were first utilised to characterise murine cardiac fibroblasts. Piezo1 
mRNA expression was investigated using RT-PCR in cultured and freshly 
isolated murine cardiac fibroblasts and cultured human cardiac fibroblasts; this 
was compared with its expression levels in other cardiac cell types. Intracellular 
Ca2+ measurements were performed to examine whether the Piezo1 activator, 
Yoda1, could induce Ca2+ entry in cardiac fibroblasts. When this was confirmed, 
chemical antagonists (Section 2.1), two Piezo1-modified murine models (Section 
2.13.3) and siRNA targeting Piezo1 (Section 2.4) were utilised to assess the 
involvement of Piezo1 in Yoda1-evoked Ca2+ entry. Alongside, novel Yoda1 
analogues (Section 2.1) were tested for their ability to induce Ca2+ influx or inhibit 
Yoda1-evoked Ca2+ entry in cells overexpressing Piezo1, in order to increase 
knowledge of the structure-activity relationship for Yoda1 activation of Piezo1. 
Finally, various methods were then used to mechanically activate cardiac 
fibroblasts; it was investigated whether cardiac fibroblasts displayed Piezo1-like 
currents following hypotonicity (Section 2.3.4) or pressure patch-clamp recording 






3.4.1 Characterisation of murine cardiac fibroblasts 
To study Piezo1 in cultured cardiac fibroblasts, it was imperative to ensure that 
fibroblast cell cultures were not contaminated with endothelial cells, cells known 
to contain high levels of Piezo1 (Li et al. 2014). Immunocytochemistry of cultured 
murine cardiac fibroblasts was used to verify that cells exhibited the expected 
myofibroblast phenotype which is classically observed in cultured fibroblasts 
mechanically activated by the rigid plastic of cell culture (Hinz et al. 2007). It was 
confirmed that cells stained positively for vimentin and α-smooth muscle actin (α-
SMA) and that no cells stained positively for the endothelial marker PECAM-1 
(CD31) (Figure 3.1). HUVECs were stained for PECAM-1 alongside, as a positive 
control (Figure 3.1). Negative control staining without any primary antibody 
applied was performed to illustrate that secondary antibody was not binding non-
specifically (Figure 3.1). 
RT-PCR analysis of cultured murine cardiac fibroblasts revealed low levels of 
Pecam1 mRNA and an absence of alpha-myosin heavy chain (Myh6) mRNA, a 
cardiac myocyte marker, but much higher mRNA expression of two common 
fibroblast markers, discoidin domain-containing receptor 2 (Ddr2) and platelet 
derived growth factor receptor alpha (Pdgfra) (Figure 3.2). 
Throughout this study, the FlexStation and the Ca2+ indicator, Fura-2, were used 
to record intracellular Ca2+ events. VEGF binds to receptors on endothelial cells; 
cardiac fibroblasts do not express these receptors. VEGF was able to induce Ca2+ 
entry in HUVECs as expected, whereas murine cardiac fibroblast cultures were 
unresponsive to VEGF, further confirming that cardiac fibroblast cultures were 
free of endothelial cell contamination (Figure 3.3).  
These data indicate that the cells present in our cultures are cardiac fibroblasts, 
the majority of which showed a myofibroblast phenotype, with no evidence for 






Figure 3.1 Characterisation of murine cardiac fibroblasts using 
immunocytochemistry. Representative images of cultured murine cardiac 
fibroblasts stained for vimentin (red), α-SMA (purple) and PECAM-1 (green). 
HUVECs are stained for PECAM-1 (green) as a positive control in the bottom 
panel. DAPI staining (blue) identifies nuclei. Secondary antibody only staining 
(without primary antibody) in cardiac fibroblasts acts as a negative control. Scale 






Figure 3.2 Cell-specific markers in cultured murine cardiac fibroblasts. RT-
PCR analysis of various cardiac cell markers: Ddr2, Pdgfra (both fibroblast 
markers), Pecam1 (endothelial cell marker) and Myh6 (cardiomyocyte marker) in 
cultured murine cardiac fibroblasts (n=3). Expression levels expressed as a % of 






























Figure 3.3 Response of cultured murine cardiac fibroblasts to VEGF. 
Representative intracellular Ca2+ traces, using the FlexStation and the Ca2+ 
indicator, Fura-2, when cultured murine cardiac fibroblasts and HUVECs were 
applied with 30 ng/mL VEGF at 60 seconds. The maximum Ca2+ entry induced is 
utilised for the mean data, which is shown in a bar chart (n/N=2/6). 
  


















































3.4.2 Detection of Piezo1 expression in cardiac fibroblasts 
Despite knowledge that Piezo1 mRNA can be detected in mouse heart (Coste et 
al. 2010), it is currently unknown whether Piezo1 is expressed in cardiac 
fibroblasts. Experiments were undertaken to measure Piezo1 mRNA expression 
in cultured human and mouse cardiac fibroblasts and mouse cardiac cell 
fractions, and Piezo1 protein expression was investigated in cultured mouse 
cardiac fibroblasts. 
3.4.2.1 Piezo1 mRNA is expressed in cultured cardiac fibroblasts 
For the accurate comparison of gene expression by RT-PCR, it is imperative to 
know the efficiency of the primers used (Svec et al. 2015). The efficiencies of the 
primers used to analyse Piezo1 and Piezo2 mRNA expression were calculated 
(Figure 3.4A); here, the efficiencies were 97 % and 83 %, respectively. Primer 
efficiencies were taken into account when calculating the relative messenger 
RNA expression levels of Piezo1 and Piezo2. Messenger RNA encoding Piezo1 
was detected at a higher level than Piezo2 in cultured murine cardiac fibroblasts 
(Figure 3.4B,C). 
Messenger RNA encoding Piezo1 was detected in both murine and human 
cultured cardiac fibroblasts (Figure 3.5). Piezo1 mRNA expression levels in 
murine cardiac fibroblasts were similar to those observed in murine pulmonary 
endothelial cells (Figure 3.5). PIEZO1 mRNA expression levels  in human cardiac 
fibroblasts were observed to be 25% higher than in human saphenous vein 
endothelial cells and double that in HUVECs (Figure 3.5); cells known to express 
high levels of Piezo1 mRNA (Li et al. 2014). These data confirm Piezo1 is 
expressed in cardiac fibroblasts at similar levels to those found in endothelial cells 






Figure 3.4 Expression levels of Piezo1 and Piezo2 mRNA in murine cardiac 
fibroblasts. (A) Graph illustrating the efficiency of the primers used during RT-
PCR analysis of Piezo1 and Piezo2 mRNA expression, the R2 value is indicated 
next to each line. Efficiencies: Piezo1 primers: 97 %, Piezo2 primers: 83 %. (B) 
End-point PCR products obtained using primers for Piezo1 and Piezo2 in murine 
cardiac fibroblasts. Lanes with (+RT) and without (-RT) reverse transcriptase 
reaction are indicated; this was performed to confirm there was no genomic DNA 
contamination. (C) Mean data of Piezo1 and Piezo2 mRNA expression as a % of 































































































Figure 3.5 Expression of Piezo1 mRNA in cultured murine and human 
cardiac fibroblasts in comparison to endothelial cells. RT-PCR analysis of 
Piezo1 mRNA expression in (A) murine cardiac fibroblasts (CF; n=3) compared 
to pulmonary endothelial cells (PEC; n=5) and (B) human cardiac fibroblasts (CF; 
n=6) compared to human saphenous vein endothelial cells (SVEC, n=3) and 
human umbilical vein endothelial cells (HUVEC; n=3). Expression measured as 
% of housekeeping control (Gapdh/GAPDH). 
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3.4.2.2 Piezo1 mRNA is expressed in the fibroblast fraction of the heart 
A magnetic antibody cell separation (MACS) technique (Bageghni et al. 2018) 
was used to successfully separate cell types isolated from mouse heart, as shown 
by RT-PCR analysis of different fractions with cell-specific markers. It was verified 
that the fibroblast-enriched fraction had much higher expression of Col1a2 mRNA 
than the endothelial cell-enriched fraction (50-fold higher) and separately isolated 
mouse cardiomyocytes (230-fold higher) (Figure 3.6). In addition, the endothelial 
cell-enriched fraction exhibited a much higher mRNA level of the endothelial 
marker Pecam1 (CD31) than the fibroblast and myocyte fractions (Figure 3.6). 
Isolated cardiomyocytes expressed almost 10 times the mRNA expression of 
Myh6 than the other fractions (Figure 3.6). This validated our separation 
technique. 
Housekeeping genes should not vary in the samples under investigation or in 
response to treatment. It has been demonstrated that housekeeping gene 
expression can fluctuate considerably and it has been suggested that, in order to 
calculate expression levels accurately, values should be normalised to multiple 
housekeeping genes, rather than only one (Vandesompele et al. 2002). With this 
in mind, expression levels of Piezo1 mRNA in cardiac cell types were normalised 
using geometric averaging of multiple internal control genes (Gapdh, Actb and 
Hprt). It was confirmed that Piezo1 mRNA was expressed in the fibroblast-
enriched (Col1a2-positive) fraction of freshly isolated cells from mouse heart at 
approximately two-thirds of the level of that in the endothelial cell-enriched 
(Pecam1-positive) fraction (Figure 3.7). The level of Piezo1 expression in murine 
cardiac fibroblasts is displayed alongside data which demonstrates much lower 
expression of Piezo1 mRNA in murine cardiac myocytes (Figure 3.7). These data 
further confirm that Piezo1 is expressed in murine cardiac fibroblasts and 
illustrate that cardiac fibroblasts and endothelial cells are the major cell types 
expressing Piezo1 in the heart, whilst cardiomyocytes have relatively low 






Figure 3.6 Validation of the separation of cardiac cell types using cell-
specific markers. RT-PCR analysis of Col1a2 (fibroblast marker), Pecam1 
(endothelial cell marker) and Myh6 (cardiomyocyte marker) mRNA expression in 
the fibroblast-enriched fraction (CF) and endothelial cell-enriched fraction (EC) 
isolated from murine heart using magnetic antibody cell separation technique 
(n=4), compared to the expression in freshly isolated cardiomyocytes (CM) from 
















































































Figure 3.7 Piezo1 mRNA expression in the fibroblast fraction of the whole 
heart. RT-PCR analysis of Piezo1 mRNA expression in the fibroblast-enriched 
fraction (CF) and endothelial cell-enriched fraction (EC) isolated from murine 
heart using magnetic antibody cell separation technique (n=4) compared to in 
freshly isolated cardiomyocytes (CM) from different mice (n=2). Expression was 
measured relative to 3 different housekeeping genes (Gapdh, Actb, Hprt) and 

















































3.4.2.3 Piezo1 protein is detected in murine cardiac fibroblasts  
Commercially available anti-Piezo1 antibodies are non-specific, and are unable 
to convincingly detect endogenous Piezo1. To overcome this, CRISPR-Cas9 
technology was used to develop a transgenic mouse globally expressing a 
mutated hemagglutinin (HA)-tagged version of Piezo1 (Piezo1-HA) at 
endogenous levels. This HA tag enables the identification of Piezo1 using anti-
HA antibodies by western blotting. Piezo1-HA was expressed in cardiac 
fibroblasts isolated from a Piezo1-HA homozygote mouse and, as expected, was 
expressed at lower levels in a Piezo1-HA heterozygous mouse; no band was 
detected in a WT mouse (Figure 3.8). This confirms that mRNA is translated and 






Figure 3.8 Detection of Piezo1 protein in murine cardiac fibroblasts. Piezo1 
protein detected by western blotting in cardiac fibroblasts isolated from a 
CRISPR-generated murine model in which native Piezo1 was modified  to contain 
a HA tag. Samples from a WT mouse, a mouse heterozygous for Piezo1-HA and 
a mouse homozygous for Piezo1-HA were immunoblotted with anti-HA antibody, 
followed by an α-tubulin antibody to confirm equal protein loading. A band was 





3.4.3 Expression of Piezo1 mRNA in cardiac fibroblasts is unaltered 
by various stimuli 
Knowledge of how the Piezo1 gene is regulated is limited. Therefore, 
investigation was undertaken to understand whether the expression of Piezo1 
was affected by stimuli which are important in fibroblast function. 
3.4.3.1 Confluency of cardiac fibroblasts has no effect on Piezo1 mRNA 
expression 
It has been reported that Piezo1 may act as a homeostatic sensor to control 
epithelial cell numbers. When epithelial cells become too crowded, they activate 
Piezo1 to trigger extrusion and apoptosis of cells (Eisenhoffer et al. 2012). 
Conversely, Gudipaty et al. (2017) found that cell division occurs in regions of low 
cell density, where epithelial cells are stretched, through activation of the Piezo1 
channel. Therefore, Piezo1 appears to act as a homeostatic sensor to control 
epithelial cell numbers by participating in these two opposing processes. For this 
reason, it was examined whether confluency of cardiac fibroblasts had an effect 
on Piezo1 mRNA expression. Murine cardiac fibroblasts were plated at varying 
densities and RNA was extracted 48 h later; there was no significant change in 
Piezo1 mRNA expression between different conditions (Figure 3.9). This 
established that plating cells at different densities during experimentation was 






Figure 3.9 Effect of cell confluency on Piezo1 mRNA expression in murine 
cardiac fibroblasts. RT-PCR analysis of Piezo1 mRNA in murine cardiac 
fibroblasts plated at different levels of confluency, ranging from 2-20 x 104 cells 
per well of a 12 well plate, prior to RNA extraction 48 h later. Expression is 
measured as % of housekeeping control (Gapdh), P=NS, not significant following 






































3.4.3.2 Cytokines do not affect Piezo1 mRNA expression in murine 
cardiac fibroblasts 
Two main stimuli have been reported to promote cardiac fibroblast differentiation: 
TGF-β1, a cytokine which is produced at the onset of pathology (Dobaczewski et 
al., 2010), and mechanical stress (Hinz et al. 2001). Cardiac fibroblasts 
stimulated with TGF-β1 in vitro have accelerated differentiation into 
myofibroblasts, measured by increased α-SMA expression and collagen 
synthesis (Samuel et al. 2004). Conversely, IL-1α has an inhibitory effect on the 
phenotypic switch of human cardiac fibroblasts to myofibroblasts induced by 
TGF-β1. For example, IL-1α has been shown to inhibit TGF-β1-induced increase 
in α-SMA protein expression and collagen gel contraction in human cardiac 
fibroblasts (van Nieuwenhoven et al. 2013). Therefore, with respect to 
myofibroblast differentiation, TGF-β1 and IL-1α have opposing effects in cardiac 
fibroblasts.  
It was investigated whether modifying the differentiation state of cardiac 
fibroblasts using these factors had an effect on Piezo1 mRNA expression. RT-
PCR analysis of Piezo1 mRNA expression revealed no change when murine 
cardiac fibroblasts were treated for 24 h with increasing concentrations of TGF-
β1 or IL1-α, compared to cells treated with vehicle (Figure 3.10A,B). Hence, 
altering the differentiation state of cardiac fibroblasts did not affect expression of 
Piezo1 mRNA. This is important as prolonged culture of cardiac fibroblasts leads 
to their differentiation (Santiago et al. 2010); these data give confidence that this 






Figure 3.10 Effect of cytokines on Piezo1 mRNA expression in murine 
cardiac fibroblasts. RT-PCR analysis of Piezo1 mRNA in murine cardiac 
fibroblasts treated for 24 h with various concentrations of (A) TGF-β1 or (B) IL1-
α, compared to cells treated with vehicle. Expression is measured as % of 
housekeeping control (Gapdh), P=NS, not significant following an ANOVA with 
Tukey’s post-hoc test (n=3). 
  



























































3.4.3.3 Mechanical stress has no effect on Piezo1 mRNA expression 
Piezo1 is a mechanosensitive ion channel, therefore it was investigated whether 
the application of mechanical stimuli to cardiac fibroblasts had an effect on Piezo1 
mRNA expression. Jin et al. (2015) have previously demonstrated that 
mechanical activation due to compressive stimuli significantly upregulated Piezo1 
mRNA expression after 30 min in human periodontal ligament cells and this was 
maintained over a 12 h time period. Three methods were employed to apply 
mechanical stress to cells; namely shear stress, altered substrate stiffness and 
cyclic stretch. 
Shear stress applied to cells at ~10 dyn.cm-2 using an orbital shaker for 24 h had 
no effect on Piezo1 mRNA expression in murine cardiac fibroblasts, in 
comparison with cells kept under static conditions (Figure 3.11A). 
Mouse cardiac fibroblasts cultured on substrates of ‘physiological’ stiffness (a 
Young’s elastic modulus of 8 kPa; (Berry et al. 2006)) maintain a quiescent 
phenotype, whereas those cultured on stiffer substrates mimicking fibrosis (20-
100 kPa; (Berry et al. 2006)) express higher levels of α-SMA and exhibit 
increased cell area (Herum et al. 2017a), indicative of cell differentiation to the 
myofibroblast phenotype. Murine cardiac fibroblasts were grown on tailored 
culture substrates (10 kPa, 30 kPa and tissue culture plastic which is 
approximately 1x106 kPa) for 24 h. Cells showed a trend for decreased 
expression of Piezo1 mRNA with decreased stiffness of substrate (10 kPa) but 
this was not quite statistically significant, possible due to the low number of 
replicates (Figure 3.11B). 
Cardiac fibroblasts are exposed to cyclic mechanical stretch with every heartbeat, 
at a frequency of ~1 Hz in humans. When cyclic stretch was applied to human 
cardiac fibroblasts for 6 h at 1 Hz, PIEZO1 mRNA expression was unaltered, 
compared with cells kept under static conditions (Figure 3.11C). Together, these 
data convey that Piezo1 mRNA expression in cardiac fibroblasts is unchanged 
when cells are activated using “outside-in” mechanical forces, i.e. forces arising 
from shear flow or stretch. However, Piezo1 mRNA expression may be 
upregulated cells when cells actively generate mechanical forces, for example, 





Figure 3.11 Effect of mechanical stimuli on Piezo1 mRNA expression levels. 
(A) RT-PCR analysis of Piezo1 mRNA levels in murine cardiac fibroblasts 
stimulated with shear stress via an orbital shaker for 24 h, compared to cells kept 
under static conditions, P=NS, not significant following a t-test (n=3). (B) RT-PCR 
analysis of Piezo1 mRNA expression in murine cardiac fibroblasts grown on 
substrates of differing stiffness: 10 kPa, 30 kPa and tissue culture plastic which 
is approximately 106 kPa for 24 h, P=0.09, P=NS, not significant following an 
ANOVA with Tukey’s post-hoc test (n=3). (C) RT-PCR analysis of PIEZO1 mRNA 
levels in human cardiac fibroblasts stimulated with 6 h cyclic stretch (1 Hz, 10 % 
stretch), in comparison with cells kept under static conditions, P=NS, not 
significant following a t-test (n=3). All expression levels are expressed relative to 
























































































3.4.4 Novel small modulators of Piezo1 
Pharmacological compounds which selectively modulate Piezo1 channels are 
attractive laboratory tools as they allow for study of the channel without the need 
for mechanical force. The first chemical activator of Piezo1, named Yoda1, was 
discovered by Syeda et al. (2015) and has since been widely used to investigate 
Piezo1 channel pharmacology. A library of ~3.25 million compounds was 
screened as activators of Piezo1 or Piezo2 using high-throughput Ca2+ imaging. 
Yoda1 was found to be an agonist of both human and mouse Piezo1 when 
overexpressed in otherwise Piezo1-null cells and was, importantly, unable to 
activate the Piezo2 channel (Syeda et al. 2015). The compound was able to 
activate purified Piezo1 channels reconstituted in an artificial bilayer, indicating 
that Yoda1 can activate Piezo1 channels in the absence of other cellular 
components (Syeda et al. 2015). Yoda1-induced Ca2+ entry was dependent on 
calcium influx, as the chelation of extracellular calcium using EGTA dramatically 
reduced responses, whilst depletion of intracellular calcium stores had no effect 
(Syeda et al. 2015). Yoda1 was utilised in the present study to investigate 
endogenously-expressed Piezo1 channels in cardiac fibroblasts. 
 
3.4.4.1 Validation of the process used for screening Yoda1 analogues 
Piezo1 pharmacology is limited; inhibitors of the channel are restricted and these 
tend to be general inhibitors of many mechanosensitive channels (Coste et al. 
2010). Although Yoda1 is a useful research tool for facilitating the study of Piezo1 
channels, its solubility is poor (Syeda et al. 2015). To develop improved Piezo1 
modulators, increased knowledge of the structure-activity relationship for Yoda1 
activation of Piezo1 is essential. The Department of Chemistry at the University 
of Leeds synthesised Yoda1 analogues and, as part of this project, these were 
tested against the Piezo1 channel in the search for an improved agonist or a 
specific antagonist of the Piezo1 channel.  
To reliably study the effects of Yoda1 analogues on overexpressed Piezo1 
channels, tetracycline-inducible human Piezo1 was stably incorporated into HEK 
293 T‐REx™ cells. These cells, referred to as HEK-T-REx-hPiezo1 throughout, 
expressed PIEZO1 mRNA following tetracycline induction (Figure 3.12A). 




cells without Piezo1 incorporation (referred to as HEK-T-REx) (Figure 3.12A). 
Similarly, western blotting with an anti-Piezo1 antibody confirmed Piezo1 protein 
expression following induction with tetracycline in HEK-T-REx-hPiezo1 cells but 
not in control HEK-T-Rex cells. (Figure 3.12B). Therefore, these cells could be 
used as a model with which to investigate Piezo1 activation by analogues of 
Yoda1.  
Intracellular Ca2+ was measured prior to, and after, application of various 
concentrations of Yoda1. As expected, Yoda1 increased the levels of intracellular 
Ca2+ in HEK-T-REx-hPiezo1 cells (Figure 3.13A). Due to poor solubility of Yoda1, 
the recommended maximum concentration of Yoda1 is 10-20 μM (Syeda et al., 
2015). HEK-T-REx-hPiezo1 cells applied with tetracycline displayed a 
concentration‐dependent Ca2+ entry in response to Yoda1, with an EC50 of 1.85 
µM (Figure 3.13A). No Ca2+ entry was observed in cells treated with vehicle  
(DMSO) (Figure 3.13A). Control HEK-T-REx cells exhibited a lack of Ca2+ entry 
when treated with Yoda1 (Figure 3.13B); cells were viable, as shown by the Ca2+ 
influx in response to ATP. 
In order to confirm that Yoda1 could also activate mouse Piezo1 channels, a HEK 
293 T‐REx™ cell line heterologously expressing mouse Piezo1 was used; these 
cells will be referred to as HEK-T-REx-mPiezo1 throughout. As expected, Yoda1 
also increased the levels of intracellular Ca2+ in these cells (Figure 3.14A). The 
Ca2+ entry occurred in a concentration-dependent manner with a Yoda1 EC50 of 
0.33 µM; no Ca2+ influx occurred upon treatment with vehicle (Figure 3.14A). The 
induction of Ca2+ entry was absent in control HEK-T-REx cells (Figure 3.14B), 
despite a large increase in intracellular Ca2+ being observed when ATP was 
applied. These data confirmed that the experimental detection system for both 






Figure 3.12 Validation of the HEK cell line used for screening Yoda1 
analogues. (A) RT-PCR analysis of PIEZO1 mRNA levels relative to 
housekeeper (GAPDH) in control HEK-T-REx (T-Rex) and Piezo1-expressing 
HEK-T-REx-hPiezo1 (P1 T-Rex) cells (n=3). (B) Western blot performed using 
the BEEC-4 anti-Piezo1 antibody in HEK-T-REx (T-REx) and HEK-T-REx-






























Figure 3.13 Effect of Yoda1 when human Piezo1 is overexpressed in an 
otherwise null cell line. (A) Ca2+ entry evoked by varying concentrations of 
Yoda1 application at 60 seconds, ranging from 0.03-10 μM in HEK-T-REx-
hPiezo1 cells. Vehicle control is illustrated by the open circles. Mean data are 
displayed as a concentration-response curve and the fitted curve is plotted using 
a Hill Equation indicating the 50 % maximum effect (EC50) of Yoda1 (n/N=3/9). 
(B) Representative trace and mean data of the Ca2+ entry evoked by 10 µM 
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Figure 3.14 Effect of Yoda1 when mouse Piezo1 is overexpressed in an 
otherwise null cell line. (A) Ca2+ entry evoked by varying concentrations of 
Yoda1 application at 60 seconds, ranging from 0.01-10 μM in HEK-T-REx-
mPiezo1 cells. Vehicle control is illustrated by the open circles. Mean data are 
displayed as a concentration-response curve and the fitted curve is plotted using 
a Hill Equation indicating the 50 % maximum effect (EC50) of Yoda1 (n/N=3/9). 
(B) Representative trace and mean data of the Ca2+ entry evoked by 10 μM 
Yoda1 or 20 μM ATP in control HEK-T-REx cells without overexpression of 
mouse Piezo1 (n/N=3/9). 
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3.4.4.2 Small molecule screening  
3.4.4.2.1 Novel Piezo1 agonists 
A number of Yoda1 analogues were screened during this study; some are 
presented and discussed here. Their structures and modifications from Yoda1 
are shown in Figure 3.15A. Analogues were screened at a concentration of 10 
μM for their ability to cause Ca2+ entry in HEK-T-REx-hPiezo1 cells and this was 
compared with the Ca2+ influx observed with the same concentration of Yoda1. 
Representative intracellular Ca2+ traces are shown in Figure 3.17A-D, alongside 
the mean data (Figure 3.16E). Compounds 2e and 2k/Dooku1 had no effect on 
intracellular Ca2+ levels (Figure 3.16A,D). Compounds 2i and 2j appeared to be 







Figure 3.15 Chemical structures of Yoda1 and its analogues. Chemical 
structures of Yoda1 and some chosen analogues tested in the screen; 
modifications from the Yoda1 structure are highlighted with colour.  
Yoda1 






Figure 3.16 Screen of Yoda1 analogues for their ability to induce Ca2+ entry 
in a Piezo1-overexpressing cell line. Intracellular Ca2+ measurement 
representative traces for four analogues of Yoda1 which were tested as part of a 
larger screen. HEK-T-REx-hPiezo1 cells were exposed to 10 μM Yoda1 
alongside (A) 2e, (B) 2i, (C) 2j and (D) 2k/Dooku1. (E) Mean data are displayed 
as a bar chart, data are calculated as a % of Yoda1 activation (n/N=5/15). 
  





















































































































































3.4.4.2.2 Novel Piezo1 antagonists 
The same compounds were then tested as antagonists of the Piezo1 channel. 10 
µM of each analogue was used to pretreat HEK-T-REx-hPiezo1 cells for 30 min, 
prior to addition of 2 μM Yoda1. This was then compared to the Ca2+ influx in cells 
pretreated with vehicle alone before application of Yoda1. Representative 
intracellular Ca2+ traces are shown in Figure 3.17A-D, alongside the mean data 
(Figure 3.17E). It was observed that compound 2e has no effect on Yoda1-
evoked Ca2+ entry (Figure 3.17A). Due to compound 2e having no agonist or 
antagonist activity against the Piezo1 channel, it was utilised in future 
experiments as a negative control to ascertain that effects were Yoda1-specific. 
Initially, compounds 2i and 2j seemed to inhibit Ca2+ entry instigated by Yoda1 
(Figure 3.17B,C). However, as was previously illustrated in Figure 3.16C,D, they 
also had agonist activity against the channel; this is shown once more by the 
elevated baseline Ca2+ signal compared with vehicle control (Figure 3.17B,C). 
Therefore, these compounds would not be appropriate to be utilised as 
antagonists of Yoda1. Compound 2k, now known and published as Dooku1 
(Evans et al. 2018), inhibited Yoda1-evoked Ca2+ entry without any agonist 
activity, as demonstrated by the unchanged baseline Ca2+ signal (Figure 3.17D). 
These initial data highlighted compound 2k/Dooku1 as a potential Yoda1 






Figure 3.17 Screen of Yoda1 analogues for their ability to inhibit Yoda1-
evoked Ca2+ entry in a Piezo1-overexpressing cell line. Intracellular 
Ca2+ measurement representative traces for four analogues of Yoda1 which were 
tested as part of a larger screen. HEK-T-REx-hPiezo1 cells were pretreated with 
(A) 2e, (B) 2i, (C) 2j or (D) 2k/Dooku1 alongside vehicle only (DMSO) for 30 min 
and then activated using 2 µM Yoda1 at 60 seconds. (E) Mean data are displayed 
as a bar chart, data are calculated relative to the Ca2+ response when cells were 
pretreated with vehicle only (n/N=5/15). 
  



















































































































































3.4.4.2.3 Identification of Dooku1 as a Yoda1 antagonist 
Further experimentation revealed Dooku1 caused a concentration‐dependent 
inhibition of Yoda1‐induced Ca2+ entry, with an IC50 value of 1.30 μM in HEK-T-
REx-hPiezo1 cells (Figure 3.18A). 2 µM Yoda1 was used to activate Piezo1 in 
this assay as this was the approximate EC50 value (Figure 3.13). Inhibition was 
incomplete at 10 μM but higher concentrations of Dooku1 were not investigated 
due to solubility limitations. The same experiment was performed in HEK-T-REx-
mPiezo1 cells; Dooku1 was again able to produce a concentration‐dependent 
inhibition of Yoda1‐induced Ca2+ entry, with an IC50 value of 2.80 μM (Figure 
3.18B). Here, 0.5 µM Yoda1 was utilised for activation as this was the respective 
EC50 value (Figure 3.14). Further work on Dooku1 illustrated that this compound 
was selective for Piezo1 channels and had no effect on ATP-mediated or store-
operated Ca2+ entry (Evans et al. 2018). It was also shown that Dooku1 could 
inhibit Yoda1-evoked Ca2+ influx through endogenous Piezo1 channels in 
HUVECs (Evans et al. 2018). 
These data have provided insight into the structure-activity relationship of Piezo1 
channel activation by Yoda1, with the goal of generating novel small-molecule 
tools for investigating Piezo1 channel function. Dooku1 was identified, which 
effectively antagonises Yoda1‐induced Piezo1 channel activity, distinguishing it 
from constitutive Piezo1 channel activity. As previously discussed, there are 
emerging roles of Piezo1 in physiology but it is not yet clear whether activating or 
inhibiting the channel may be advantageous. Gaining knowledge of Piezo1 
channel interactions with small molecules promises to be an important aspect of 






Figure 3.18 Effect of a Yoda1 antagonist, Dooku1, on Yoda1-evoked Ca2+ 
entry through human and mouse Piezo1. Ca2+ entry in (A) HEK-T-REx-
hPiezo1 cells evoked by 2 µM Yoda1 application and (B) HEK-T-REx-mPiezo1 
cells evoked by 0.5 µM Yoda1 at 60 seconds after cells have been pretreated for 
30 min with various concentrations (0.01-10 µM) of Dooku1. Mean data are 
displayed as concentration-response curves and the fitted curves are plotted 
using a Hill Equation indicating the 50 % inhibitory effect (IC50) of Dooku1 against 
Yoda1-evoked Ca2+ entry (n/N=3/9). 
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3.4.5 Piezo1 is a functional ion channel in cardiac fibroblasts 
3.4.5.1 Optimising the intracellular Ca2+ measurement assay 
Having demonstrated that cardiac fibroblasts express Piezo1 mRNA and protein 
(Section 3.4.2), we proceeded to investigate whether Piezo1 protein was able to 
form a functional ion channel in these cells. Firstly, it was examined whether 
Yoda1 could activate endogenous Piezo1 channels in cardiac fibroblasts. Using 
the standard Fura-2 Ca2+ indicator assay, it was revealed that Yoda1 elicited an 
increase in intracellular Ca2+ in murine and human cardiac fibroblasts (Figure 
3.19A,B). However, this increase was relatively small and would make future 
results from experiments manipulating this response difficult to interpret. It was 
hypothesised that this may be due to extrusion of the Fura-2 indicator in 
fibroblasts, as has been observed previously in Chinese hamster ovary (CHO) 
cells (Edelman et al. 1994), rather than low Piezo1 activity per se. Hence, 
probenecid, a compound which prevents secretion and sequestration of the Fura-
2 indicator (Di Virgilio, Steinberg and Silverstein 1989), was included in the bath 
solution to enable more robust Ca2+ responses to be observed. When probenecid 
was present in the SBS throughout the experiment, the Ca2+ entry signal was 
amplified by 3-4-fold in both murine and human cardiac fibroblasts; this made 
results easier to decipher (Figure 3.19A,B). Therefore, this compound was used 
in all future Ca2+ measurements involving cardiac fibroblasts. 
In order to determine the optimal cardiac fibroblast number to use for the Fura-2 
assay using the FlexStation, varying densities of murine cardiac fibroblasts 
(20,000-60,000) were plated in 96-well plates. 20,000 cells displayed the 
optimum Ca2+ response to 10 µM Yoda1 (Figure 3.20). Therefore, going forward, 







Figure 3.19 Effect of probenecid on the Yoda1-induced Ca2+ influx in murine 
and human cardiac fibroblasts. Representative Ca2+ traces illustrating the Ca2+ 
entry evoked by 10 μM Yoda1 in (A) murine and (B) human cardiac fibroblasts in 
the presence of 2.5 mM probenecid, compared to 0 mM probenecid in the SBS 
throughout experimentation. The mean data are displayed as bar charts, *P<0.05 
following a t-test (n/N=3/9). 
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Figure 3.20 Optimisation of cardiac fibroblast cell number for the Fura-2 
assay. Representative Ca2+ traces illustrating the Ca2+ entry evoked by 10 μM 
Yoda1 in murine cardiac fibroblasts plated at different densities ranging from 








































































3.4.5.2 Yoda1 causes Ca2+ entry in murine cardiac fibroblasts 
Application of Yoda1 increased intracellular Ca2+ levels in a concentration-
dependent manner in cardiac fibroblasts with a detectable effect being observed 
at 0.3 µM and the maximal response at 10 μM; the 50 % maximum effect (EC50) 
of Yoda1 was calculated to be 0.72 μM (Figure 3.21A). This was almost identical 
to the EC50 generated in human cardiac fibroblasts in similar experiments (0.71 
µM) (Figure 3.21B). The poor solubility of Yoda1 limits meaningful interpretation 
of the EC50 value as concentrations above 10uM could not be prepared. These 
data were highly comparable with those from HEK-T-REx-mPiezo1 cells, in which 
the EC50 of Yoda1 was 0.33 μM (Figure 3.14) or HEK-T-REx-hPiezo1 cells, where 
the EC50 of Yoda1 was 1.85 µM (Figure 3.13). These data confirm that the Piezo1 
agonist, Yoda1, causes Ca2+ entry in murine and human cardiac fibroblasts. 
It was important to confirm that Yoda1 was activating plasma membrane Piezo1 
channels and inducing Ca2+ entry, rather than causing Ca2+ release from 
intracellular stores. To investigate this, murine and human cardiac fibroblasts 
were maintained in either media containing EGTA to chelate free Ca2+ or in media 
with physiological levels of extracellular Ca2+ (1.5 mM) and activated using 
Yoda1. The Ca2+ signal was abolished completely in human cardiac fibroblasts 
and reduced by >90 % in murine cardiac fibroblasts when extracellular Ca2+ was 
absent (Figure 3.22A,B), confirming Yoda1 is activating plasma membrane 
Piezo1 channels. However, as the response was not fully abolished in the 
absence of extracellular Ca2+ in murine cardiac fibroblasts, there is the possibility 







Figure 3.21 Effect of Yoda1 on the intracellular Ca2+ concentration in 
cardiac fibroblasts. Ca2+ entry evoked by varying concentrations of Yoda1 
(0.01-10 μM) applied at 60 seconds to (A) murine and (B) human cardiac 
fibroblasts. Vehicle control is illustrated by the open circles. Mean data are 
displayed as concentration-response curves and fitted curves are plotted using a 
Hill Equation indicating the 50 % maximum effect (EC50) of Yoda1 (n/N=3/9). 
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Figure 3.22 Effect of extracellular Ca2+ on Yoda1-evoked Ca2+ influx in 
cardiac fibroblasts. Representative Ca2+ traces indicating the Ca2+ entry evoked 
by 10 µM Yoda1 in (A) murine and (B) human cardiac fibroblasts in the presence 
or absence of extracellular Ca2+. Mean data are shown in bar charts, ***P<0.001 
following a t-test (n/N=3/9). 
  

















































































































































3.4.6 Piezo1 has the expected pharmacological properties in cardiac 
fibroblasts 
After confirming that Yoda1 evokes Ca2+ entry in cardiac fibroblasts, it was 
essential to investigate if this was Piezo1-mediated. Therefore, chemical 
inhibition of Piezo1 was explored. Gadolinium and ruthenium red, both non-
specific inhibitors of mechanosensitive ion channels including Piezo1 (Coste et 
al. 2010), were used to inhibit Yoda1-evoked Ca2+ entry. Yoda1 was used at a 
sub-maximal dose of 2 μM, which was estimated to be the approximate EC85 in 
both murine and human cardiac fibroblasts (Figure 3.21A,B). Murine cardiac 
fibroblasts pre-incubated with either of the two inhibitors exhibited significantly 
reduced Yoda1-evoked Ca2+ entry (>70 % reduction in both cases) (Figure 
3.23A). The data were very similar in human cardiac fibroblasts, where again the 
inhibitors significantly reduced the Ca2+ influx in response to Yoda1 (Figure 
3.23B). Using knowledge from previous studies exploiting these compounds, 
these findings are consistent with the theory that Piezo1 channels are mediating 
the Ca2+ response to Yoda1 in cardiac fibroblasts. 
Yoda1-evoked Ca2+ entry was significantly reduced by >50 % by the novel 
antagonist of Yoda1, Dooku1, in both mouse (Figure 3.24A) and human (Figure 
3.24B) cardiac fibroblasts. These data show that Dooku1 can effectively inhibit 
Yoda1-induced Ca2+ entry through the endogenous Piezo1 channel, in addition 
to in overexpression systems. 
The Yoda1 analogue, compound 159, is an agonist of Piezo1 discovered during 
subsequent structure-activity relationship investigations of the Yoda1 compound 
series. Compound 159 has higher solubility compared to Yoda1, probably due to 
the addition of its carboxylic acid group; the structures can be compared in Figure 
3.25. Analysis of intracellular Ca2+ levels revealed that compound 159 activated 
Piezo1 in a similar manner to Yoda1 in murine cardiac fibroblasts (Figure 3.25B). 
As the compound has better physicochemical properties, it may be suited to 






Figure 3.23. Effect of Piezo1 inhibitors on Yoda1-evoked Ca2+ entry in 
cardiac fibroblasts. Representative intracellular Ca2+ traces from (A) murine 
and (B) human cardiac fibroblasts exposed to 10 μM gadolinium (Gd3+), 30 μM 
ruthenium red (RuR) or vehicle for 30 min before activation of Piezo1 by 
application of 2 μM Yoda1. Mean data are shown following normalisation to 
vehicle-treated cells, ***P<0.001 versus vehicle-treated cells following an 
ANOVA with Tukey’s post-hoc test  (n/N=3/9). 
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Figure 3.24. Effect of Dooku1 on Yoda1-evoked Ca2+ entry in cardiac 
fibroblasts. Representative intracellular Ca2+ traces and mean data from (A) 
murine and (B) human cardiac fibroblasts exposed to 10 μM Dooku1 or vehicle 
for 30 min before activation of Piezo1 by application of 2 μM Yoda1. Mean data 
were normalised to vehicle-treated cells, ***P<0.001 versus vehicle-treated cells 
following a t-test (n/N=3/9). 
  




















































































































Figure 3.25. Effect of the novel compound, 159, on Yoda1-evoked Ca2+ entry 
in murine cardiac fibroblasts. (A) Chemical structures of Yoda1 and compound 
159; chemical modifications of compound 159 from Yoda1 are shown in green. 
(B) Representative intracellular Ca2+ traces and mean data from murine cardiac 
fibroblasts exposed to 10 μM Yoda1 or compound 159, P=NS, not significant 
following a t-test (n/N=3/9). 
  



























































3.4.7 Yoda1-evoked Ca2+ entry is mediated via Piezo1 
3.4.7.1 Genetically modifying the Piezo1 gene causes changes in Yoda1-
evoked Ca2+ entry 
Despite inhibitors of the Piezo1 channel being useful molecular tools for acutely 
blocking the channel and investigating its pharmacology, these are non-selective 
pore blockers. Consequently, it was imperative to use a complementary 
molecular biology approach to confirm that Yoda1 responses were due to Piezo1 
activation. Two Piezo1-modifed murine models were utilised; the first was a 
global heterozygous Piezo1 KO and the other was a line in which Piezo1 
contained a gain-of-function mutation (M2240R).  
A global homozygous Piezo1 full KO has previously been revealed to profoundly 
disturb the developing vasculature and be embryonically lethal within days of the 
heart beating (Li et al. 2014). Hence, the Ca2+ entry elicited by Yoda1 application 
was investigated in cardiac fibroblasts isolated from a global heterozygous (Het) 
Piezo1+/- KO mouse, which was viable. The Het Piezo1+/- KO mouse displayed 
reduced alignment of endothelial cells but had no major phenotype (Li et al. 
2014). RT-PCR analysis confirmed the predicted 50 % reduction in Piezo1 mRNA 
expression in cardiac fibroblasts derived from Piezo1+/- hearts, compared with 
those isolated from WT mice (Figure 3.26A). The Ca2+ entry upon Yoda1 
application was also reduced by 50 % (Figure 3.26B), indicating that the scale of 
the Yoda1 response in these cells is proportional to the amount of Piezo1 
expression. ATP was used as a positive control to validate that all cells had the 
equivalent Ca2+ content; the response to ATP was similar in cells from WT and 
Piezo1+/- mice (Figure 3.26C).  
The first report of the M2225R mutation in Piezo1 in humans was by Zarychanski 
et al. (2012). Investigations into the properties of the mutated channel revealed 
that the mutation caused the Piezo1 channel to exhibit delayed inactivation 
kinetics, leading to a gain-of-function mutation which caused the channel to 
remain open for longer, leading to increased Ca2+ influx (Albuisson et al. 2013; 
Bae et al. 2013). A mouse line was generated, using CRISPR/Cas9 technology, 
in which mice had a M2240R mutation in Piezo1 globally; this is the mouse 
equivalent of the human M2225R mutation. These mice are referred to as M-R 




doubling of the Ca2+ entry in response to Yoda1 activation, compared with cardiac 
fibroblasts from WT mice (Figure 3.27A). Cardiac fibroblasts from both sets of 
mice were confirmed to display identical ATP-evoked Ca2+ entry (Figure 3.27B). 
Together, these data using cells from genetically modified mice indicate that 
Yoda1-induced Ca2+ entry in cardiac fibroblasts is dependent on Piezo1 






Figure 3.26 Effect of altering Piezo1 mRNA expression on Yoda1-evoked 
Ca2+ entry in murine cardiac fibroblasts. (A) RT-PCR analysis of Piezo1 
mRNA expression in cultured murine cardiac fibroblasts isolated from wild-type 
(WT) and Piezo1+/- (Het) mice. Expression is measured as % of housekeeping 
control, Gapdh, ***P<0.001 following a t-test (n=8). (B) Representative Ca2+ 
traces and mean data illustrating Ca2+ entry elicited by 10 μM Yoda in cardiac 
fibroblasts from WT (n/N=8/24) and Piezo1+/- Het mice (n/N=5/15), ***P<0.001 
following a t-test. (C) Representative Ca2+ traces and mean data illustrating the 
Ca2+ entry evoked by 5 μM ATP in cardiac fibroblasts from WT (n/N=4/12) and 
Piezo1+/- Het (n/N=3/9) mice, P=NS, not significant following a t-test. 
  




















































































































































Figure 3.27 Effect of altering Piezo1 activity on Yoda1-evoked Ca2+ entry. 
(A) Representative Ca2+ traces and mean data illustrating Ca2+ entry elicited by 
2 μM Yoda in cardiac fibroblasts from wild-type (WT; n/N=3/9) and gain-of-
function M2240R Piezo1-mutated mice (M-R; n/N=5/15) mice, **P<0.01 following 
a t-test. (B) Representative Ca2+ traces and mean data illustrating the Ca2+ entry 
evoked by 20 μM ATP in cardiac fibroblasts from wild-type (WT; n/N=3/9) and 
gain-of-function Piezo1-mutated mice (M-R; n/N=5/15) mice, P=NS, not 




















































































































3.4.7.2 Yoda1-induced Ca2+ entry is abolished by Piezo1-specific siRNA 
A complementary method to the transgenic studies was sought to confirm the 
relationship between Piezo1 and Yoda1-evoked Ca2+ entry. This was the 
utilisation of siRNA targeting Piezo1 to genetically disrupt its expression. 
Optimisation was required to source an appropriate siRNA which silenced mouse 
Piezo1 but had no off-target effects. Higher concentrations of siRNA are more 
likely to cause off-target effects; therefore, the aim was to acquire an siRNA which 
could silence Piezo1 at a low concentration. Murine cardiac fibroblasts were 
transfected with two Piezo1-specific siRNAs from different suppliers at different 
concentrations, alongside their respective control siRNAs and a transfection 
protocol in the absence of siRNA (mock transfection). The effectiveness of gene 
silencing was evaluated by RT-PCR 48 h after transfection. There was no 
difference in Piezo1 mRNA expression between mock-transfected cardiac 
fibroblasts and cells transfected with control siRNA (Figure 3.28). 10 nM Piezo1-
specific siRNA from Dharmacon achieved a 46 % reduction in Piezo1 mRNA 
expression; the respective figure for Ambion Piezo1-specific siRNA was 53 % 
(Figure 3.28). There was minimal difference between Piezo1 mRNA expression 
following transfection with 10 nM or 20 nM of siRNA (Figure 3.28). Therefore, 10 
nM of Ambion Piezo1-specific siRNA was selected for use in subsequent 
experiments to silence Piezo1 in murine cardiac fibroblasts to minimise any off-
target effects. 
With further optimisation of the protocol, Piezo1-specific siRNA decreased 
Piezo1 mRNA expression by 80 % in murine cardiac fibroblasts (Figure 3.29A). 
The resulting Piezo1 knockdown markedly reduced the Yoda1-evoked Ca2+ entry 
by 84 % which was consistent with the level of Piezo1 mRNA knockdown (Figure 
3.29B); control siRNA was without effect. Similar data were obtained using 
human cardiac fibroblasts, in which Piezo1-specific siRNA knocked down 
PIEZO1 mRNA levels by 77 %, compared to cells treated with a control siRNA 
(Figure 3.29C). Once again, this dramatically reduced Yoda1-evoked Ca2+ entry 
(by 62 %) (Figure 3.29D). Thus, it was confirmed that Ca2+ influx in response to 
Yoda1 was dependent on Piezo1 and proportional to its expression levels. 
To confirm that Piezo1 siRNA could also reduce Piezo1 protein levels, and to 
also confirm that the band detected in cardiac fibroblasts isolated from mice with 




fibroblasts isolated from these mice were transfected with control siRNA and 
siRNA targeting Piezo1. Piezo1-HA protein was not detected in WT mice, as 
expected (Figure 3.30). In cardiac fibroblasts from Piezo1-HA mice transfected 
with control siRNA, a 295 kDa band corresponding to Piezo1 protein was 
detected; however in Piezo1-specific siRNA-transfected cells, Piezo1 protein 
expression was fully knocked down, confirming that this band is Piezo1 (Figure 
3.30). 
Through the combined use of pharmacological blockers of the Piezo1 channel, 
murine models with genetic disruption of Piezo1, and Piezo1-specific siRNA, it 
has been confirmed that the Ca2+ influx observed in cardiac fibroblasts activated 






Figure 3.28 Optimisation of Piezo1-specific siRNA protocol. RT-PCR 
analysis of Piezo1 mRNA expression 48 h after transfection of murine cardiac 
fibroblasts with Piezo1-specific (P1) siRNA from two different suppliers (purple 
bars), with their accompanying control (C) siRNA (white bars), alongside mock-
transfected cells (grey bar). Expression is measured as % of housekeeping 




































Figure 3.29 Effect of Piezo1 knockdown on Yoda1-evoked Ca2+ entry in 
murine and human cardiac fibroblasts. (A) RT-PCR analysis of Piezo1 mRNA 
expression following transfection of murine cardiac fibroblasts with no siRNA 
(mock), control (C) siRNA or Piezo1-specific (P1) siRNA. Expression is measured 
as % of housekeeping control, Gapdh, ***P<0.001 versus mock-transfected cells 
following an ANOVA with Tukey’s post-hoc test (n=3). (B) Representative Ca2+ 
traces and mean data showing the response of murine cardiac fibroblasts to 2 
μM Yoda1 after transfection with Piezo1-specific (P1) siRNA, compared to mock-
transfected cells and cells treated with control (C) siRNA, ***P<0.001 versus 
mock-transfected cells following an ANOVA with Tukey’s post-hoc test (n/N=3/9). 
(C) As for (A) but in human cardiac fibroblasts, ***P<0.001 versus mock-
transfected cells following an ANOVA with Tukey’s post-hoc test (n=3). (D) As for 
(B) but in human cardiac fibroblasts, *P<0.05 versus mock-transfected cells 
following an ANOVA with Tukey’s post-hoc test (n/N=3/9). 
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Figure 3.30 Effect of Piezo1-specific siRNA on protein levels in murine 
cardiac fibroblasts. Representative image and mean densitometric data of 
Piezo1 protein detected by western blotting in cardiac fibroblasts isolated from a 
CRISPR-generated murine model in which Piezo1 was modified to contain a HA 
tag. Samples from WT and Piezo1-HA mice were transfected with control (C) or 
Piezo1-specific (P1) siRNA and immunoblotted with anti-HA antibody, followed 
by an α-tubulin antibody to confirm equal protein loading (n=3). Data are 
normalised to control siRNA (C. si.). A band is detected at the expected size: 295 
kDa.  






























































3.4.8 Mechanical activation of Piezo1 in cardiac fibroblasts 
3.4.8.1 Hypotonic stress evokes Ca2+ entry in murine cardiac fibroblasts 
in a Piezo1-independent manner 
Increased deposition of ECM has been correlated with high glucose levels seen 
in diabetes; Tang et al. (2007) demonstrated that high glucose promoted 
production of collagen types I and III in rat cardiac fibroblasts through an ERK1/2 
pathway. Osmotic swelling and increased stretch of cells transpire in the infarcted 
or pressure-overloaded myocardium and these factors can increase 
cardiomyocyte hypertrophy and mediate fibrotic responses through the activation 
of cardiac fibroblasts (Lu et al. 2012). Moreover, Piezo1 has been implicated in 
volume control in RBCs; RBCs from blood-cell-specific Piezo1 KO mice are 
overhydrated whereas activation of Piezo1 using Yoda1 causes calcium influx 
and subsequent dehydration of RBCs (Cahalan et al. 2015). A 96-well plate assay 
was developed to elicit hypotonic stress in cardiac fibroblasts, to determine 
whether this activated Piezo1. The FlexStation and Fura-2 assay were again 
utilised to investigate intracellular Ca2+ levels and a buffer was used in which Na+ 
was replaced with decreasing concentrations of NMDG-Cl to make solutions 
increasingly hypotonic. 135 mM NMDG-Cl was used as an isotonic control 
throughout all experiments. Firstly, it was assessed whether murine cardiac 
fibroblasts respond to hypotonic stimulation. Application of decreasing 
concentrations of NMDG-Cl, which causes cells to swell and pressure to 
increase, caused transient increases in intracellular Ca2+ levels in a 
concentration-dependent manner (Figure 3.31), indicating that these cells are 
responsive to hypotonic stress. 
Subsequently, the involvement of Piezo1 channels in hypotonic stress-evoked 
Ca2+ entry was assessed. The non-selective cation channel ion pore blocker, 
gadolinium (+Gd3+), or its vehicle, were used to pretreat murine cardiac 
fibroblasts to establish whether Ca2+ entry into cells was affected. Vehicle-treated 
cardiac fibroblasts showed concentration-dependent hypotonic responses 
(Figure 3.32A). However, these responses were reduced by 70 % when 
gadolinium was used prior to the addition of NMDG-Cl solutions (Figure 3.32A). 
The EC50 values without and with gadolinium pretreatment were comparable at 
74.3 mM and 76.8 mM, respectively (Figure 3.32B,C), indicating that the 




channels which have not been inhibited. These data indicate that 
mechanosensitive non-selective cation channels, such as Piezo1, may be 
facilitating the increase in intracellular Ca2+ induced by cell swelling. 
A more specific approach of gene silencing was employed to analyse whether 
Piezo1 channels specifically were responsible for the Ca2+ entry evoked by cell 
swelling. Piezo1-specific siRNA had no effect on intracellular Ca2+ levels in 
response to hypotonic stress in murine cardiac fibroblasts, compared to cells 
transfected with control siRNA (Figure 3.33A). This can be seen clearly in the 
mean data illustrating Ca2+ entry evoked by the most hypotonic solution (Figure 
3.33B,C). Together with the Gd3+ experiments, these data suggest that the 
hypotonicity-evoked Ca2+ response in cardiac fibroblasts is mediated by a ion 







Figure 3.31 Effect of hypotonic stress on intracellular Ca2+ levels in murine 
cardiac fibroblasts. Representative intracellular Ca2+ measurement traces and 
mean data from murine cardiac fibroblasts during application of a range of 
concentrations of NMDG-Cl (55-90 mM) which evoke hypotonic stress, alongside 
an isotonic solution (135 mM) (n/N=3/9).  


























































Figure 3.32 Effect of gadolinium pretreatment on Ca2+ entry evoked by 
hypotonicity. (A) Example intracellular Ca2+ measurement traces from murine 
cardiac fibroblasts during application of varying concentrations of NMDG-Cl (55-
135 mM). Left: after 30 min pretreatment with the vehicle of gadolinium (-Gd3+). 
Right: After 30 min pretreatment with 10 μM gadolinium (+Gd3+). (B) 
Concentration-response data from the type of experiments in (A) (n/N=3/9). The 
fitted curve is a Hill equation indicating the 50 % maximum effect (EC50) at 74.3 
mM NMDG without gadolinium pretreatment and 76.8 mM NMDG with gadolinium 
pretreatment. (C) Mean data are shown in a bar chart comparing the EC50 values 
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Figure 3.33 Effect of Piezo1 knockdown on the response of murine cardiac 
fibroblasts to hypotonicity. (A) Example intracellular Ca2+ measurement traces 
from murine cardiac fibroblasts during application of varying concentrations of 
NMDG-Cl (55-135 mM). Left: cells transfected with control (C) siRNA. Right: cells 
transfected with Piezo1-specific (P1) siRNA. (B) Concentration-response data for 
NMDG-Cl from the type of experiments in (A), data are normalised to isotonic 
control (135 mM NMDG-Cl) (n/N=3/9). (C) Mean data for the peak response at 
55 mM for the experiment in (A), P=NS, not significant following a t-test (n=3). 
  

























































































































































3.4.8.2 Human cardiac fibroblasts express mechanically-activated ionic 
currents which depend on Piezo1 
Cell-attached patch recordings were used as an alternative method to 
mechanically activate Piezo1 in cardiac fibroblasts. Mechanical force was applied 
to patches using a fast pressure-clamp system which generated pressure pulses 
and increased membrane tension. Increased pressure caused increased current 
in human cardiac fibroblasts (Figure 3.34A,B), consistent with the presence of 
Piezo1 channels (Coste et al. 2010; Bae et al. 2013). The currents were noisy 
which suggests the presence of multiple individual channels producing the overall 
current. The pressure required for 50% activation was estimated to be -61.3 
mmHg (Figure 3.34A). To test if currents were Piezo1-dependent, human cardiac 
fibroblasts were transfected with control or Piezo1-specific siRNA. Piezo1 siRNA-
transfected cells showed no meaningful current in response to pressure steps, 
unlike in cells transfected with control siRNA (Figure 3.34B,C). Data for all 45 
recordings show that pressure-activated currents were more common in the 
control siRNA-transfected cells (Figure 3.34D) than in Piezo1 siRNA-transfected 
cells (Figure 3.34E). This was shown to be statistically significant and, therefore, 
these data suggest that human cardiac fibroblasts express mechanically 
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Figure 3.34 Effect of Piezo1 knockdown on ionic currents evoked by 
mechanical pressure in human cardiac fibroblasts. (A) Recordings were 
made from cell-attached patches on human cardiac fibroblasts. A constant 
holding voltage of +80 mV was applied to the patch pipette and a rapid pressure 
clamp system applied 200-ms negative pressure (suction) steps to the patch 
pipette of increasing magnitude. Mean ± SEM data are shown for experiments in 
which the total current during 180-ms of each pressure pulse was summed (n=7-
8 patches per data point). The fitted curve is the Boltzmann function, which gave 
a mid-point for 50% activation of -61.3 mmHg. (B) Example data from an 
untransfected cell analysed in (A). The colour of the pressure steps (lower panel) 
matches the colour of the current traces in the upper panel. (C) As for (B) but 
from a cell transfected with Piezo1 siRNA. (D,E) Individual data from cells 
transfected with control siRNA (D, n=24) or Piezo1 siRNA (E, n=21). Two-way 
ANOVA comparison with Tukey’s post-hoc test of control v Piezo1 siRNA gave 
*P<0.05 over all pressure steps. Experiments were performed by Professor 




3.5 Discussion  
The heart experiences electrical, biochemical, and mechanical stimulations as it 
contracts; thus, cardiac cells express mechanosensitive apparatus which is 
capable of detecting mechanical stimulation (Peyronnet, Nerbonne and Kohl 
2016). There is currently no information on Piezo1 in cardiac fibroblasts, despite 
knowledge that they express other mechanically-activated ion channels (Yue, Xie 
and Nattel 2011) and that the molecular mechanisms by which they sense 
mechanical signals remain elusive (Hinz and Gabbiani 2010). For these reasons, 
the aims of this study were to examine the chemical and mechanical activation of 
Piezo1 in cardiac fibroblasts. 
Messenger RNA encoding Piezo1 was detected in the murine heart by Coste et 
al. (2010). There have since been publications investigating Piezo1 expression 
in cardiomyocytes (Liang et al. 2017; Wong et al. 2018) but none exploring the 
ion channel in cardiac fibroblasts. The only current publication on Piezo1 in 
fibroblasts from other sources is a recent paper by Chubinskiy-Nadezhdin et al. 
(2019). In that study, RT-PCR and immunofluorescent staining were used to 
confirm the presence of native Piezo1 in a mouse fibroblast cell line and 
functional expression of Piezo1 was illustrated using calcium measurements. The 
current study is the first to establish that cultured cardiac fibroblasts express 
Piezo1 mRNA. It was established that Piezo2 mRNA expression was expressed 
at lower levels than Piezo1 mRNA. This result was expected as Coste et al. 
(2010) found there to be low expression of Piezo2 in whole heart; this protein has 
been shown to be more important in somatosensation (Woo et al. 2014; Woo et 
al. 2015; Dubin et al. 2012). 
Cultured murine and human cardiac fibroblasts expressed Piezo1 mRNA at 
levels similar to those found in endothelial cells from various sources, cells known 
to express high levels of functional Piezo1 (Li et al. 2014). Piezo1 mRNA 
expression was revealed to be approximately 25-times higher in cardiac 
fibroblasts than cardiomyocytes. This finding correlates with data from Liang et 
al. (2017) who found that Piezo1 was only expressed at low levels in mouse 
ventricular myocytes isolated from control animals but was significantly increased 
in myocytes isolated from mice that had undergone MI. Alongside demonstrating 
that Piezo1 mRNA is expressed in cultured cardiac fibroblasts, expression in 




that Piezo1 is expressed in native cardiac fibroblasts, and that its expression is 
not due to alterations in phenotype induced by culturing. Piezo1 protein was 
detected in cardiac fibroblasts with the use of a novel transgenic mouse globally 
expressing a mutated hemagglutinin (HA)-tagged version of Piezo1, developed 
using CRISPR-Cas9 technology. This allowed the identification of Piezo1 using 
anti-HA antibodies by western blotting; this was essential as current Piezo1 
antibodies are non-specific. This transgenic mouse will be invaluable for future 
studies into Piezo1, for example, for immunocytochemistry or 
immunoprecipitation experiments to investigate Piezo1 localisation or interacting 
partners, respectively. The aforementioned paper by Liang et al. (2017) found 
that Piezo1 mRNA and protein expression were enhanced by Ang II in neonatal 
rat ventricular myocytes via an AT1 receptor-ERK1/2 pathway but, generally, 
information on how Piezo1 expression is regulated is scarce. Applying 
mechanical stimuli directly to cells or altering the confluency or differentiation 
state of cardiac fibroblasts had no effect on Piezo1 mRNA expression. These 
findings were beneficial to the study as they confirmed that effects observed 
throughout were due to Piezo1 activity, rather than due to altered Piezo1 
expression. However, there was a hint that, although Piezo1 mRNA expression 
is unchanged when cells are activated using “outside-in” mechanical forces, i.e. 
forces arising from shear flow or stretch, expression may be downregulated when 
cells themselves generate less mechanical force (on softer substrates), i.e. 
traction forces caused by changes in the local environment. Cellular traction 
forces have been demonstrated to generate Piezo1-mediated Ca2+ flickers in the 
absence of externally-applied mechanical forces (Ellefsen et al. 2019).  
One major disadvantage of using Yoda1 to activate Piezo1 is its lack of drug-like 
properties i.e. it has poor solubility, a short half-life and a high clearance rate 
(Kevin Cuthbertson PhD thesis, 2019). Investigation into the properties of 
analogues of Yoda1 has provided increased knowledge of the structure-activity 
relationship of Piezo1 channel activation by Yoda1. The goal is to generate novel 
small-molecule tools for investigating Piezo1 channel function, such as an 
agonist with improved absorption, distribution, metabolism and excretion (ADME) 
properties or a specific antagonist of the Piezo1 channel. Yoda1 appears to have 
a very tight structure-activity relationship as any slight structural changes have 




previously demonstrated that the effect of Yoda1 appears to critically depend on 
the dichlorophenyl group, as similar compounds lacking the chlorines were not 
identified in their screen. Data published by Evans et al. (2018) confirmed the 
dichlorophenyl moiety of Yoda1 to be essential for activating the Piezo1 channel 
when overexpressed in HEK-293 cells. This is illustrated herein as compounds 
containing the dichlorophenyl group, 2i and 2j, were partial agonists of Piezo1 
whereas compound 2e, which lacks the dichlorophenyl group, was inactive. 
Using this logic, it was unexpected that compound 2k/Dooku1 did not trigger Ca2+ 
influx, due to the compound possessing a dichlorophenyl group. Experiments 
performed to analyse the ability of the same Yoda1 analogues to inhibit Piezo1 
revealed that compound 2k/Dooku1 was in fact able to block Yoda1-evoked Ca2+ 
influx. These data confirmed that the dichlorophenyl group is important for 
compounds interacting with the channel in any way, whether as agonists or 
antagonists. This screening process led to the development of Dooku1 as a 
small-molecule which antagonises Yoda1-evoked Piezo1 channel activation 
(Evans et al. 2018). Dooku1 inhibits Yoda1-evoked Piezo1 activation but is 
unable to block physiological Piezo1 channels (Evans et al. 2018). Therefore, it 
is probable that its binding site is the same as for Yoda1 and the compound 
prevents Yoda1 from binding to the Piezo1 channel. Despite being unable to 
block constitutively active Piezo1 channels, Dooku1 provides a useful tool 
compound to study Yoda1-evoked Piezo1 channel activation and signalling. 
Further screening of Yoda1 analogues led to the discovery of compound 159. In 
vitro ADME analysis demonstrated that, compared to Yoda1, KC159 had greater 
solubility and did not precipitate in aqueous solution until it reached 76.6 µM 
(Kevin Cuthbertson PhD thesis, 2019). Additionally, KC159 had a half-life almost 
40-times greater than Yoda1 and a clearance rate 35-times lower than Yoda1. 
This analogue of Yoda1 was proven to be able to evoke similar Ca2+ influx to its 
parent compound in murine cardiac fibroblasts. These characteristics render 
KC159 a more desirable drug with which to analyse Piezo1-mediated signalling 
and to take forward for in vivo investigation but more work is needed to further 
characterise this compound. 
Despite demonstrating mRNA and protein expression of Piezo1, it was vital to 
corroborate that Piezo1 formed a functional channel in cardiac fibroblasts. This 




The advantage of utilising a chemical agonist over mechanical activation to 
stimulate Piezo1 channel opening is the specificity. While the latter could activate 
a plethora of cellular mechanosensors, Yoda1 is specific to Piezo1, with no 
agonist activity against other ion channels, including Piezo2 (Syeda et al. 2015). 
Using the Ca2+ indicator, Fura-2, it was established that Yoda1 had EC50 values 
of 0.72 μM and 0.71 µM in murine and human cardiac fibroblasts, respectively, 
implying that Piezo1 forms a functional, Ca2+-permeable channel in cardiac 
fibroblasts. When artificially overexpressed in cell lines, the respective data on 
mouse (EC50 = 0.33 μM) and human (EC50 = 1.85 μM) Piezo1 overexpressed in 
HEK T-REx-293 cells were somewhat lower than those originally reported in 
HEK-293 cells transiently transfected with mouse (EC50 = 17.1 μM) or human 
(EC50 = 26.6 μM) Piezo1 (Syeda et al. 2015). The data were more comparable 
with a previous report from our laboratory where Evans et al. (2018) 
demonstrated an EC50 of 0.23 μM in HUVECs. As discussed, Yoda1 has poor 
solubility so could only be used at concentrations up to 10 μM; therefore these 
EC50 values are estimates and, along with the fact that the data was produced by 
different groups, could be the reason for any discrepancies. When cardiac 
fibroblasts were pretreated in the absence of  extracellular Ca2+, the Yoda1 
response was blunted in murine cells and completely abolished in human cells, 
indicating that the majority of the response is through plasma membrane Piezo1 
channels. The residual response in murine cardiac fibroblasts may be due to 
Yoda1 activating Piezo1 channels present in internal store membranes and 
triggering the release of Ca2+; previous reports have demonstrated expression of 
Piezo1 in the endoplasmic reticulum (McHugh et al. 2010). This would need to 
be investigated further in cardiac fibroblasts, however, it is evident that the 
majority of the Ca2+ influx observed in response to Yoda1 is mediated by Ca2+ 
entry from extracellular sources. 
The ability of common inhibitors of mechanosensitive ion channels, gadolinium 
and ruthenium red (Coste et al. 2010), and the novel Yoda1 antagonist, Dooku1 
(Evans et al. 2018), to decrease Yoda1-evoked Ca2+ entry in murine and human 
cardiac fibroblasts correlated with the expected properties of the channel. We 
further verified that the Yoda1-evoked Ca2+ influx in cardiac fibroblasts was 
proportional to the expression and activity of Piezo1. Small interfering RNA-




heterozygous KO mouse model both reduced Yoda1-evoked Ca2+ entry and this 
was proportional to the expression of Piezo1 mRNA expression. Li et al. (2014) 
generated and characterised the Piezo1 heterozygous KO mouse and found that, 
although the animals were phenotypically normal, there were differences in the 
organisation of endothelial cells lining the vessels (a more cobblestone-like 
appearance rather than the linear appearance in the direction of flow seen in 
Piezo1+/+ littermate controls). In addition, Ca2+ entry due to Yoda1 was amplified 
in cardiac fibroblasts isolated from mice with a global gain of function M2220R 
mutation in Piezo1, which is the murine equivalent of the human M2225R 
mutation (Zarychanski et al. 2012). The mutation causes an imbalance in 
intracellular cation concentrations, leading to defective RBC membrane 
properties. This has since been revealed to be due to delayed inactivation kinetics 
of the Piezo1 channel, leading to a gain-of-function mutation which causes the 
channel to remain open for longer, allowing increased Ca2+ influx (Albuisson et 
al. 2013; Bae et al. 2013). This renders patients with severe haemolytic anaemia 
in a disease named dehydrated hereditary stomatocytosis. The CRISPR-
generated mice utilised also display symptoms of anaemia (Evans et al. 
unpublished). Thus, it was confirmed that Yoda1 responses observed in cardiac 
fibroblasts were unequivocally due to the activation of Piezo1. 
Despite hypotonicity-evoked Ca2+ signals being observed in murine cardiac 
fibroblasts which were able to be inhibited by gadolinium, knockdown of Piezo1 
by specific siRNA had no effect on this Ca2+ influx. It may be that alternative non-
selective cation channels are responsible for the changes in intracellular Ca2+ 
levels. It is known that many of the TRP channels are expressed in cardiac 
fibroblasts and have been associated with activation due to mechanical stretch 
(Yue et al. 2013). Several of these, for example, TRPV2 (Muraki et al. 2003) and 
TRPV4 (Vriens et al. 2004), have been shown to be activated by osmotic cell 
swelling and can also be inhibited by Gd3+ (Bouron, Kiselyov and Oberwinkler 
2015). 
Cell-attached patch clamp electrophysiology was used as an alternative method 
to mechanically activate Piezo1 in human cardiac fibroblasts. The amplitude of 
the current was greatly variable between patches; it is suggested that the variable 
amount of suction needed to form the initial seal was a contributor to this 




was shown that increased pressure pulses generated increased inward current. 
The estimated pressure for 50% activation (-61.3 mmHg) varies from previous 
work which suggested that overexpressed human Piezo1 channels require -43 
mmHg for 50% activation (Bae et al. 2013); this difference may be due to the 
impact of the native environment (Romero et al. 2019). The kinetics of the 
currents were relatively slow and did not inactivate which disagrees with data on 
overexpressed Piezo1 channels (Coste et al. 2010). However, it has been 
proposed that endogenous Piezo1 channels have slower kinetics and do not 
inactivate or inactivate slowly (Li et al. 2014; Del Mármol et al. 2018). Piezo1-
specific siRNA was utilised to test if the currents were Piezo1-dependent. 
Pressure-activated currents were more frequent in control siRNA-transfected 
cells, in comparison with the Piezo1-siRNA-transfected group. It is proposed that 
the only 2 large recordings in the Piezo1 siRNA-transfected group were from cells 
unsuccessfully transfected with Piezo1-specific siRNA, as transfection efficiency 
was estimated to be 90 %. These data therefore suggest that Piezo1 can be 
activated using mechanical stimuli in cardiac fibroblasts. 
Together, data in this chapter have established that, in both mouse and human 
cardiac fibroblasts, Piezo1 mRNA is expressed and Piezo1 protein is translated 
and able to form a functional cation channel. Piezo1 mRNA expression remained 
unaffected when cardiac fibroblasts were stimulated using cytokines and 
mechanical stimuli such as shear stress and stretch but its expression appeared 
to be decreased when cells were plated on softer substrates. The Piezo1 channel 
had the expected pharmacological properties and the Yoda1-induced Ca2+ entry 
was dependent on Piezo1 expression, as evidenced by a variety of methods. 
Mechanical force applied via cell-attached patch clamp electrophysiology was 







Chapter 4 Yoda1-induced activation of Piezo1 alters the 
expression of remodelling genes in cardiac fibroblasts 
4.1 Introduction 
Cardiac fibroblasts are the fundamental cell type responsible for ECM 
homeostasis in health and its remodelling in heart disease. Cardiac fibroblasts 
produce both structural ECM proteins (e.g. collagens, fibronectin) and MMPs, 
which enzymatically digest ECM proteins. The activity of MMPs is regulated at 
the level of transcription, by activation of the precursor zymogens and by the 
inhibition by TIMPs (Nagase, Visse and Murphy 2006). Cardiac fibroblasts also 
synthesise and secrete a variety of bioactive molecules, including cytokines, 
active peptides and growth factors, which function in the myocardium in autocrine 
and/or paracrine fashions (Fan et al. 2012). In response to changes in 
haemodynamic burden of the heart, mechanical stress (generated by ECM 
stiffness) induces the differentiation of fibroblasts into myofibroblasts, cells with 
increased expression of α-SMA, periostin and pro-fibrotic cytokines (Deb and Ubil 
2014; Turner and Porter 2013; Oka et al. 2007). If this burden persists, it can lead 




In the previous chapter, it was established that Piezo1 is expressed by cardiac 
fibroblasts and acts as a mechanosensitive ion channel in this cell type. The 
primary aims of this chapter were to investigate whether activating the channel, 
using chemical activation, such as Yoda1, or mechanical stimulation, leads to 








Cardiac fibroblasts were treated with the Piezo1 activator, Yoda1, and it was 
assessed whether the compound had any effect on cell viability using the 
LIVE/DEAD cell assay, as described in Section 2.8. Gene expression was 
analysed using RT-PCR (Section 2.5). It was then investigated whether Yoda1-
induced changes in gene expression were dependent on Piezo1; this was 
performed utilising Piezo1-modified murine models (Section 2.13.3) and siRNA 
targeting Piezo1 (Section 2.4). It was also explored whether mechanical 
stimulation (shear stress, controlling substrate stiffness or cell stretching, which 
are described in Section 2.11) induced similar changes in gene expression and, 







4.4.1 Activation of Piezo1 and the effect on gene expression 
4.4.1.1 Yoda1 has no impact on cardiac fibroblast viability after 24 h of 
treatment 
To gain insight into the functional role of Piezo1 activation in cardiac fibroblasts, 
the effect of activating the Piezo1 channel using Yoda1 was investigated. A 
LIVE/DEAD cell viability assay was firstly performed to identify whether Yoda1 
had any effect upon murine cardiac fibroblast viability over prolonged time 
periods. A maximal concentration of 10 µM Yoda1 was utilised, as this was the 
highest concentration used throughout the study. When applied with Yoda1, 90 
% of cardiac fibroblasts were alive after 24 h treatment (illustrated by green 
staining), compared to 97 % after treatment with the vehicle control; this 
difference was not statistically significant (Figure 4.1). 1 µM staurosporine (SSP) 
was used as a positive control as a compound which causes cell death; SSP 
treatment resulted in 38 % cell death as visualised by the increased red staining 
(Figure 4.1). This suggests that an extended period of Yoda1 exposure does not 
adversely affect cardiac fibroblast viability. It is notable that Yoda1 induced a 
morphological change in the cells towards a more spindle-like, less rhomboid 
shape, in comparison with vehicle-treated cells; this will be discussed in more 






Figure 4.1 Effect of 24 h Yoda1 treatment on murine cardiac fibroblast 
viability. Representative images from the LIVE/DEAD cell viability assay 
performed on cultured murine cardiac fibroblasts treated with either vehicle, 10 
μM Yoda1 or 1 µM staurosporine (SSP) for 24 h. Green indicates live cells; red 
indicates dead cells. Scale bar = 300 µm. Bar chart displays mean data of viable 
cells as a percentage of total cells, **P<0.01, P=NS, not significant versus 
vehicle-treated cells following an ANOVA with Tukey’s post-hoc test (n=3). 
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4.4.1.2 Activating Piezo1 causes changes in the expression of key 
remodelling genes 
The expression of remodelling genes following 24 h treatment with 0.5-10 μM 
Yoda1 was investigated by RT-PCR. Prolonged Yoda1 treatment did not 
modulate Piezo1 gene expression itself (Figure 4.2A). However, three genes 
associated with myofibroblast differentiation were altered. Expression of Acta2 
mRNA, the gene that encodes α-SMA, decreased by over 50 % following 10 µM 
Yoda1 treatment (Figure 4.2B) and expression of the gene encoding the 
profibrotic cytokine TGF-β (Tgfb1) was significantly reduced in a concentration-
dependent manner (Figure 4.2C). Expression of Postn mRNA, the gene encoding 
periostin, a described marker of the myofibroblast that is expressed in adult 
tissues only after injury (Snider et al. 2009), was also significantly decreased by 
Yoda1 treatment at concentrations greater than 2 µM for 24 h (Figure 4.2D). As 
with Piezo1 mRNA expression, Yoda1 treatment did not affect expression of 
genes involved in ECM turnover, including collagens I and III (Col1a1, Col3a1) or 
Mmp3 or Mmp9 (Figure 4.2E-H). 
In contrast, the expression levels of Tnc, a molecule closely associated with 
tissue injury and active inflammation, was significantly increased after treatment 
with Yoda1 (Figure 4.2I). A concentration-dependent increase in mRNA 
expression of the inflammatory/hypertrophic cytokine interleukin-6 (Il6) was also 
observed; with a significant 4-fold increase in response to 10 μM Yoda1 (Figure 
4.2J). This was not a generic inflammatory response, as mRNA levels of the 
proinflammatory cytokine Il1β remained unchanged by Yoda1 treatment (Figure 
4.2K). These data reveal that activation of Piezo1 using Yoda1 is coupled to 






Figure 4.2 Effect of Yoda1 on the expression of genes associated with 
fibroblast function. (A-K) RT-PCR analysis of 11 genes in murine cardiac 
fibroblasts treated with concentrations of Yoda1 ranging from 0.5-10 μM, or 
DMSO vehicle, for 24 h. All mRNA expression levels were normalised to those of 
the housekeeping gene, Gapdh, *P<0.05, **P<0.01, ***P<0.001 versus vehicle-
treated cells following an ANOVA with Tukey’s post-hoc test (n=3). 
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4.4.2 The effect of Yoda 1 on genes associated with myofibroblast 
differentiation 
TGF-β1 is a cytokine released from a variety of inflammatory cells which migrate 
in large numbers to damaged or fibrotic tissue (Darby et al. 2014); but activated 
cardiac fibroblasts are the primary producers (Chen et al. 2004). TGF-β1 
stimulates cardiac fibroblast proliferation, differentiation, migration, apoptosis and 
initiates the deposition of ECM via the upregulation of collagens and TIMPs and 
downregulation of MMPs (Leask and Abraham 2004); these processes all 
exacerbate the pro-fibrotic environment. TGF-β1 is the factor which largely 
regulates fibroblast to myofibroblast differentiation in order to drive effective 
wound healing and, despite an increase in this cytokine being associated with 
most of the fibrotic diseases in humans (Border and Noble 1994), regulatory 
mechanisms remain unclear. The transition of fibroblasts into myofibroblasts is 
accompanied by the upregulation of α-SMA both in vitro and in vivo (Santiago et 
al. 2010) and α-SMA is a commonly used marker to identify activated 
myofibroblasts. Given the important role of myofibroblast differentiation in cardiac 
remodelling, the finding that the expression of three genes associated with 
myofibroblast differentiation (Acta2, Postn, Tgfb1) were downregulated following 
Yoda1 treatment was intriguing. Therefore, the effect of Piezo1 activation on 
markers of cardiac myofibroblasts was examined further. 
 
4.4.2.1 Expression of markers of myofibroblast differentiation following 
Yoda1 treatment 
The Yoda1-induced reduction in Acta2 and Tgfb1 mRNA expression data (Figure 
4.2B,C) appeared to correlate with the morphological change towards a more 
spindle-like shape observed in cardiac fibroblasts following prolonged exposure 
to Yoda1 (Figure 4.1), which is indicative of a less differentiated state. The time 
courses of the Yoda1-induced decrease in Acta2 and Tgfb1 mRNA expression 
were investigated. Acta2 mRNA expression was briefly increased after 2 h Yoda1 
treatment, but was then reduced by a third after 24 h treatment, compared to 
control-treated cells (Figure 4.3A). Tgfb1 mRNA expression also decreased by 
approximately a third after 24 h of Yoda1 treatment (Figure 4.3B). Despite both 




difference in the area under the curves was not statistically significant between 
vehicle- and Yoda1-treated cells (Figure 4.3A,B), indicating unchanged mRNA 
expression over the entire 24 h period. 
To more specifically explore whether the Yoda1-induced decrease in Acta2 and 
Tgfb1 mRNA expression at 24 h was due to the Piezo1 channel and not a non-
specific effect of Yoda1, siRNA targeting Piezo1 was utilised. As expected, there 
was a significant reduction in Acta2 mRNA expression (Figure 4.4A) and a trend 
for a decrease in Tgfb1 mRNA expression (Figure 4.4B) following Yoda1 
treatment in murine cardiac fibroblasts transfected with control siRNA. These 
outcomes were unaffected by the use of Piezo1-specific siRNA (Figure 4.4A,B), 
indicating that these effects of Yoda1 may be Piezo1-independent. 
To investigate if α-SMA protein expression was affected by Yoda1-evoked Piezo1 
activation, murine cardiac fibroblasts were stained for α-SMA following Yoda1 
treatment, with either vehicle or TGF-β1 present. TGF-β1 treatment increased 
the expression and organisation of α-SMA fibres and led to larger cells (Figure 
4.5A), consistent with a myofibroblast phenotype, as has been shown previously 
in human cardiac fibroblasts (van Nieuwenhoven et al. 2013). α-SMA 
immunocytochemistry of cultured murine cardiac fibroblasts revealed that, as in 
Figure 4.1, Yoda1 treatment had the opposite effect and altered the morphology 
of fibroblasts to a smaller, more spindle-like, less rhomboid shape, in comparison 
with vehicle-treated cells (Figure 4.5A). When cells were exposed to both TGF-
β1 and Yoda1, cell morphology was more similar to control untreated cells (Figure 
4.5A). Together, the mRNA and cell morphology data indicate that Piezo1 
activation using Yoda1 is opposing myofibroblast differentiation. However, it was 
apparent that untreated cardiac fibroblasts already exhibited a myofibroblast 
phenotype, as shown by the appearance of α-SMA fibres, which are absent from 
undifferentiated cardiac fibroblasts, indicating that cells have already undergone 
differentiation to some extent in culture (Figure 4.5A). 
A similar experiment was performed to quantify the effect of Yoda1 on α-SMA 
protein expression in murine cardiac fibroblasts by western blotting. α-SMA was 
expressed in vehicle-treated cells and did not increase further in response to  
TGF-β1 treatment (Figure 4.5B). This differed from data in human cardiac 
fibroblasts where α-SMA protein levels were upregulated by TGF-β1 treatment 




fibroblasts were already differentiated in culture. It became apparent that Yoda1 
did not reduce α-SMA protein levels (Figure 4.5B). 
 
 
Figure 4.3 Time course of Acta2 and Tgfb1 mRNA expression following 
Yoda1 treatment. Murine cardiac fibroblasts were treated with vehicle or 10 µM 
Yoda1 for 0, 2, 6 or 24 h before measuring (A) Acta2 and (B) Tgfb1 mRNA 
expression, relative to Gapdh, *P<0.05 following an ANOVA with Tukey’s post-
hoc test (n=3). 
  





Figure 4.4 Effect of Piezo1-specific siRNA on Acta2 and Tgfb1 mRNA 
expression following Yoda1 treatment. Murine cardiac fibroblasts were 
transfected with control (C) or Piezo1-specific (P1) siRNA and subsequently 
treated with either vehicle or 10 μM Yoda1 for 24 h before measuring (A) Acta2 
and (B) Tgfb1 mRNA expression by RT-PCR, relative to Gapdh, *P<0.05 
following an ANOVA with Tukey’s post-hoc test (n=3). 
  



























































Figure 4.5 Effect of Yoda1 on TGF-β1-induced changes in cell morphology 
and α-SMA expression. (A) Representative images of cultured murine cardiac 
fibroblasts treated for 24 h with vehicle, 10 µM Yoda1, 10 ng/ml TGF-β1 or 10 
ng/ml TGF-β1 plus Yoda1 and then immunostained for α-SMA (green); DAPI 
staining (blue) identifies nuclei. Scale bar = 20 µm. (B) Cells were treated for 24 
h with vehicle, 10 µM Yoda1, 10 ng/ml TGF-β1 or 10 ng/ml TGF-β1 plus Yoda1 
and probed for α-SMA protein; equal loading of samples was confirmed by 
probing for α-tubulin. Graph shows mean densitometric data, P=NS, not 
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4.4.2.2 The effect of Yoda1 on myofibroblast-mediated collagen gel 
contraction 
The ability of fibroblasts to contract collagen gels is a marker of their 
differentiation to the myofibroblast phenotype, i.e. increased gel contraction 
correlates with increased myofibroblast activity. To functionally investigate the 
effect of Yoda1 on cardiac myofibroblast differentiation, collagen gel contraction 
assays were therefore employed. Collagen gels seeded with mouse cardiac 
fibroblasts were treated with TGF-β1 or vehicle, with and without Yoda1 for 24 h. 
As expected, there was a trend for TGF-β1 to reduce collagen gel weight and 
area, compared to untreated gels, which implies increased myofibroblast 
differentiation (Figure 4.6A-C). Yoda1 stimulated a significant 39% decrease in 
collagen gel weight and decreased the collagen gel area by a third, compared to 
unstimulated gels (Figure 4.6A-C), indicating even more pronounced 
myofibroblast differentiation than TGF-β1 treatment. These data suggest that 
Yoda1 is inducing myofibroblast differentiation, contrary to the previous gene 
expression data. 
It was important to investigate if Yoda1-evoked myofibroblast differentiation was 
dependent on Piezo1. Yoda1-induced gel contraction was not affected by Piezo1-
specific siRNA (Figure 4.6D-F). Further evidence that this effect was Piezo1-
independent came from the use of compound 159, an alternative activator of 
Piezo1. This compound found in the analogue screen has similar properties and 
effects to Yoda1 and, when applied to murine cardiac fibroblasts, did not instigate 
a decrease in collagen gel weight or area as had been observed with Yoda1 
(Figure 4.6D-F). These data imply that Yoda1 increases the ability of cardiac 
myofibroblasts to contract collagen gels in a Piezo1-independent manner.  
A previous publication suggested that not all Yoda1 effects occur through Piezo1 
and that Yoda1 could activate both the Akt and ERK signalling pathways in 
human endothelial cells independently of Piezo1 (Dela Paz and Frangos 2018). 
With this study in mind, it was investigated whether the ERK pathway was 
important for Yoda1-induced collagen gel contraction. Collagen gels seeded with 
mouse cardiac fibroblasts were pretreated for 1 h with an inhibitor of the ERK 
pathway, PD98059, and then treated with Yoda1 or vehicle for 24 h. Increased 




the ERK pathway inhibitor (Figure 4.7A-C). These data suggest that the ERK 
pathway is important for the Yoda1-evoked increase in collagen gel contraction. 
 
Figure 4.6 Effect of Piezo1 knockdown on Yoda1-evoked collagen gel 
contraction. (A) Representative images of contracted gels containing murine 
cardiac fibroblasts after 24 h treatment with vehicle, 10 µM Yoda1 or 10 ng/ml 
TGFβ +/- Yoda1. Mean data are illustrated in bar charts showing (B) collagen gel 
weight and (C) collagen gel area (as a % of the well) after 24 h treatment, 
*P<0.05, **P<0.01 following an ANOVA with Tukey’s post-hoc test (n=3). (D) 
Representative images of contracted gels containing murine cardiac fibroblasts 
after 24 h treatment with vehicle, 10 µM Yoda1 or 10 µM compound 159 (a Piezo1 
activator) following transfection with control (C) or Piezo1-specific (P1) siRNA. 
Mean data are shown in bar charts illustrating the (E) collagen gel weight and (F) 
collagen gel area (as a % of the well) after 24 h treatment, P=NS, not significant 
following an ANOVA with Tukey’s post-hoc test (n=2). 
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Figure 4.7 Role of the ERK pathway in Yoda1-evoked collagen gel 
contraction. (A) Representative images of contracted gels containing murine 
cardiac fibroblasts after 24 h treatment with vehicle or 10 µM Yoda1 following 
pretreatment for 1 h with vehicle or 30 µM PD98059 (ERK pathway inhibitor). Bar 
charts show mean data illustrating (B) collagen gel weight and (C) collagen gel 
area (as a % of the well), *P<0.05 following an ANOVA with Tukey’s post-hoc test 
(n=4). 
  

































































4.4.3 The effect of Yoda1 on Tenascin C 
TNC, a matricellular protein discussed in Chapter 1, is the founding member of a 
family of four tenascins and was discovered to be highly expressed in embryonic 
ECM (Chiquet-Ehrismann et al. 1988). TNC is virtually undetected in healthy adult 
tissue but becomes transiently re-expressed upon myocardial injury and down-
regulated following tissue repair (Willems, Arends and Daemen 1996). Increasing 
circulating TNC levels correlate with poor prognosis and mortality in patients 
following MI (Sato et al. 2006) and it is thought that the protein may promote 
tissue healing but enhance fibrosis and inflammation (Midwood et al. 2011). It 
had been established in the earlier screen that Tnc mRNA expression was 
increased in murine cardiac fibroblasts treated with Yoda1 for 24 h, compared to 
vehicle-treated cells (Figure 4.2I). Considering this, the investigation into the 
altered expression of TNC following Piezo1 activation was continued. 
4.4.3.1 Yoda1 induces TNC mRNA expression in cardiac fibroblasts 
In further experiments, Tnc mRNA expression was shown to increase in a time-
dependent manner in response to Yoda1 (Figure 4.8A). After 6 h, Tnc mRNA 
expression was significantly increased by 15-fold, compared to the expression at 
0 h or the expression when cells were treated with vehicle only (Figure 4.8A). 
Data were similar in human cardiac fibroblasts but over a slower time course, with 
TNC mRNA expression being significantly increased after 24 h Yoda1 treatment. 
The increase was not as substantial as that in mouse cells, with mRNA increasing 






Figure 4.8 Effect of Yoda1 on Tnc / TNC mRNA expression in murine and 
human cardiac fibroblasts. (A) Murine and (B) human cardiac fibroblasts were 
exposed to vehicle or 10 μM Yoda1 for 2-24 h before measuring Tnc / TNC mRNA 
levels by RT-PCR, **P<0.01 following an ANOVA with Tukey’s post-hoc test 
(n=3). Data are expressed relative to the housekeeper, Gapdh / GAPDH. 
  




4.4.3.2 Yoda1 induces TNC protein expression in cardiac fibroblasts 
Western blotting was performed to explore if there was also a change in TNC 
protein following Yoda1 treatment. TNC protein expression increased 2.5-fold 
following 24 h Yoda1 treatment in murine cardiac fibroblasts and this was 
maintained over 72 h of treatment (Figure 4.9A). A time course at earlier time 
points revealed a doubling in TNC protein expression following 6 h Yoda1 
treatment, in comparison with vehicle-treated cells (Figure 4.9B). Therefore a 6 h 
time point was used for all future experiments investigating TNC mRNA and 






Figure 4.9 Effect of Yoda1 on TNC protein expression in murine cardiac 
fibroblasts. (A) Murine cardiac fibroblasts exposed to vehicle or 10 μM Yoda1 
for 24-72 h before measuring TNC protein expression, mean data showing TNC 
expression relative to α-tubulin is shown on the right (n=3). (B) Murine cardiac 
fibroblasts exposed to vehicle or 10 μM Yoda1 for 2 or 6 h before measuring TNC 





























































































4.4.3.3 Yoda1-induced TNC expression is dependent on Piezo1 
To investigate whether Yoda1-evoked Tnc mRNA expression was dependent on 
Piezo1, cardiac fibroblasts from Piezo1+/- heterozygous KO (Het) mice and gain-
of-function Piezo1-mutated (M-R) mice were utilised. As expected, there was a 
10-fold increase in Tnc mRNA expression after 6 h Yoda1 treatment in cardiac 
fibroblasts isolated from WT mice (Figure 4.10A). However, when Yoda1 was 
applied to cardiac fibroblasts isolated from Piezo1+/- (Het) mice, the respective 
increase in Tnc mRNA was reduced by ~50% (Figure 4.10A). The increase in 
Tnc mRNA expression was not observed when cardiac fibroblasts were treated 
with the inactive analogue of Yoda1, compound 2e, which was identified during 
the screening process in Chapter 3, implying that the response was Yoda1-
specific. Furthermore, Yoda1-evoked TNC protein expression, was reduced by 
~50% in cardiac fibroblasts from Piezo1+/- heterozygous knockout mice (Figure 
4.10B). 
A gain-of-function mutation in human Piezo1 (M2225R) which causes delayed 
inactivation kinetics of the channel (Albuisson et al. 2013) has been shown to 
lead to increased Yoda1-evoked Ca2+ influx in murine cardiac fibroblasts which 
have the equivalent mutation (M2220R) (Figure 3.27). The Yoda1-induced 
increase in Tnc mRNA expression in WT cardiac fibroblasts was increased a 
further 4-fold in M-R cells (Figure 4.10C). Similar changes were observed at the 
protein level (Figure 4.10D). These data imply that Yoda1-induced TNC 
expression is dependent on Piezo1 as two genetically modified mouse models 
with opposing Piezo1 activity showed a corresponding alteration of Yoda1-
evoked TNC expression. 
To further explore whether the increase in TNC protein expression was due to 
activation of Piezo1, siRNA targeting Piezo1 was employed. As expected, there 
was a 3-fold increase in TNC protein expression after Yoda1 treatment in murine 
cardiac fibroblasts transfected with control siRNA, and importantly this response 







Figure 4.10 Effect of altering Piezo1 expression or activity on Yoda1-
induced TNC expression. (A) Cardiac fibroblasts from wild-type (WT; n=4) and 
Piezo1+/- heterozygous knockout (Het; n=3) mice were treated with vehicle, 10 
μM Yoda1 or compound 2e for 6 h before measuring Tnc mRNA expression 
relative to Gapdh, **P<0.01, ***P<0.001, P=NS, not significant following an 
ANOVA with Tukey’s post-hoc test. (B) Cardiac fibroblasts from WT (n=4) and 
Het (n=3) mice were treated with vehicle or 10 μM Yoda1 for 6 h before measuring 
TNC protein expression. On the right, this is quantified relative to α-tubulin and 
normalised to the expression at 0 h, **P<0.01, p=NS, not significant following an 
ANOVA with Tukey’s post-hoc test. (C) Cardiac fibroblasts from WT and gain-of-
function Piezo1-mutated mice (M-R) mice were treated with vehicle or 10 μM 
Yoda1 for 6 h before measuring Tnc mRNA expression, relative to Gapdh, 
***P<0.001, P=NS, not significant following an ANOVA with Tukey’s post-hoc test 
(n=3). (D) Cardiac fibroblasts from WT and gain-of-function Piezo1-mutated mice 
(M-R) mice were treated with vehicle or 10 μM Yoda1 for 6 h before measuring 
TNC protein expression. On the right, quantified data are shown, relative to α-































































































































































Figure 4.11 Effect of Piezo1 knockdown on Yoda1-induced TNC expression. 
Representative blot of murine cardiac fibroblasts transfected with either control 
(C) or Piezo1-specific (P1) siRNA before treatment with vehicle or 10 µM Yoda1 
for 6 h. Samples were immunoblotted for TNC and re-probed with α-tubulin 
antibody to confirm equal protein loading. Graph on the right shows the mean 
densitometric data, *P<0.05, P=NS, not significant following an ANOVA with 
Tukey’s post-hoc test (n=3). 
  























































4.4.3.4 Mechanical stress has no effect on TNC expression in cardiac 
fibroblasts 
Yoda1 is a useful pharmacological tool with which to activate the Piezo1 channel 
and learn about its role in cardiac fibroblasts. However, it is crucial to investigate 
whether Yoda1 mimics mechanical activation of the channel which occurs in vivo. 
Therefore, in this section, different strategies were employed to stimulate 
mechanical stress in cardiac fibroblasts. 
TNC is abundantly expressed in all musculoskeletal regions transmitting high 
mechanical forces from one tissue component to another (Järvinen et al. 2003) 
and demonstrates high expression at the branching point of arteries (Mackie et 
al. 1992). Thus, TNC is considered a mechanosensitive gene.  
Firstly, the effects of shear stress were investigated. Murine cardiac fibroblasts 
subjected to 10 dyn.cm-2 shear stress using an orbital shaker for 24 h had 
unaltered Tnc mRNA expression, compared to cells kept in parallel under static 
conditions (Figure 4.12A). 
Secondly, murine cardiac fibroblasts were grown on tailored culture substrates 
(10 kPa, 30 kPa and tissue culture plastic which is approximately 1x106 kPa) to 
determine whether the stiffness on which the cells grow affects Tnc mRNA 
expression. Increasing the stiffness of the substrate led to a trend of increased 
Tnc mRNA expression but this was not statistically significant (Figure 4.12B). This 
occurred independently of Piezo1 as it was not affected by Piezo1 gene silencing 
(Figure 4.12B). 
Thirdly, cyclic stretching (1 Hz, 10% stretch) of human cardiac fibroblasts for 6 h 
increased TNC mRNA expression by approximately 25 % compared to cells kept 
under static conditions, although this was not statistically significant (Figure 
4.12C). However, once more this was not dependent on Piezo1, as shown by 
silencing the PIEZO1 gene (Figure 4.12C). Despite the previously discussed 
evidence that TNC is a mechanosensitive gene, none of the mechanical stimuli 
investigated in the present study modulated TNC expression. It may be that 
alternative stimuli which are able to mechanically activate Piezo1 could induce 






Figure 4.12 Effect of Piezo1 knockdown on Tnc / TNC mRNA expression 
induced by mechanical stimuli. (A) RT-PCR analysis of Tnc mRNA levels in 
murine cardiac fibroblasts exposed to 10 dyn.cm-2 shear stress for 24 h using an 
orbital shaker, compared to cells kept in parallel under static conditions, P=NS, 
not significant following a t-test (n=3). (B) RT-PCR analysis of Tnc mRNA 
expression when murine cardiac fibroblasts were plated on substrates of differing 
levels of stiffness for 24 h. TC=tissue culture plate (106 kPa). Cardiac fibroblasts 
were previously transfected with either control (C) or Piezo1-specific (P1) siRNA, 
P=NS, not significant following an ANOVA with Tukey’s post-hoc test (n=3). (C) 
RT-PCR analysis of TNC mRNA expression after exposure of human cardiac 
fibroblasts to 6 h cyclic stretch (1 Hz, 10% stretch), compared to fibroblasts 
maintained in parallel under static conditions. Cardiac fibroblasts were previously 
transfected with either control (C) or Piezo1-specific (P1) siRNA. Data are 
normalised to static control, P=NS, not significant following an ANOVA with 
Tukey’s post-hoc test (n=7). All expression levels are expressed relative to the 
relevant housekeeper, Gapdh / GAPDH. 
  



















































































4.4.4 The effect of Yoda1 on interleukin-6 
IL-6 is a pleiotropic cytokine which has been shown to be mechanosensitive. 
Fibroblasts from several sources have been shown to secrete IL-6 in response to 
mechanical stretch (House et al. 2012; Skutek et al. 2001), including coronary 
artery fibroblasts which showed higher expression of IL-6 after 24 h of stretch (Li 
et al. 2013). IL-6 has pro-inflammatory, anti-inflammatory and fibrotic roles in the 
heart depending on the context and duration of its effect (Fontes, Rose and 
Čiháková 2015). In vitro studies have shown that IL-6 is secreted from cardiac 
fibroblasts in response to several well-known hypertrophic stimuli, including β-
adrenergic receptor stimulation and Ang II (Porter and Turner 2009). IL-6 can 
directly induce cardiomyocyte hypertrophy in vitro (Zhao et al. 2016a; Ancey et 
al. 2003) and Ang II- or phenylephrine-induced cardiomyocyte hypertrophy is 
impaired in myocytes isolated from IL-6 KO mice (Zhao et al. 2016a), implying 
that IL-6 secretion is necessary for induction of myocyte hypertrophy by these 
stimuli. Given the causative link between mechanical stimulation and cardiac 
hypertrophy (Tarone and Lembo 2003), investigation into changes in IL-6 
expression following Piezo1 activation was pursued further. 
 
4.4.4.1 Yoda1 induces IL-6 mRNA expression and secretion 
It was shown previously that 24 h Yoda1 treatment increased Il6 mRNA 
expression in murine cardiac fibroblasts in a concentration dependent manner 
(Figure 4.2J). It was subsequently established that the increase in Il6 mRNA 
expression occurred in a time-dependent manner with a significant increase 
being observed after 24 h (Figure 4.13A). The data were similar in human cardiac 
fibroblasts but, in these cells, a significant increase in IL6 mRNA occurred earlier, 
with a doubling in expression after 2 h Yoda1 treatment (Figure 4.13B). The 
Yoda1-evoked increase in Il6 mRNA expression in murine cardiac fibroblasts 
correlated with an increase in IL-6 secretion quantified using ELISA (Figure 4.14). 
In Yoda1-treated cells, the secretion of IL-6 was over 4-fold greater than that 
observed in vehicle-treated cells (Figure 4.14). 
The inactive Yoda1 analogue, compound 2e (described in Section 3.4.4.2), did 
not induce Ca2+ influx (Figure 4.15A) or Il6 mRNA expression (Figure 4.15B) in 





Figure 4.13 Il6 / IL6 mRNA expression following Yoda1 treatment in murine 
and human cardiac fibroblasts. (A) Murine and (B) human cardiac fibroblasts 
were exposed to vehicle or 10 μM Yoda1 for 2-24 h before measuring Il6 / IL6 
mRNA levels by RT-PCR. Data are expressed as % of housekeeper, Gapdh / 
GAPDH, *P<0.05, **P<0.01 versus vehicle-treated cells following an ANOVA with 
Tukey’s post-hoc test (n=3). Data are normalised to 0 h. 
  





Figure 4.14 Effect of Yoda1 on IL-6 secretion from murine cardiac 
fibroblasts. Murine cardiac fibroblasts were exposed to vehicle or 10 μM Yoda1 
for 2-24 h before analysing conditioned medium for IL-6 levels by ELISA, 
***P<0.001 versus vehicle-treated cells following an ANOVA with Tukey’s post-






Figure 4.15 Effect of compound 2e, an inactive analogue of Yoda1, on Ca2+ 
entry and Il6 mRNA expression in murine cardiac fibroblasts. (A) 
Representative Ca2+ traces illustrating Ca2+ entry evoked by 10 μM Yoda1 or 
compound 2e in murine cardiac fibroblasts. The mean data are shown to the right, 
**P<0.01 following a t-test (n/N=3/9). (B) Murine cardiac fibroblasts were treated 
with either vehicle, 10 μM Yoda1 or 10 µM compound 2e for 6 h before measuring 
Il6 mRNA expression by RT-PCR. Data are expressed relative to the 
housekeeper, Gapdh, *P<0.05, p=NS, not significant versus vehicle-treated cells 
following an ANOVA with Tukey’s post-hoc test (n=4). 
  













































































4.4.4.2 Yoda1-evoked IL-6 expression and secretion are dependent on 
Piezo1 
To investigate if Yoda1-evoked IL-6 induction was dependent on Piezo1, cardiac 
fibroblasts were isolated from Piezo1+/- heterozygous KO mice and gain-of-
function Piezo1 (M-R) mice. The Yoda1-induced Il6 mRNA expression was 
reduced by  approximately 50 % in cardiac fibroblasts isolated from Piezo1+/- 
mice, compared to in cells from WT mice (Figure 4.16A). The Yoda1-induced 
increase in IL-6 protein secretion was also reduced by approximately 50 %, in 
cardiac fibroblasts isolated from hearts of Piezo1+/- Het mice compared to those 
from WT hearts (Figure 4.16B). This is in keeping with the reduction in Piezo1 
expression and Ca2+ influx in response to Yoda1 in these cells (Figure 3.26). 
Similarly to the mRNA expression data, IL-6 secretion was unchanged following 
treatment of cardiac fibroblasts with compound 2e, an inactive analogue of Yoda1 
(Figure 4.16B). Conversely,  the Yoda1-induced increase in Il6 mRNA expression 
after 6 h treatment was increased by 3-fold in cardiac fibroblasts isolated from 
gain-of-function M-R mice, compared with those from WT mice (Figure 4.16C). 
To investigate further whether the induction in IL-6 was due to Piezo1, siRNA 
targeting Piezo1 in both murine and human cardiac fibroblasts was utilised. There 
was a doubling in Il6 mRNA expression in control siRNA-transfected murine 
cardiac fibroblasts after Yoda1 treatment; this was reduced to basal levels in cells 
transfected with Piezo1-specific siRNA (Figure 4.17A). These data were 
replicated when conditioned media was analysed, as evidenced by the 
attenuation of IL-6 secretion from murine cardiac fibroblasts transfected with 
Piezo1-specific siRNA, compared to those transfected with control siRNA (Figure 
4.17B). 
A similar relationship was observed in human cardiac fibroblasts. Piezo1-specific 
siRNA successfully reduced PIEZO1 mRNA expression by >75% (Figure 4.18A) 
and, subsequently, the Yoda1-evoked increase in IL6 mRNA expression was 
attenuated back to basal levels (Figure 4.18B). The inactive Yoda1 analogue, 2e, 
had no effect on IL6 mRNA expression, indicating a specific Yoda1 effect (Figure 
4.18B). These data establish that Yoda1 induces IL-6 expression and secretion 





Figure 4.16 Effect of altering Piezo1 expression or activity on Yoda1-evoked 
Il6 mRNA expression and IL-6 secretion. (A) Cardiac fibroblasts isolated from 
wild-type (WT; n=4) and Piezo1+/- heterozygous knockout (Het; n=3) mice were 
treated with vehicle or 10 μM Yoda1 for 6 h before measuring Il6 mRNA 
expression, relative to Gapdh. (B) Cardiac fibroblasts from WT (n=4) and Het 
(n=3) mice were treated with vehicle, 10 μM Yoda1 or compound 2e for 24 h 
before measuring IL-6 levels in conditioned medium using ELISA, *P<0.05, 
***P<0.001, P=NS, not significant following an ANOVA with Tukey’s post-hoc 
test. (C) Cardiac fibroblasts isolated from WT (n=6) and gain-of-function Piezo1-
mutated (M-R; n=7) mice were treated with vehicle or 10 μM Yoda1 for 6 h before 
measuring Il6 mRNA expression, relative to Gapdh, *P<0.05, P=NS, not 






















































































Figure 4.17 Effect of Piezo1 knockdown on Yoda1-induced IL-6 expression 
and secretion in murine cardiac fibroblasts. Cells were transfected with 
control (C) or Piezo1-specific (P1) siRNA and treated with either vehicle or 10 μM 
Yoda1 for 24 h before (A) measuring Il6 mRNA expression, relative to Gapdh or 
(B) collecting conditioned media and measuring IL-6 levels by ELISA, *P<0.05, 
P=NS, not significant versus-vehicle-treated cells following an ANOVA with 
Tukey’s post-hoc test (n=3). 
  




























































Figure 4.18 The effect of Piezo1 on Yoda1-evoked IL6 mRNA expression in 
human cardiac fibroblasts. Human cardiac fibroblasts transfected with control 
(C) or Piezo1-specific (P1) siRNA were exposed to vehicle, 10 µM Yoda1 or 
compound 2e for 6 h before measuring (A) PIEZO1 mRNA  or (B) IL6 mRNA by 
RT-PCR. Data are expressed as % of housekeeper, GAPDH, **P<0.01, 
***P<0.001, P=NS, not significant following (A) a t-test and (B) an ANOVA with 


























































4.4.4.3 The effect of mechanical stimuli on IL6 mRNA expression and 
secretion in cardiac fibroblasts  
Fibroblasts from several sources have been shown to secrete IL-6 in response to 
mechanical stretch (House et al. 2012; Skutek et al. 2001). Therefore, it was 
explored whether mechanical activation of cardiac fibroblasts was coupled to IL-
6 expression and whether this occurred via a Piezo1-dependent mechanism.  
Exposing murine cardiac fibroblasts to 10 dyn.cm-2 shear stress for 24 h had no 
effect on Il6 mRNA expression (Figure 4.19A). Tailored culture plates coated with 
fibronectin used to observe whether changes in substrate stiffness affect Il6 
mRNA expression revealed that plating murine cardiac fibroblasts on substrates 
of increasing stiffness for 24h led to a trend of increasing Il6 mRNA expression; 
but gene silencing of Piezo1 suggested this was not a Piezo1-dependent effect 
(Figure 4.19B). Finally, cyclic stretching (1 Hz, 10% stretch) of human cardiac 
fibroblasts for 6 h did not induce an increase in IL6 mRNA expression, in 
comparison with cells kept under static conditions (Figure 4.19C). Stretching of 
cells was performed on collagen-coated plates which had a stiffness of 930 kPa. 
It was hypothesised that the stretch stimulus was not applied to cells for long 
enough; therefore, 24 h of 1 Hz, 10% stretch was tested. At this point, human 
cardiac fibroblasts were also transfected with Piezo2-specific siRNA in order to 
investigate if Piezo2 had a role in stretch-evoked IL-6 induction as both channels 
have previously been observed to function in tandem (Zeng et al. 2018). PIEZO2 
mRNA expression in human cardiac fibroblasts was reduced by 62% when cells 
were transfected with Piezo2-specific siRNA, in comparison with control siRNA-
transfected cells; this was maintained when siRNA targeting PIEZO1 and 
PIEZO2 were used concurrently (48 h after transfection, data not shown, n=1). 
When both PIEZO1 and PIEZO2 were silenced in human cardiac fibroblasts, 
there was no change in IL6 mRNA expression following 24 h stretch on collagen-
I-coated membranes, compared to cells kept under in parallel under static 
conditions (Figure 4.20A). However, a role for Piezo1 under basal conditions was 
indicated as there was a marked reduction in IL6 mRNA expression in both static 
and stretched human cardiac fibroblasts transfected with Piezo1-specific siRNA 
or both Piezo1- and Piezo2-specific siRNAs, compared to control siRNA-
transfected cells (Figure 4.20A). This did not occur in cells transfected only with 




with the amount of IL-6 secreted from human cardiac fibroblasts. There was a 
slight trend for an increase in IL-6 secretion when mechanical load was applied 
to cells but this was not statistically significant (Figure 4.20B). The data correlated 
with mRNA data; following 24 h cyclic stretching (1 Hz, 10% stretch), IL-6 
secretion was reduced by >50 % in both static and stretched cells transfected 
with Piezo1-specific siRNA and with both Piezo1- and Piezo2-specific siRNAs, in 
comparison with cells transfected with control siRNA (Figure 4.20B). These data 
imply that, although Piezo1 activation using mechanical stimuli does not induce 
IL-6 production, Piezo1 may have a role in the basal production of IL-6 expression 
in cardiac fibroblasts. This effect was not seen when cardiac fibroblasts were 
plated on much softer substrates (10, 30 kPa) or tissue culture plastic (Figure 
4.19B). The plates of 10/30 kPa stiffness were coated with fibronectin whereas 
the FlexCell plates utilised in the stretch experiment in Figure 4.20 were coated 
with collagen. Therefore, the effect which Piezo1 has on basal IL-6 levels appears 
to be dependent on the mechanical and/or chemical environment in which the 





Figure 4.19 Effect of Piezo1 knockdown on Il6 / IL6 mRNA expression 
following application of mechanical stimuli. (A) RT-PCR analysis of Il6 mRNA 
levels after murine cardiac fibroblasts were exposed to 24 h of 10 dyn.cm-2 shear 
stress, compared to cells kept under static conditions, P=NS, not significant 
following a t-test (n=3). (B) RT-PCR analysis of Il6 mRNA expression after murine 
cardiac fibroblasts were plated on substrates of differing stiffness for 24 h. 
TC=tissue culture plate (106 kPa). Cardiac fibroblasts were previously transfected 
with either control or Piezo1-specific siRNA, P=NS, not significant following an 
ANOVA with Tukey’s post-hoc test (n=3). (C) RT-PCR analysis of IL6 mRNA 
expression after exposure of human cardiac fibroblasts to 6 h cyclical stretch (1 
Hz, 10% stretch), compared to fibroblasts maintained in parallel under static 
conditions. Cardiac fibroblasts were previously transfected with either control (C) 
or Piezo1-specific (P1) siRNA, P=NS, not significant following an ANOVA with 
Tukey’s post-hoc test (n=10). All expression levels are expressed relative to the 














































































Figure 4.20 The effect of Piezo1 and Piezo2 knockdown on basal IL-6 levels 
in human cardiac fibroblasts. Human cardiac fibroblasts were transfected with 
either control (C) siRNA, Piezo1-specific (P1) siRNA, Piezo2-specific (P2) siRNA 
or Piezo1 plus Piezo1-specific (P1+2) siRNAs, before exposure  to cyclical 
stretch (1 Hz, 10% stretch, 24 h). (A) IL6 mRNA expression relative to GAPDH 
and (B) IL-6 levels in conditioned medium using ELISA, in comparison with 
fibroblasts maintained in parallel under static conditions, *P<0.05, **P<0.01 in 
comparison with control-siRNA transfected cells from the same group, following 
an ANOVA with Tukey’s post-hoc test (n=3). 
  
A B

























































The primary aim of this chapter was to investigate whether activation of the 
Piezo1 channel, using chemical activation such as Yoda1, or mechanical 
stimulation, leads to changes in the expression of genes associated with 
fibroblast function and cardiac remodelling. 
Yoda1 was revealed to have no impact on the viability of murine cardiac 
fibroblasts after 24 h treatment, despite Yoda1 instigating cell death in endothelial 
cells after this prolonged period (Adam Hyman PhD thesis, 2018). Exposure to 
Yoda1 for 24 h modulated the expression of several genes in murine cardiac 
fibroblasts in a concentration-dependent manner, including increasing Il6 and Tnc 
expression and decreasing Acta2 (i.e. α-SMA), Tgfb1 and Postn (i.e. periostin). 
Yoda1 had no effect on genes involved in ECM turnover (collagens, MMPs) or on 
Piezo1 mRNA expression itself. 
The decrease in Acta2, Tgfb1 and Postn mRNA expression with Yoda1 was of 
interest as these molecules are key markers of myofibroblast differentiation. 
Further evidence for an effect of Yoda1 on fibroblast differentiation came from 
florescence microscopy illustrating that Yoda1 treatment induced a morphological 
change in cells towards a more spindle-like shape, similar to that observed in 
human cardiac fibroblasts after treatment with IL-1 (van Nieuwenhoven et al. 
2013). A previous publication by Chubinskiy-Nadezhdin et al. (2019) on Piezo1 
in a mouse fibroblast cell line also identified an altered cellular morphology 
caused by Yoda1 treatment. They observed increased cell perimeter and 
decreased roundness of cells following Yoda1 treatment, compared to vehicle-
treated cells. This supports qRT-PCR data illustrating decreased mRNA 
expression of myofibroblast markers and the immunocytochemistry performed in 
the present study. Chubinskiy-Nadezhdin et al. (2019) also observed a 
concentration-dependent inhibition of cellular migration by Yoda1. Myofibroblasts 
are more migratory cells than fibroblasts and migrate to the wound area following 
cardiac injury (Baum and Duffy 2011). Therefore, knowledge that Yoda1 inhibits 
migration of fibroblasts correlates with the idea that Yoda1 induces the 
dedifferentiation of cardiac fibroblasts. These data combined suggest that Piezo1 
activation is opposing myofibroblast differentiation. This observation is intriguing 
as mechanical stimulation is known to be an important driver of myofibroblast 




including upregulation of α-SMA (Hinz and Gabbiani 2010). However, it is worth 
noting that although mRNA expression of Acta2 and Tgfb1 were decreased after 
24 h Yoda1 treatment, there was no change in the overall expression over the 
entire 24 h. Further work using Piezo1-specific siRNA revealed that the Yoda1-
evoked reduction in the expression of myofibroblast markers was not dependent 
on Piezo1. It was examined whether Yoda1 was able to oppose TGF-β-induced 
myofibroblast differentiation. Data obtained from immunocytochemistry and 
western blotting indicated that murine cells were already well differentiated in 
culture and the myofibroblast phenotype could not be induced any further. This 
prevented us investigating whether Yoda1 could oppose TGF-β-induced 
myofibroblast differentiation. 
In the aforementioned study by van Nieuwenhoven et al. (2013), morphological 
changes induced by IL-1 were confirmed to be due to a reduced level of 
myofibroblast differentiation, as evidenced by an impaired capacity to contract 
collagen gels. In the present study, when murine cardiac fibroblasts were seeded 
into collagen gels, Yoda1 had the opposite effect and induced collagen gel 
contraction. This was suggested to be independent of Piezo1 as silencing Piezo1 
using siRNA had no effect on Yoda1-evoked collagen gel contraction. Moreover, 
no effect was observed when gels were treated with compound 159, an agonist 
of Piezo1. It is possible that the outcome observed here is due to an off-target 
effect of Yoda1 or that the level of knockdown of Piezo1 is not sufficient to abolish 
the response. Further work would be essential in order to define if Piezo1 has a 
role in regulating myofibroblast differentiation; cardiac fibroblasts with a complete 
KO of Piezo1 would be helpful to confirm which theory is correct. From the 
contrasting evidence found during this study; Yoda1 does not appear to be 
inducing the "classical" myofibroblast phenotype. It may be that Yoda1 is inducing 
a phenotype with slightly different characteristics as recent studies have identified 
a range of phenotypes which serve different functions during post-MI cardiac 
remodelling (Ma et al. 2017; Fu et al. 2018).  
It has been suggested that Yoda1 has Piezo1-independent effects in endothelial 
cells. Dela Paz and Frangos (2018) revealed that Yoda1-induced activation of 
both the Akt and ERK signalling pathways in human endothelial cells was not 
entirely dependent on Piezo1 activation. They came to this conclusion as, 




phosphorylation and ruthenium red blocked Yoda1-induced ERK1/2 
phosphorylation, the Piezo1 inhibitor GsMTx4 had no effect. They proposed that 
Yoda1 may be non-specific in its activation of Piezo1. However, the group did not 
attempt to knockdown Piezo1 using molecular methods; this would have been 
beneficial in order to come to a more definite conclusion. In the present study, 
ERK activation was investigated by pretreating collagen gels with an ERK 
pathway inhibitor; it was revealed that the ERK pathway may be involved in 
Yoda1-induced myofibroblast differentiation, independently of Piezo1 activation. 
Following cardiac injury, TNC is thought to promote tissue healing but enhance 
fibrosis and inflammation (Midwood et al. 2011); increased circulating TNC levels 
have been shown to correlate with poor prognosis and mortality following MI 
(Sato et al. 2006). TNC has been associated with mechanical stress due to its 
high expression in locations which withstand high pressure such as 
myotendinous and myofascial junctions and the branching points of arteries 
(Mackie et al. 1992; Järvinen et al. 2003) and mechanical stimulation prompts 
TNC expression in vitro (Chiquet, Sarasa-Renedo and Tunç-Civelek 2004). In the 
present study, Yoda1 treatment led to increased TNC mRNA and protein 
expression in cardiac fibroblasts; this was dependent on Piezo1 based on studies 
utilising murine models with genetically modified Piezo and Piezo1-specific 
siRNA. 
Lewis et al. (2017) state that, in the heart and arterial endothelial cells, 
mechanical forces from blood pressure oscillate sharply at frequencies of ~1-3 
Hz (60–180 heart beats per minute), and that Piezo1 is able to respond to 
repetitive stimulation in this frequency range. This is in contrast to Piezo2, which 
the group suggest is not particularly efficient at continuously transducing high-
frequency stimuli (Lewis et al. 2017). Cyclic stretching at 1 Hz has previously 
been employed to look at the effect of mechanical stress in the myocardium 
(Wong et al. 2018). To investigate if increased TNC expression in cardiac 
fibroblasts could be observed using mechanical, rather than chemical, activation 
of Piezo1, methods of applying mechanical stress were explored. Shear stress 
had no effect on Tnc mRNA expression in murine cardiac fibroblasts but this type 
of stress may be more relevant for endothelial cells, as cardiac fibroblasts are not 
in direct contact with blood flow. Therefore, an alternative method of inducing 




stiffness and cyclic stretch both caused trends for increased mRNA expression 
of Tnc / TNC, this was not statistically significant. Although there is evidence in 
the literature that TNC is a mechanosensitive gene in cardiac fibroblasts (Herum 
et al. 2017a), its expression was not induced using the particular mechanical 
stimuli applied in this study. 
Cardiac fibroblasts secrete IL-6, a pleiotropic pro-inflammatory cytokine that 
promotes cardiac fibroblast proliferation and fibrosis (Banerjee et al. 2009), as 
well as cardiac hypertrophy through its actions on cardiomyocytes (Meléndez et 
al. 2010). It was revealed that Yoda1 increased Il6 / IL6 gene expression in both 
murine and human cardiac fibroblasts and increased secretion of IL-6 in murine 
cardiac fibroblasts. It was established that these effects were mediated via Piezo1 
using various approaches. Interesting, this result may tie in with the previously 
discussed observation that Yoda1 evokes TNC expression, as inflammatory 
cytokines have been shown to induce TNC, which subsequently activates toll-like 
receptor 4 (TLR4) signalling, leading to increased cytokine secretion and 
additional TNC synthesis, creating a positive feedback loop (Midwood et al. 2009; 
Maqbool et al. 2016). 
Mechanical stretching of cardiac fibroblasts induces the expression of several 
pro-fibrotic cytokines (Deb and Ubil 2014). IL-6 is also a mechanically-regulated 
gene, and increased IL-6 secretion occurs upon skeletal muscle contraction 
where it is thought to play a beneficial role (Pedersen and Fischer 2007). 
Fibroblasts from several sources have been shown to secrete IL-6 in response to 
mechanical stretch (House et al. 2012; Li et al. 2013; Skutek et al. 2001). 
However, the literature is varied; Tanaka et al. (2018) found that hydrostatic 
pressure inhibited IL6 mRNA expression in human cardiac fibroblasts. A recent 
paper has shed light on Piezo1 activation and inflammation. Solis et al. (2019) 
very recently demonstrated that Piezo1 could sense cyclical hydrostatic pressure 
and initiate an inflammatory response in myeloid cells by triggering the 
expression of numerous pro-inflammatory mediators, including interleukins. Mice 
deficient in Piezo1 in innate immune cells had ablated pulmonary inflammation 
and increased susceptibility to bacterial infection; conversely, Piezo1 signalling 
exacerbated a model of pulmonary fibrosis. This study implicates force as a major 




not induced by shear stress, altering substrate stiffness or cyclic stretching for 6 
h. 
Piezo1 and Piezo2 have previously been found to work in tandem, with both being 
required for arterial baroreceptor activity and function (Zeng et al. 2018). Genetic 
ablation of both Piezo1 and Piezo2 in the nodose and petrosal sensory ganglia 
of mice abolished drug-induced baroreflex and transgenic animals were found to 
have labile hypertension and increased blood pressure variability (Zeng et al. 
2018). Cyclic stretching of cells was performed once more, this time for the longer 
period of 24 h and it was investigated whether both members of the Piezo1 family 
were involved in mechanically-induced IL-6. Although stretching of cells did not 
induce IL-6, knockdown of Piezo1 caused a reduction in basal levels of both IL-6 
mRNA expression and secretion in both static and stretched cells. This indicates 
that Piezo1 may have a role in the production of IL-6 under basal conditions. 
However, Piezo1-specific siRNA did not reduce basal IL-6 levels in experiments 
where Yoda1 was applied to cells grown on normal tissue culture plates. A 
possible explanation for this is that stretched cardiac fibroblasts were seeded on 
collagen-coated silicon membranes (930 kPa), whereas cells treated with Yoda1 
were plated on uncoated tissue culture plastic (106 kPa). This effect of Piezo1 
knockdown on basal IL-6 levels did not occur in the experiment investigating 
substrates of 10 and 30 kPa stiffness but these varied greatly from the 930 kPa 
substrate utilised in the FlexCell experiments. These different effects on basal IL-
6 secretion may be due to the surrounding environment, whether this be the 
stiffness or the coating of the substrate (FlexCell plates are collagen I-coated, 
whereas the plates used for the other experiment are coated with fibronectin). 
Cells continuously react to mechanical stresses inflicted on them by their 
environment and sense the stiffness of the substrate on which they adhere. Matrix 
rigidity is known to affect cell spreading areas, the stability of adhesion complexes 
and stress fibres, motility and cell proliferation (Lembong et al. 2015). It has 
previously been reported that substrate compliance modulates Ca2+ signalling in 
fibroblasts. When cells from a mouse fibroblast cell line are plated on a soft 
polyacrylamide gel, more cells exhibit calcium oscillations than in cultures on a 
rigid substrate in response to ATP stimulation and the stiffer substrate instigates 
a faster Ca2+ decay following excitation (Lembong et al. 2015). Moreover, growing 




increasing stiffness or enhancing intracellular stress by altering cell adhesion and 
spreading increases the occurrence of Ca2+ oscillations (Godbout et al. 2013); 
this has been shown to correlate with contractile events in these cells (Castella 
et al. 2010). Therefore, it is evident that calcium events in fibroblasts are 
regulated by the mechanical environment. It has been established that the 
mechanical environment also has effects on Piezo1-mediated Ca2+ events; Ca2+ 
flickers which could be attributed to Piezo1 were found to be localised to regions 
of high-traction forces in human foreskin fibroblasts (Ellefsen et al. 2019). 
To summarise, data discussed show that activation of Piezo1 in cardiac 
fibroblasts using Yoda1 leads to an increase in the expression of genes involved 
in cardiac remodelling. TNC and IL-6 are upregulated following myocardial injury; 
these genes were revealed to be amplified following Yoda1 treatment in cardiac 
fibroblasts in a Piezo1-dependent manner. These changes in gene expression 
could not be replicated when the channel was activated mechanically using shear 
stress or stretch. However, Piezo1 was indicated to play a role in the production 
of IL-6 under basal conditions in cardiac fibroblasts; this was dependent on the 




Chapter 5 Role of p38α MAPK and Src signalling in Piezo1-
induced IL-6 production 
5.1 Introduction 
In the previous chapter it was demonstrated that chemical activation of Piezo1 
led to changes in the expression of genes which are important in fibroblast 
function and cardiac remodelling. The most well-defined evidence was for the 
pro-inflammatory cytokine, IL-6. Information on IL-6 is valuable in this setting as 
this cytokine is known to promote cardiac fibroblast proliferation and fibrosis 
(Banerjee et al. 2009) and the importance of cardiac fibroblast-derived IL-6 in 
modulating cardiac hypertrophy has been proposed (Bageghni et al. 2018). 
Therefore, the mechanism by which Piezo1 activation was coupled to IL-6 
expression and secretion was interrogated. 
 
5.2 Aim 
The key aim of this chapter was to examine the downstream signalling events 
mediating Piezo1-induced IL-6 expression in cardiac fibroblasts. 
 
5.3 Methods 
PamChip multiplex serine/threonine and tyrosine kinase activity profiling were 
utilised to establish kinases activated by Yoda1 treatment in murine cardiac 
fibroblasts (Section 2.12). These arrays provided us with key data which was 
followed up by western blotting to confirm that kinases highlighted in the arrays 
were activated by Yoda1 treatment (Section 2.6). Piezo1-targeting siRNA was 
utilised to confirm the specificity of the data (Section 2.4) and pharmacological 
inhibitors were used to ascertain the hierarchy of the signalling pathway (Section 
2.1). Finally, it was explored which members of a key kinase family activated by 
Yoda1 activation of Piezo1 were expressed in cardiac fibroblasts utilising RT-






5.4.1 Piezo1 activation induces MAP kinase signalling 
PamChip multiplex serine/threonine kinase activity profiling was used to assess 
differences in kinase activity following treatment of murine cardiac fibroblasts with 
vehicle or 10 μM Yoda1 for 10 min. Combinatorial analysis of phosphorylation of 
140 peptide substrates revealed predicted serine/threonine kinases that were 
activated downstream of Piezo1. The complete data set of kinases identified 
based on peptide substrate phosphorylation and ranked by median final score 
are shown in Table 5.1. Within the top hits, two major kinase families were 
identified; MAP kinases (extracellular signal-regulated kinases ERK1/2/5, c-Jun 
N-terminal kinases JNK1/2/3, p38 mitogen-activated protein kinases p38α/β/δ/γ) 
and cyclin-dependent kinases (CDKs1-7,9,11) (Figure 5.1). Kinase families 
activated can be seen more clearly in the dendrogram in Figure 5.2. 
The primary role of CDK-family kinases is to phosphorylate cell cycle proteins 
and thereby regulate cell cycle progression; although it has also been reported 
that specific CDKs can regulate inflammatory gene expression through 
interaction with the NF-kB pathway (Schmitz and Kracht 2016). However, given 
that kinases within the NF-kB pathway (IKKα, IKKβ) were not revealed to be 
activated in response to Yoda1 (Table 5.1), the role of CDKs was not pursued 













1  p38[beta] 4.36 2.32 1.75 
2  CDK5 4.28 2.47 1.63 
3  p38[gamma] 4.10 1.97 1.28 
4  CDK2 4.08 2.65 1.39 
5  ERK2 4.04 2.70 1.39 
6  ERK1 3.95 2.70 1.30 
7  JNK2 3.88 2.70 1.19 
8  p38[delta] 3.84 2.63 1.30 
9  JNK3 3.76 2.70 1.04 
10  JNK1 3.74 2.70 1.03 
11  CDC2/CDK1 3.70 2.34 1.24 
12  CDK11 3.40 1.78 1.65 
13  CDK9 3.08 1.83 1.27 
14  CDK6 2.99 1.55 1.50 
15  CDK4 2.96 1.50 1.44 
16  ERK5 2.86 1.74 1.04 
17  CDK3 2.69 1.77 1.18 
18 p38[alpha] 2.66 1.64 0.93 
19  ICK 2.64 1.37 1.26 
20  CDK7 2.40 1.44 0.93 
21  CDKL2 2.22 1.22 1.00 
22  CDKL5 2.11 1.16 0.94 
23  GSK3[alpha] 1.91 0.93 0.75 
24  TBK1 1.81 1.07 0.94 
25  GSK3[beta] 1.64 0.87 0.65 
26  ROCK1 1.52 0.80 0.71 
27  AurA/Aur2 1.38 0.72 0.62 
28  PKN1/PRK1 1.37 0.66 0.63 
29  IKK[epsilon] 1.35 0.79 0.59 
30  MSK1 1.29 0.73 0.55 
31  RSK2 1.28 0.74 0.53 
32  PCTAIRE2 1.17 0.63 0.54 
33  RSK3 1.12 0.64 0.46 
34  ARAF 1.01 0.61 0.41 
35  BRAF 1.00 0.59 0.40 
36  ROCK2 0.97 0.35 0.43 
37  ADCK3 0.89 0.40 0.42 
38  PKC[delta] 0.80 0.27 0.34 
39  RSKL2 0.78 0.43 0.35 
40  PAK1 0.78 0.43 0.35 
41  Pim1 0.77 0.51 0.41 
42  CDK10 0.76 0.40 0.39 
43  AurB/Aur1 0.75 0.42 0.36 
44  RSK1/p90RSK 0.72 0.39 0.33 
45  Pim3 0.71 0.42 0.40 
46  RAF1 0.70 0.36 0.33 
47  PFTAIRE2 0.69 0.42 0.38 
48  PKG1 0.69 0.30 0.36 
49  Pim2 0.64 0.36 0.39 
50  PKC[iota] 0.63 0.23 0.34 
51  DAPK3 0.63 0.30 0.33 
52  PKC[zeta] 0.62 0.29 0.37 
53  CDKL1 0.62 0.30 0.37 
54  MSK2 0.60 0.30 0.30 
55  PKD1 0.60 0.32 0.28 
56  DCAMKL1 0.59 0.29 0.29 














58  SGK1 0.56 0.28 0.27 
59  CK2[alpha]1 0.56 0.33 0.23 
60  HGK/ZC1 0.53 0.23 0.24 
61  CHK1 0.51 0.23 0.30 
62  Akt2/PKB[beta] 0.51 0.21 0.33 
63  PRKY 0.46 0.29 0.31 
64  PKG2 0.45 0.15 0.31 
65  p70S6K 0.45 0.19 0.32 
66  mTOR/FRAP 0.45 0.16 0.21 
67  NuaK1 0.44 0.20 0.23 
68  IKK[beta] 0.42 0.22 0.24 
69  Akt1/PKB[alpha] 0.41 0.14 0.29 
70  PKC[alpha] 0.39 0.10 0.30 
71  PKC[epsilon] 0.35 0.11 0.28 
72  MAPKAPK2 0.32 0.05 0.26 
73  PKC[eta] 0.32 0.12 0.28 
74  PKC[theta] 0.31 0.05 0.26 
75  MAPKAPK3 0.30 0.03 0.26 
76  PKC[gamma] 0.29 0.08 0.23 
77  ANP[alpha] 0.25 0.04 0.22 
78  PRKX 0.24 0.02 0.21 
79  CK1[epsilon] 0.24 0.10 0.14 
80  ATR 0.23 0.08 0.15 
81  CK1[alpha] 0.22 0.12 0.20 
82  PKA[alpha] 0.20 0.00 0.22 
83  CHK2 0.20 0.02 0.18 
84  p70S6K[beta] 0.20 0.02 0.19 
85  PFTAIRE1 0.20 0.08 0.12 
86  DAPK2 0.19 0.05 0.13 
87  IKK[alpha] 0.18 0.09 0.13 
88  AMPK[alpha]1 0.14 0.01 0.13 
89  CaMK4 0.13 0.01 0.12 
90  SGK2 0.10 0.00 0.10 
91  CaMK2[alpha] 0.02 0.01 0.01 
Table 5.1 Effect of Yoda1 on serine/threonine protein kinase activity. Mouse 
cardiac fibroblasts were stimulated with vehicle or 10 μM Yoda1 for 10 min before 
analysing serine/threonine protein kinase activity with PamChip multiplex kinase 
activity profiling (n=6). The complete data set of kinases identified are shown 
based on peptide substrate phosphorylation and ranked by median final score 






Figure 5.1 Top 40 serine/threonine protein kinases activated by Yoda1. 
Mouse cardiac fibroblasts were stimulated with vehicle or 10 μM Yoda1 for 10 
min before analysing serine/threonine protein kinase activity with PamChip 
multiplex kinase activity profiling (n=6). Kinases identified based on peptide 
substrate phosphorylation and ranked by specificity and statistical significance; 
the top 40 hits from the analysis in Table 5.1 are shown. The top kinase families 
predicted to be activated by Yoda1 were the MAP kinases (ERK1/2/5, JNK1/2/3, 
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Figure 5.2 Dendrogram illustrating the effect of Yoda1 on serine/threonine 
protein kinase activity. KinMap-generated summary of serine/threonine protein 
kinase activity using PamChip multiplex kinase activity profiling shown in Table 
5.1 and Figure 5.1. The top kinase families predicted to be activated by Yoda1 
are illustrated by colour; MAP kinases (ERK1/2/5, JNK1/2/3, p38α/β/γ/δ; yellow) 
and cyclin-dependent kinases (CDKs1-7,9,11; pink). Circle size indicates median 
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5.4.2 Yoda1-evoked p38 MAPK and ERK phosphorylation 
5.4.2.1 Yoda1 induces p38 MAPK and ERK phosphorylation in murine 
cardiac fibroblasts 
The PamChip activity profiling revealed predictions of kinase activity based on 
phosphorylation sites derived from literature or computational predictions that are 
correlated with one or more upstream kinases; this explains why families of 
kinases are often highlighted in this array (see dendrogram in Figure 5.2). Of the 
four p38 subtypes, p38β had the highest ranking in the serine/threonine kinase 
activity profiling array following Yoda1 treatment (Table 5.1, Figure 5.1). This was 
followed by p38γ (ranking: 3rd), p38δ (ranking: 8th) and p38α (ranking: 18th) (Table 
5.1, Figure 5.1). However, it is known that p38β is not expressed in cardiac 
fibroblasts and p38α is more highly expressed than p38δ or γ (Turner 2011; 
Sinfield et al. 2013). p38α  has been reported to be involved in the production of 
IL-6 in cardiac fibroblasts (Du et al. 2005; Sinfield et al. 2013; Bageghni et al. 
2018). Therefore, it was investigated whether the p38α MAPK pathway was 
stimulated following Piezo1 activation with Yoda1 in murine cardiac fibroblasts. 
Western blotting revealed that Yoda1 significantly increased p38 (i.e. p38α) 
phosphorylation by 3-fold after 10 min treatment, before returning to basal levels 
by 20-30 min (Figure 5.3A). Accordingly, 10 min Yoda1 treatment was utilised for 
future experiments.  
Alongside the p38 family, members of the ERK family were also in the top 20 
predicted serine/threonine kinases activated downstream of Piezo1 (ERK1 and 
ERK2 ranking: 6th and 5th respectively – Table 5.1, Figure 5.1). It was confirmed 
that ERK1 and 2 were also phosphorylated following Yoda1 treatment in murine 
cardiac fibroblasts by western blotting. There was a significant difference in 
ERK1/2 phosphorylation between vehicle-treated and Yoda1-treated cells after 
10 and 20 min treatment (Figure 5.3B). The shortest time point in which Yoda1 
was able to significantly phosphorylate ERK1/2 (10 min) was chosen for all further 
experiments. 
Further studies revealed that both Yoda1-induced p38α and ERK1/2 
phosphorylation occurred in a concentration-dependent manner, with maximal 
p38α phosphorylation occurring in response to 10 µM Yoda1 (Figure 5.4A,B). 




Correlating with earlier data on Ca2+ measurements and Il6 mRNA expression 
(Figure 4.15A,B), neither p38α nor ERK1/2 were activated in response to the 
inactive Yoda1 analogue, 2e (Figure 5.4A,B). Compound 159, which was shown 
to induce Ca2+ entry in a similar manner to Yoda1 in murine cardiac fibroblasts 
(Figure 3.25B) also caused phosphorylation of p38α MAPK and ERK1/2, by a 
similar magnitude as 5 µM Yoda1, when applied to murine cardiac fibroblasts for 





Figure 5.3 Time course of p38α and ERK1/2 activation following Yoda1 
treatment. Murine cardiac fibroblasts were treated with vehicle (V) or 10 µM 
Yoda1 (Y) for 5-30 min. Samples were immunoblotted for (A) p-p38α expression 
and re-probed with total p38α antibody to confirm equal protein loading (n=6) or 
(B) p-ERK1/2 and reprobed with total ERK1/2 antibody to confirm equal protein 
loading (n=3). The bands at 44 kDa and 42 kDa represent ERK1 and ERK2, 
respectively. Graphs show mean densitometric data, *P<0.05 versus vehicle-
treated cells following an ANOVA with Tukey’s post-hoc test. 
  




























































































































Figure 5.4 Effect of Yoda1 and its analogues on p38α MAPK and ERK1/2 
phosphorylation. Murine cardiac fibroblasts were treated for 10 min with vehicle, 
varying concentrations of Yoda1 (2-10 µM), 10 µM compound 2e or 10 µM 
compound 159. Samples were immunoblotted for (A) p-p38α and reprobed with 
antibody for total p38α, to confirm equal protein loading (n=3) or (B) p-ERK1/2 
and reprobed with antibody for total ERK1/2, to confirm equal protein loading 
(n=2). The bands at 44 kDa and 42 kDa represent ERK1 and ERK2, respectively. 
Graphs show mean densitometric data, *P<0.05, P=NS, not significant versus 
vehicle-treated cells following an ANOVA with Tukey’s post-hoc test (n=3).  















































































































5.4.2.2 Yoda1-induced phosphorylation of p38α and ERK1/2 are 
dependent on Piezo1 
It was important to ascertain if Yoda1-evoked phosphorylation of p38α and 
ERK1/2 were due to Piezo1 activation. Cardiac fibroblasts isolated from Piezo1+/- 
heterozygote KO mice (Het) displayed a marked reduction in the Yoda1-evoked 
p38α phosphorylation in comparison with cells from WT mice (Figure 5.5A). 
Conversely, cardiac fibroblasts isolated from gain-of-function M-R mice revealed 
increased Yoda1-induced p38α phosphorylation, compared to cardiac fibroblasts 
from WT mice (Figure 5.5B). Although not statistically significant, the basal level 
of p38α phosphorylation shows a trend for being increased in cardiac fibroblasts 
from M-R mice, compared to those from WT mice; this may be due to constitutive 
activity of Piezo1. This was observed occasionally but was not reproducible. 
These data indicate that Yoda1-evoked p38α activation is dependent on the 
activation/expression level of Piezo1 in murine cardiac fibroblasts. 
To further confirm that Yoda1-evoked p38α activation was due to Piezo1, Piezo1 
gene silencing was employed. Murine and human cardiac fibroblasts transfected 
with control siRNA exhibited a four-fold increase in p38α phosphorylation 
following Yoda1 treatment, compared to vehicle-treated cells (Figure 5.6A,B). 
Piezo1-specific siRNA reduced Yoda1-induced activation of p38α to basal levels 
in both murine (Figure 5.6A) and human (Figure 5.6B) cardiac fibroblasts. 
Similarly, Yoda1-induced ERK1/2 activation was inhibited by Piezo1 gene 
silencing (Figure 5.6C). Together, these data confirm the essential role of Piezo1 






Figure 5.5 Effect of altering Piezo1 expression or activity on Yoda1-evoked 
phosphorylation of p38α.  Cardiac fibroblasts isolated from (A) wild type (WT, 
n=3) and Piezo1+/- heterozygote knockout (Het, n=3) mice or (B) WT (n=6) and 
gain-of-function Piezo1-mutated (M-R, n=7) mice and treated with vehicle or 10 
µM Yoda1 for 10 min. Samples were immunoblotted for p-p38α and reprobed 
with total p38α antibody to confirm equal protein loading. Graph shows mean 
densitometric data, *P<0.05, P=NS, not significant following an ANOVA with 

















































































































Figure 5.6 Effect of Piezo1 knockdown on Yoda1-evoked phosphorylation 
of p38α and ERK1/2 in murine and human cardiac fibroblasts. (A) Murine or 
(B) human cardiac fibroblasts were transfected with either control (C) or Piezo1-
specific (P1) siRNA before treatment with vehicle or 10 µM Yoda1 for 10 min. 
Samples were immunoblotted for phospho-p38α antibody and reprobed with total 
p38α antibody to confirm equal protein loading. (C) Murine cardiac fibroblasts 
were transfected with either control (C) or Piezo1-specific (P1) siRNA prior to 
treatment with vehicle or 10 µM Yoda1 for 10 min. Samples were immunoblotted 
for p-ERK1/2 and reprobed with total ERK1/2 antibody to confirm equal protein 
loading. The bands at 44 kDa and 42 kDa represent ERK1 and ERK2, 
respectively. Graphs show mean densitometric data, *P<0.05, **P<0.01, P=NS, 
not significant following an ANOVA with Tukey’s post-hoc test (n=3). 



































































































































































5.4.2.3 Yoda1-induced activation of p38α MAPK is reduced by a p38 
inhibitor 
p38α and β have high sequence homology and share sensitivity to 
pharmacological inhibition by pyridinyl imidazole molecules such as SB203580 
whereas p38γ and δ have only 60% homology to p38α and are resistant to 
SB203580 inhibition (Eyers et al. 1999). Pretreatment of murine cardiac 
fibroblasts with SB203580 significantly reduced the Yoda1-induced 






Figure 5.7 Effect of a p38 MAPK inhibitor on Yoda1-evoked p38α MAPK 
phosphorylation. Murine cardiac fibroblasts were exposed to 10 μM SB203580 
for 1 h before treatment with vehicle or 10 µM Yoda1 for 10 min. Samples were 
immunoblotted for p-p38α and reprobed with total p38α, to confirm equal protein 
loading. Graph shows mean densitometric data, **P<0.01, ***P<0.001, P=NS, 





























































5.4.2.4 Yoda1-evoked p38α and ERK1/2 phosphorylation are dependent 
on Ca2+ 
In order to confirm that the phosphorylation of p38α and ERK1/2 were due to Ca2+ 
entry into the cell upon Piezo1 activation by Yoda1, murine cardiac fibroblasts 
were treated with either vehicle or Yoda1 for 10 min in either standard DMEM 
media or in media containing 1.75 mM EGTA to chelate extracellular free Ca2+. 
The Yoda1-induced phosphorylation of p38α that was observed in Ca2+-
containing medium was abolished in the absence of Ca2+ (Figure 5.8A). Similar 
data were obtained for ERK1/2 activation (Figure 5.8B). These data indicate that 
it is Ca2+ entry through the Piezo1 channel which is important for activation of 
these signalling cascades. 
Together, these data illustrate that Piezo1 activation using Yoda1 and the 







Figure 5.8 Effect of extracellular Ca2+ on Yoda1-induced p38α and ERK1/2 
phosphorylation. Murine cardiac fibroblasts were treated for 10 min with vehicle 
or 10 μM Yoda1 in either standard DMEM or in DMEM containing 1.75 mM EGTA 
to chelate extracellular free Ca2+. Samples were immunoblotted for (A) p-p38α 
and reprobed with total p38α antibody to confirm equal protein loading or (B) p-
ERK1/2 and reprobed with total ERK1/2 antibody to confirm equal protein loading. 
The bands at 44 kDa and 42 kDa represent ERK1 and ERK2, respectively. 
Graphs show mean densitometric data, *P<0.05, ***P<0.001, P=NS, not 






































































































































5.4.3 Yoda1-evoked IL-6 expression and secretion is abolished by a 
p38 inhibitor 
Informed by the PamChip multiplex serine/threonine kinase activity profiling 
where three MAP kinase families were activated, subsequent experiments were 
undertaken to identify which family was required for the Piezo1-mediated 
induction of IL-6. Selective pharmacological inhibitors of the ERK (PD98059), 
JNK (SP600125) and p38 MAPK (SB203580) pathways were used. In addition, 
specific pharmacological inhibitors of pathways activated by Ca2+ entry were also 
tested: PI-3 kinase (LY294002), Ca2+/calmodulin-dependent protein kinase II 
(KN-93)  and NFAT (11R-VIVIT). There was a non-significant trend for KN-93 
increasing basal Il6 mRNA expression therefore this result was not studied further 
(Figure 5.9E). Of the pharmacological inhibitors, only SB203580 significantly 
reduced the Yoda1-induced increase in Il6 mRNA expression back to basal levels 
(Figure 5.9), suggesting an important role for the p38 MAPK pathway in Yoda1-
induced Il6 gene expression, but not the other kinase pathways. In agreement, 
SB203580 also inhibited Yoda1-induced IL-6 protein secretion by 77% (Figure 
5.10). 
Together, these data imply that Ca2+-induced p38 MAPK activation is essential 






Figure 5.9 Effect of kinase inhibitors on Yoda1-evoked Il6 mRNA expression 
in murine cardiac fibroblasts. RT-PCR analysis of Il6 mRNA expression after 
exposure of murine cardiac fibroblasts to (A) 30 μM PD98059 (ERK pathway 
inhibitor), (B) 10 µM SP600125 (JNK inhibitor), (C) 10 μM SB203580 (p38 MAPK 
inhibitor), (D) 10 μM LY294002 (Phosphoinositide 3-kinase (PI3K)/Akt pathway 
inhibitor), (E) 10 μM KN-93 (CaM kinase II inhibitor) or (F) 10 µM 11R-VIVIT 
(NFAT Inhibitor) for 1 h followed by treatment with vehicle or 10 μM Yoda1 for a 
further 24 h. Expression is measured as % of housekeeping control, Gapdh, 
***P<0.001, P=NS, not significant for effect of inhibitor following an ANOVA with 


































































































































































Figure 5.10 Effect of p38 inhibitor on Yoda1-induced IL-6 secretion from 
murine cardiac fibroblasts. Murine cardiac fibroblasts were pretreated with 
vehicle or 10 µM SB203580 for 1 h and then applied with either vehicle or 10 μM 
Yoda1 for 24 h before collecting conditioned media and measuring IL-6 levels by 
































5.4.4 The role of Src-family kinases in Piezo1-induced p38α 
phosphorylation and IL-6 expression 
5.4.4.1 Src-family and Src-related kinases are activated by Yoda1 
treatment in murine cardiac fibroblasts 
Having identified p38 MAPK as being important for Piezo1-mediated Il6 mRNA 
expression, we sought to identify upstream tyrosine kinases that could couple 
Piezo1 activation and Ca2+ entry to p38 MAPK activation. Again PamChip 
multiplex kinase activity profiling was used, but this time, differences in activity of 
the tyrosine kinome were focussed on following treatment of murine cardiac 
fibroblasts with 10 µM Yoda1 for 10 min. Combinatorial analysis of 
phosphorylation of 196 peptide substrates (mapping to ~100 tyrosine kinases) 
generated predicted tyrosine kinases that were activated by Yoda1 (Table 5.2). 
Within the top hits were 8 SFKs (Lyn, Blk, Src, Hck, Fgr, Yes, Lck and Fyn) and 
2 Src-related kinases (Frk and Srm) (Figure 5.11). Families of kinases are 













1  FRK 3.25 2.41 0.84 
2  ALK 2.86 2.04 0.83 
3  Lyn 2.83 1.65 0.84 
4  BLK 2.71 1.91 0.86 
5  Abl 2.38 1.65 0.80 
6  Src 2.22 1.88 0.83 
7  RYK 2.08 1.16 0.88 
8  HCK 2.05 1.22 0.84 
9  Fgr 2.02 1.12 0.84 
10  Arg 2.02 1.32 0.82 
11  Srm 2.01 1.16 0.80 
12  IGF1R 2.00 1.51 0.84 
13  InSR 1.98 1.23 0.84 
14  Yes 1.92 1.18 0.84 
15  Lck 1.91 1.31 0.79 
16  LTK 1.75 0.95 0.82 
17  Fyn 1.70 0.85 0.80 
18  KDR 1.62 0.77 0.87 
19  EphA1 1.53 0.80 0.80 
20  EphA4 1.52 0.98 0.86 
21  Tyro3/Sky 1.51 0.64 0.80 
22  Axl 1.38 0.87 0.81 
23  HER3 1.36 0.56 0.78 
24  Met 1.34 0.51 0.82 
25  CTK 1.32 0.56 0.80 
26  FGFR3 1.29 0.47 0.76 
27  Ron 1.28 0.47 0.76 
28  TRKC 1.26 0.35 0.77 
29  FLT3 1.24 0.40 0.81 
30  FGFR2 1.24 0.48 0.78 
31  FAK1 1.23 0.41 0.80 
32  Ret 1.22 0.52 0.76 
33  Fer 1.18 0.41 0.75 
34  FmS/CSFR 1.15 0.44 0.78 
35  PDGFR[beta] 1.15 0.40 0.73 
36  CSK 1.15 0.35 0.77 
37  EphA3 1.14 0.40 0.74 
38  TRKA 1.12 0.31 0.77 
39  EphA5 1.11 0.38 0.75 
40  EphB3 1.11 0.39 0.72 
41  Fes 1.10 0.41 0.74 
42  EphA2 1.10 0.41 0.74 
43  FLT4 1.06 0.31 0.79 
44  FGFR1 1.05 0.22 0.79 
45  Mer 1.04 0.30 0.77 
46  CCK4/PTK7 1.04 0.25 0.80 
47  Syk 1.03 0.31 0.77 
48  FGFR4 1.03 0.34 0.79 
49  Brk 1.02 0.23 0.79 
50  HER4 0.98 0.23 0.78 
51  TXK 0.97 0.24 0.76 
52  TEC 0.95 0.20 0.75 
53  BTK 0.95 0.24 0.74 
54  TRKB 0.94 0.26 0.76 
55  EphB2 0.91 0.25 0.66 
56  EphA8 0.90 0.19 0.69 














58  EphB4 0.87 0.22 0.65 
59  ITK 0.85 0.13 0.75 
60  HER2 0.85 0.13 0.74 
61  ZAP70 0.84 0.07 0.76 
62  Lmr1 0.84 0.18 0.66 
63  FAK2 0.83 0.13 0.74 
64  IRR 0.83 0.19 0.65 
65  EGFR 0.81 0.03 0.76 
66  JAK2 0.80 0.05 0.74 
67  PDGFR[alpha] 0.80 0.27 0.71 
68  EphA7 0.80 0.16 0.64 
69  Kit 0.76 0.06 0.71 
70  FLT1 0.68 0.01 0.67 
71  JAK1~b 0.68 0.10 0.60 
72  DDR1 0.64 0.10 0.55 
73  EphB1 0.60 0.04 0.54 
74  Tyk2 0.51 0.02 0.50 
75  JAK3 0.35 0.00 0.34 
Table 5.2 Effect of Yoda1 on tyrosine protein kinase activity. PamChip 
multiplex kinase activity profiling of Yoda1-induced tyrosine kinase activity. 
Mouse cardiac fibroblasts (n=6) were treated with 10 µM Yoda1 for 10 min before 
extracting cell lysates and assessing activity of the tyrosine kinome (~100 TKs). 
The complete data set of kinases identified are shown based on peptide substrate 






Figure 5.11 Top 40 tyrosine kinases activated by Yoda1. Mouse cardiac 
fibroblasts were stimulated with vehicle or 10 μM Yoda1 for 10 min before 
analysing tyrosine protein kinase activity with PamChip multiplex kinase activity 
profiling (n=6). Kinases were identified based on peptide substrate 
phosphorylation and ranked by specificity and statistical significance; the top 40 
hits from Table 5.2 are shown. The top kinase families predicted to be activated 
by Yoda1 were the Src-family kinases (Lyn, Blk, Src, Hck, Fgr, Yes, Lck, Fyn; 
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Figure 5.12 Dendrogram illustrating the effect of Yoda1 on tyrosine protein 
kinases. KinMap-generated summary of tyrosine protein kinase activity using 
PamChip multiplex kinase activity profiling shown in Table 5.2 and Figure 5.11. 
Circle size indicates median score (combination of specificity and significance). 
The top kinase families are illustrated by colour; Src-family kinases (yellow) and 




5.4.4.2 A SFK inhibitor abolished Yoda1-evoked p38 MAPK and ERK1/2 
phosphorylation 
SFKs are the largest family of non-receptor protein tyrosine kinases; three 
members of the family (Src, Fyn, and Yes) are ubiquitously expressed, whereas 
the other members exhibit a more restricted expression pattern (Davis et al. 
2001). To establish whether SFKs play a role in Yoda1-evoked p38 MAPK and/or 
ERK1/2 phosphorylation, an inhibitor of SFKs was used to pretreat murine 
cardiac fibroblasts. PP1 is an inhibitor of four of the SFKs; inhibiting Lck and Fyn 
at very low nanomolar concentrations and Src and Hck with slightly less potency 
(Hanke et al. 1996). PP1 pretreatment for 30 min prior to Yoda1 treatment 
revealed a substantial inhibitory effect on Yoda1-induced p38α MAPK 
phosphorylation in murine cardiac fibroblasts (Figure 5.13A). Pretreatment of 
murine cardiac fibroblasts with PP1 also eliminated ERK1/2 phosphorylation 
upon Yoda1 application (Figure 5.13B). These data indicate that SFKs are 






Figure 5.13 Effect of Src-family kinase inhibitor PP1 on Yoda1-induced  
p38α MAPK and ERK1/2 activation. Murine cardiac fibroblasts were pretreated 
with 5 µM PP1 or vehicle for 30 min, before treatment with vehicle or 10 µM Yoda1 
for 10 min. Samples were immunoblotted for (A) p-p38α and reprobed with total 
p38α antibody or (B) p-ERK1/2 and reprobed with total ERK1/2 antibody to 
confirm equal protein loading. Graphs show mean densitometric data, *P<0.05, 





















































































































5.4.4.3 A SFK inhibitor reduced Yoda1-evoked Il6 expression 
As PP1 was observed to reduce Yoda1-evoked phosphorylation of p38α MAPK, 
the next step was to investigate whether PP1 affected Yoda1-evoked Il6 mRNA 
expression, which was previously shown to be dependent upon p38 MAPK 
(Figure 5.9). PP1 pretreatment abolished the Yoda-induced increase in Il6 mRNA 
expression in murine cardiac fibroblasts (Figure 5.14). These data reveal SFKs 
as the link between activation of the Piezo1 channel and p38 MAPK activation, 






Figure 5.14 Effect of Src-family kinase inhibitor PP1 on Yoda1-induced Il6 
mRNA expression. RT-PCR analysis of Il6 mRNA expression after exposure of 
murine cardiac fibroblasts to vehicle or 5 μM PP1 for 30 min, followed by 
treatment with vehicle or 10 μM Yoda1 for a further 24 h. Expression measured 
as % of housekeeping control, Gapdh, *P<0.05, **P<0.01, P=NS, not significant 































5.4.4.4 A SFK inhibitor had no effect on Ca2+ entry through Piezo1  
The effect of PP1 on Yoda1-evoked Ca2+ entry was investigated to ascertain 
whether the SFK inhibitor was interfering with Ca2+ entry through the activated 
Piezo1 channel, or whether the compound was having an effect further 
downstream. Fluorescence calcium imaging revealed that pretreatment of murine 
cardiac fibroblasts with PP1 had no effect on the Ca2+ entry seen upon application 
of 2 µM Yoda1, compared with cells pretreated with vehicle (Figure 5.15). These 
data indicate that SFKs are involved downstream of the Ca2+ influx induced 
following activation of Piezo1 with Yoda1, rather than interacting with the Piezo1 
channel in some way. 
Together, the results suggest that Yoda1-evoked Ca2+ entry through the Piezo1 
channel instigates p38α MAPK phosphorylation and Il6 mRNA expression 






Figure 5.15 Effect of Src-family kinase inhibitor PP1 on Yoda1-induced  Ca2+ 
entry. Representative intracellular Ca2+ traces and mean data after murine 
cardiac fibroblasts were exposed to 5 μM PP1 or vehicle for 30 min before 
activation of Piezo1 using 2 μM Yoda1, P=NS, not significant compared to 
































































5.4.4.5 Human cardiac fibroblasts express various SFKs 
Expression of individual SFKs varies between different cell types; RT-PCR 
analysis was performed to determine which SFKs are expressed by cardiac 
fibroblasts. Human cardiac fibroblasts expressed mRNA encoding Fyn, Src, Lyn 
and Yes only (Figure 5.16A). Fyn and Yes kinase were most highly expressed 
and Src kinase was expressed at lower levels (approximately 25% of that of Fyn 
and Yes). These results were obtained using SYBR™ Green and in house 
designed primers, rather than Taqman primer/probe sets. Hence,  products were 
run on a gel to confirm correct product size (Figure 5.16B). Primers were 
confirmed to be effective by including a commercial human brain sample as a 
control, which should express many members of the SFK family (Figure 5.16C). 
These results implicate Fyn, Src or Yes kinase, alone or in combination, as the 






Figure 5.16 Expression of individual Src-family kinases in human cardiac 
fibroblasts. (A) RT-PCR analysis illustrating the differential expression of 
individual SFKs in human cardiac fibroblasts (n=4). Data are expressed relative 
to β–ACTIN housekeeping gene. (B,C) End-point PCR products obtained with 
primers for Fyn, Hck, Src, Fgr, Lyn, Blk, Yes and Lck in (B) human cardiac 
fibroblasts and (C) human brain mRNA after reverse transcriptase reaction (+RT) 
or without (-RT) to generate cDNA. Expected product sizes are shown beneath 
and L=100 bp ladder. 
  



































Chemical activation of Piezo1, using Yoda1, initiates changes in the expression 
of genes associated with fibroblast function and cardiac remodelling. Of particular 
interest was the Yoda1-mediated increase in IL-6 expression and secretion in 
cardiac fibroblasts as this was revealed to be Piezo1-dependent. Piezo1 was also 
suggested to participate in maintaining basal levels of IL-6. IL-6 gene transcription 
in cardiac fibroblasts has been demonstrated to be induced via several different 
intracellular signalling pathways, including ERK, p38 MAPK and NF-κB (Vanden 
Berghe et al. 2000). In neonatal mouse cardiac fibroblasts, IL-6 expression was 
upregulated via activation of p38 MAPK following stimulation of the β2-adrenergic 
receptor (Yin et al. 2006). Yet, Ang II-evoked IL-6 production in neonatal rat 
cardiac fibroblasts required p38 MAPK and ERK activation (Sano et al. 2001), 
while Gα13 G-protein-induced IL-6 expression required NF-κB activation 
(Nagamatsu et al. 2006). Turner et al. (2007) found that TNF-α-evoked IL-6 
expression in human cardiac fibroblasts occurred via p38 MAPK, PI3K/Akt and 
NF-κB pathways. These studies illustrate that the production of IL-6 expression 
in cardiac fibroblasts can arise following the activation of multiple pathways, 
depending on the initiating stimulus. The aim of this chapter was to establish the 
signalling pathway that coupled Piezo1 activation to IL-6 induction. 
Multiplex serine/threonine kinase activity profiling revealed that, following Yoda1 
treatment of murine cardiac fibroblasts, two major kinase families were activated: 
MAP kinases (extracellular signal-regulated kinases ERK1/2/5, c-Jun N-terminal 
kinases JNK1/2/3, p38 mitogen-activated protein kinases p38α/β/δ/γ) and cyclin-
dependent kinases (CDKs1-7,9,11). Follow up experiments using western 
blotting revealed that both p38α MAPK and ERK1/2 were phosphorylated in 
murine cardiac fibroblasts applied with Yoda1 and these effects were both 
dependent on Piezo1 and extracellular Ca2+. Further investigation using qRT-
PCR demonstrated that it was p38 MAPK which was important for Yoda1-induced 
IL-6 expression and secretion in murine cardiac fibroblasts. 
The p38 family of stress-activated MAPKs are known to play an important role in 
cardiac signalling and are activated in both acute and chronic cardiac pathologies 
(Zhang et al. 2003). The α subtype of the p38 family is the most abundantly 
expressed subtype and (along with p38β) can be inhibited by the pyridinyl 




induce p38 signalling in cardiac fibroblasts are mostly stresses, including 
inflammatory cytokines (e.g. IL-1, TNF-α), profibrotic cytokines (e.g. TGF-β), 
DAMPs, G-protein coupled receptor agonists (e.g. Ang II, β-adrenoceptors), 
ischemia and mechanical stretch (Turner 2016; Sinfield et al. 2013; Dostal, 
Glaser and Baudino 2015; Turner 2014). In contrast, the ERK1/2 pathway is 
activated only to a smaller degree by stress stimuli; instead growth factors, 
serum, and phorbol esters strongly activate the pathway (Rose, Force and Wang 
2010). Crosstalk has previously been demonstrated between ERK1/2 and p38 
MAPK; Papakrivopoulou et al. (2004) found that both pathways were activated 
by cyclic mechanical load in cardiac fibroblasts and could regulate mechanical 
load-induced collagen I gene expression, albeit in opposite directions. Inhibition 
of ERK1/2 activity abolished expression whereas inhibition of p38 MAPK 
potentiated this process (Papakrivopoulou et al. 2004). These observations 
demonstrate a key role of these pathways in the regulation of pro-fibrotic gene 
expression induced by mechanical load. 
SB203580, a compound confirmed to have suitable potency and selectivity for 
use as a p38 MAPK inhibitor in cell-based assays (Bain et al. 2007), was used to 
pretreat murine cardiac fibroblasts and was shown to abolish Yoda1-evoked Il6 
mRNA expression. It was also determined that SB203580 itself could 
substantially inhibit Yoda1-evoked p38α phosphorylation. This implies that p38α 
MAPK undergoes autophosphorylation upon Yoda1 treatment, which is 
prevented by reducing p38α MAPK activity via SB203580. Various upstream 
kinases are involved in the phosphorylation cascades leading to p38 activation, 
including MST1, MEKK1-4, MLK3, TAK1 and ASK1 at the MAPKKK level and 
MKK3/4/6 at the MAPKK level (Turner and Blythe 2019). Alternatively, p38 can 
also be activated by at least two non-canonical mechanisms, independently of 
upstream kinases. One of these is through TAB1 (TGF-β-activated protein 1 
(TAK1)-binding protein 1), which binds to p38α MAPK and leads to its 
autophosphorylation (Tanno et al. 2003; Lu et al. 2006); this has been revealed 
to contribute to injury during myocardial ischemia (Tanno et al. 2003). Therefore, 
logically, as Yoda1 is inducing the autophosphorylation of p38, it is possible that 
TAB is important in this pathway, rather than classical MAPKKs. 
The p38 pathway can regulate gene and protein expression via various 




methylation (Li et al. 2018), directly modifying gene transcription by 
phosphorylating transcription factors (Whitmarsh 2010) and regulating mRNA 
stability. The latter is mediated by the phosphorylation of RNA binding proteins, 
including HuR (human antigen R) which stabilises mRNA, and TTP 
(tristetraprolin) which partakes in mRNA destabilisation (Dean et al. 2004); the 
phosphorylation of both proteins leads to increased mRNA levels. RNA binding 
proteins bind to regulatory sites called adenosine/uridine-rich elements (AREs) in 
the 3′ untranslated regions (UTRs) of mRNAs (Bevilacqua et al. 2003). The 
majority of evidence implies that the p38 substrate, MAPK-activated protein 
kinase 2 (MK2), is involved in the phosphorylation of RNA binding proteins (Soni 
et al. 2019). Various proinflammatory cytokines secreted by cardiac fibroblasts, 
including IL-6, are modulated by p38-evoked MK2-mediated modulation of RNA-
binding proteins (Turner and Blythe 2019). The p38 pathway can mediate 
myocardial IL-6 expression through multiple mechanisms; Ang II evokes Il6 
transcription via p38-mediated phosphorylation of the CREB transcription factor 
in rat cardiac fibroblasts (Sano et al. 2001) and IL-6 mRNA stability has been 
revealed to be promoted by p38α via the 3'-UTR (Zhao, Liu and Kirkwood 2008). 
Transgenic mouse studies have demonstrated support for p38α playing a role in 
regulating fibroblast-derived IL-6 in various cardiac pathologies. Fibroblast-
specific KO of Mapk14, the gene encoding p38α, revealed a critical role for this 
kinase in driving cardiac myofibroblast differentiation and fibrosis (Molkentin et al. 
2017) and in stimulating IL-6-induced cardiac hypertrophy following chronic β-
adrenergic stimulation (Bageghni et al. 2018). p38 signalling has also previously  
been demonstrated to be regulated by mechanical stress-evoked Piezo1 
activation in mesenchymal stem cells (Sugimoto et al. 2017). These data 
combined therefore suggest it is possible that Piezo1-mediated activation of p38α 
in cardiac fibroblasts and the subsequent secretion of IL-6 may be important in 
cardiac remodelling. 
Multiplex activity profiling of the tyrosine kinome revealed that Src-family and Src-
related kinases may be the link between Piezo1-mediated Ca2+ influx and p38 
activation. The activation of SFKs is achieved by either phosphorylation of 
Tyr416, dephosphorylation of Tyr527, or their association with different proteins, 
including ion channels (Bjorge, Jakymiw and Fujita 2000; Holmes et al. 1996). 




The exchange is reciprocal; SFKs can play a part in pathways leading to the 
generation of the Ca2+ signal, as well as the Ca2+ signal being able to modulate 
the activity and function of SFKs (Anguita and Villalobo 2017). There is evidence 
that Src binds to regions of the α1c L-type Ca2+ channel to modulate channel 
activity (Dubuis et al. 2006). Moreover, it is known that SFKs interact with the 
Ca2+-permeable TRP channels; Src interacts with TRPC channels via the SH2 
domain and Fyn interacts with TRPC1/3/6/7 channels, regulating their 
functionality (Anguita and Villalobo 2017). This confirms the ability of SFKs to 
directly interact with ion channels. Reports of associations between Src kinase 
and Piezo1 have come to light in recent years. Wang et al. (2016) found that 
shear stress induced phosphorylation of Src kinase in endothelial cells and Zhong 
et al. (2019) demonstrated that Src kinase was cleaved in response to 
mechanical stretch in endothelial alveolar-capillary barriers; both processes 
occurred in a Piezo1-dependent manner. SFKs are also known upstream 
activators of the p38 MAPK pathway; Kim et al. (2008) reported that the GTPase, 
Rac1, was the link between Src kinase and p38 MAPK activation in a cancer cell 
line. Moreover, hypoxia-induced p38 MAPK activation and subsequent IL-6 
production in mouse Kupffer cells and mechanically-activated calcium currents 
leading to activation of the ERK1/2 and p38 MAPK pathways in an osteoblast cell 
line were both found to involve upstream SFKs (Katz, Boland and Santillán 2006; 
Thobe et al. 2006). Therefore, it is postulated that SFKs may represent the link 
between Piezo1 activation and p38 MAPK activation in cardiac fibroblasts. 
Utilisation of an inhibitor of SFKs (PP1) revealed a substantial inhibitory effect on 
Yoda1-induced p38α MAPK and ERK1/2 phosphorylation and reduced Yoda1-
evoked Il6 mRNA expression, implying that SFKs are indeed involved in Yoda1-
evoked, p38 MAPK-mediated Il6 expression. PP1 had no effect on Ca2+ influx, 
implying that SFKs are involved downstream of Ca2+ entry induced by Piezo1 
activation using Yoda1, rather than interacting with the Piezo1 channel. RT-PCR 
data illustrating the expression levels of each member of the family suggested 
that either Src and/or Fyn kinase are involved in this pathway as PP1 inhibits only 
four of the kinases in the family (Fyn, Src, Lck and Hck) (Hanke et al. 1996) and, 
of these, only Src and Fyn kinase were found to be expressed in human cardiac 
fibroblasts. SFKs have a segment of residues called the unique domain which 




conserved in Src, Fyn, and Yes (Amata, Maffei and Pons 2014). These 3 SFKs 
are often co-expressed and a deficiency in one can be compensated by the action 
of the others (Amata, Maffei and Pons 2014). This, along with the fact that Src 
and Fyn are similarly regulated (Ingley 2008), makes the study into individual 
SFKs more difficult. 
Together, data in this chapter revealed that p38α MAPK and ERK1/2 are 
phosphorylated in cardiac fibroblasts upon Piezo1 activation by Yoda1. 
Phosphorylation was dependent on Piezo1 expression/activity and extracellular 
Ca2+. Investigation into whether activation of these signalling pathways led to 
Yoda1-evoked IL-6 expression and secretion using a variety of pharmacological 
kinase inhibitors ascertained that only p38α MAPK was involved. Yoda1 
treatment activated SFKs in cardiac fibroblasts; this was also dependent on 
Piezo1 and Ca2+ and occurred upstream of p38α MAPK activation. In summary, 
Ca2+ entry through Piezo1 leads to the phosphorylation of SFKs which cause the 
activation of p38α MAPK, with the end result being an induction in IL-6. This is 











Figure 5.17 Schematic of the proposed mechanism linking Yoda1-mediated 
Piezo1 activation to IL-6 secretion. Yoda1 activates Piezo1 channels to cause 
Ca2+ influx, this activates Src-family kinases (SFK) which phosphorylate both 
extracellular signal-regulated kinases 1 and 2 (ERK) and p38 mitogen-activated 
protein kinase (MAPK). P38 MAPK activation stimulates interleukin-6 (IL-6) 




Chapter 6 The role of Piezo1 in cardiac fibroblasts in vivo 
6.1 Introduction 
In the previous three chapters, evidence was presented establishing that Piezo1 
is expressed in cardiac fibroblasts and that its activation leads to changes in the 
expression of genes which are important for fibroblast function and cardiac 
remodelling. All experiments leading up to this point have been in vitro using 
cultured cardiac fibroblasts. To investigate the physiological role of Piezo1 in 
cardiac fibroblasts, it was necessary to develop a fibroblast-specific Piezo1 KO 
model. A global KO approach has been used previously to investigate 
endothelial-specific deletion of mouse Piezo1; it was discovered that this 
profoundly disturbed the developing vasculature and was embryonically lethal 
within days of the heart beating (Li et al. 2014). 
6.2 Aims 
The aim of this chapter was to generate and validate an inducible KO mouse 
model of Piezo1 specifically in cardiac fibroblasts in order to examine the role of 
Piezo1 in cardiac remodelling. The intention was to investigate whether cardiac 
function or molecular markers of remodelling were affected following cardiac 
injury in mice with fibroblast-specific deletion of Piezo1, in comparison with 
control mice. 
6.3 Methods 
Genetic manipulation to generate Piezo1 KO mice was performed using the Cre-
loxP system (Section 2.13.4.1). Ca2+ measurements (Section 2.3) and RT-PCR 
(Section 2.5) were utilised to confirm KO of Piezo1. 10-12 week old mice 
underwent a surgical procedure, either a permanent left anterior descending 
(LAD) coronary artery ligation model of experimental MI (Section 2.13.5.1) or a 
pressure overload model caused by constriction of the transverse aorta (TAC) 
(Section 2.13.5.2). The following week, mice were injected with tamoxifen to 
induce Cre activity (Section 2.13.4.2) and cardiac function and gene expression 






6.4.1 Fibroblast-specific Piezo1 knockout murine model 
6.4.1.1 Generation of the fibroblast-specific Piezo1 knockout murine 
model 
To study the role of cardiac fibroblast Piezo1 in vivo, C57BL/6 Piezo1flx/flx mice 
were crossed with C57BL/6 mice expressing Cre recombinase (Col1a2-Cre-
ER(T)) to generate a tamoxifen-inducible fibroblast-specific Piezo1 KO murine 
model line (Col1a2-Cre-Piezo1flx/flx). Fibroblast specificity of Cre expression (and 
hence Piezo1 deletion) was driven by a 6 kb transcriptional enhancer sub-cloned 
from the far-upstream region of the mouse collagen I alpha 2 gene (Col1a2), 
linked to an endogenous minimal promoter (Zheng et al. 2002). This method has 
previously been used successfully by our group to delete p38α and IL-1R1 in 
fibroblasts (Bageghni et al. 2018; Bageghni et al. 2019). Cre- Piezo1flx/flx mice 
were used as control animals and Cre+ Piezo1flx/flx mice as experimental animals. 
Three week-old Col1a2-Cre-Piezo1flx/flx mice were injected intraperitoneally with 
tamoxifen, which induces the activity of Cre and, therefore, floxed gene deletion 
exclusively in fibroblasts. The strategy for breeding animals is illustrated in 
Section 2.14.4 (Figure 2.6) and information on how the deletion of Piezo1 is 
achieved using the Cre-loxP technique is detailed in Figure 2.7. Figure 6.1 
displays examples of agarose gels used to identify the genotype of mice. Figure 
6.1A illustrates PCR products attained using primers for LoxP confirming that all 
6 Col1a2-Cre-Piezo1flx/flx mice have LoxP sites flanking exons 19-23 of Piezo1, 
as expected. Figure 6.1B reveals products from PCR using primers for Cre. Of 
the 6 Col1a2-Cre-Piezo1flx/flx mice, mice numbered 1, 3 and 4 were Cre- and 2, 5 
and 6 were Cre+. Following tamoxifen administration, deletion bands were 
detected in both ear notches and cultured cardiac fibroblasts from Cre+ mice only, 






Figure 6.1 Validation of the fibroblast-specific Piezo1 knockout murine 
model. (A) PCR genotyping for presence of LoxP sites (189 bp) in DNA extracted 
from ear notches from mice 1-6. Band size was 155 bp if no LoxP sites were 
present. *Asterisk indicates non-specific bands. (B) PCR genotyping for presence 
of the Cre allele (408 bp) in DNA extracted from ear notches from mice 1-6. (C) 
PCR genotyping for presence of a band indicating a deletion of Piezo1 (379 bp) 
in DNA extracted from ear notches and cultured cardiac fibroblasts from mice 1-
6. This was performed using primers which were only capable of amplifying a 
product if exons 19-23 of Piezo1 had been deleted. Gels indicate positive and 









6.4.1.2 Validation of the fibroblast-specific Piezo1 knockout murine model  
Despite Piezo1 deletion bands being detected in Cre+ samples, RT-PCR analysis 
and Ca2+ measurements revealed only a modest 20 % reduction in Piezo1 mRNA 
expression and a lessening of 10 % in the Yoda1-evoked Ca2+ influx in cultured 
cardiac fibroblasts from tamoxifen-treated Cre+ (Piezo1 KO) mice, compared to 
those from Cre- (Ctrl) mice (Figure 6.2A,B). ATP was used to confirm cell viability; 
the response was comparable in cardiac fibroblasts isolated from both control 
and Piezo1 KO animals (Figure 6.2C). 
These data suggest that the (small) level of Piezo1 deletion observed at PCR and 
gene expression level was unlikely to be sufficient to observe functional effects 







Figure 6.2 Piezo1 mRNA expression and intracellular Ca2+ measurements 
following fibroblast-specific Piezo1 knockout. (A) RT-PCR analysis of Piezo1 
mRNA expression in cultured murine cardiac fibroblasts isolated from control and 
Piezo1 KO mice, P=NS, not significant following a t-test. Group sizes: control 
n=10, Piezo1 KO n=9. (B, C) Representative Ca2+ traces following (B) 5 μM Yoda 
or (C) 5 µM ATP application at 60 seconds in cardiac fibroblasts isolated from 
control and Piezo1 KO mice. The mean data are shown alongside, P=NS, not 













































































































































6.4.2 Myofibroblast-specific Piezo1 knockout murine model 
The second strategy involved generating an alternative KO murine model where 
C57BL/6 Piezo1flx/flx mice were crossed with C57BL/6 mice expressing Cre 
recombinase under control of the periostin (Postn) promoter (The Jackson 
Laboratory) to obtain a tamoxifen-inducible myofibroblast-specific Piezo1 KO 
murine model (Postn-Cre-Piezo1flx/flx). This is a Mer-Cre-Mer (MCM) model; the 
tamoxifen inducible Cre recombinase is flanked by two modified estrogen 
receptor ligand binding domains and is more potent than the ER(T) Cre used in 
the Col1a2-promotor mice. This model has been used previously to investigate 
myofibroblast function following MI (Kanisicak et al. 2016). 
Periostin expression in normal myocardium is high during the neonatal period, 
but subsequently falls to low levels (Frangogiannis 2012). Its expression 
reappears following cardiac injury as, irrespective of their lineage, periostin is a 
common marker for myofibroblasts in the adult mouse heart (Kanisicak et al. 
2016). Therefore, cardiac injury is required prior to the administration of tamoxifen 
in order to induce periostin expression and the deletion. Cardiac hypertrophy, due 
to pressure overload induced by TAC, has been associated with cardiac periostin 
upregulation (Stansfield et al. 2009). Oka et al. (2007) revealed increased 
periostin expression 7 days after TAC surgery, which was absent in sham-
operated animals. It has also been demonstrated that there is marked periostin 
expression 4 days after acute infarction in mice; this persisted for several weeks 
after the acute event (Stanton et al. 2000; Oka et al. 2007). On this basis, MI and 
TAC were the two methods utilised for generating cardiac injury. 
 
6.4.2.1 Generation of the myofibroblast-specific Piezo1 knockout murine 
model 
As with the previous model, Cre- Piezo1flx/flx mice were used as control animals 
and Cre+ Piezo1flx/flx mice as experimental animals. An example DNA agarose gel 
used for identifying the genotype of each mouse is shown in Figure 6.3. In DNA 
isolated from ear notches of 8 mice, all animals were positive for LoxP sites, as 
expected, and of these, mice numbered 2, 5, 6 and 8 were Cre+ and 1, 3, 4 and 
7 were Cre-. Mice underwent surgery at 10-12 weeks of age and were then 




week. This time point was chosen because, as previously discussed, periostin 
expression is upregulated 7 days after both TAC and MI induction in mice (Oka 
et al. 2007). 4 weeks after surgery, physiological measurements of cardiac 
function were obtained by Millar catheter analysis. Stroke volume (SV), ejection 
fraction (EF), end systolic/diastolic volume (ESV/EDV), end systolic/diastolic 
pressure (ESP/EDP) and myocardial contractility (dP/dtmax) were calculated. 
Cardiac hypertrophy was investigated by calculating heart weight/tibia length 
(HW/TL) and heart weight/body weight (HW/BW) ratios. Cardiac gene expression 
was also investigated using RT-PCR. The timeline for experimentation is shown 






Figure 6.3 Validation of the myofibroblast-specific knockout of Piezo1 
murine model. PCR genotyping in Postn-Cre-Piezo1flx/flx mice for presence of 
LoxP sites (189 bp; band size was 155 bp if no LoxP sites were present) and the 
Cre allele (408 bp) in DNA extracted from ear notches from 8 mice. Gels indicate 
positive and negative controls and L=100 bp ladder. Staining below 100 bp 




Figure 6.4 Timeline for the TAC- and MI-induced models of cardiac injury. 
Experimental timeline indicating the timing of tamoxifen injection and 
experimental myocardial infarction (MI) / thoracic aortic constriction (TAC) in 10-
12 week old Postn-Cre-Piezo1flx/flx mice, as well as timings for collection of RNA 






6.4.2.2 MI-induced cardiac injury 
Ligation of the coronary artery to induce MI was chosen as one of two methods 
for inducing cardiac injury in mice. MI is characterised by ischaemic necrosis, left 
ventricular dilatation and at a later stage, collagen deposition, which results in the 
formation of a scar. Cre- animals were referred to as “Ctrl MI” and Cre+ animals 
as “KO MI” throughout; these animals were compared to animals undergoing a 
sham procedure (surgery without ligation of the coronary artery). 
 
6.4.2.2.1 Validation of MI-induced Piezo1 deletion 
RNA taken from the apex of the heart was analysed for Postn and Piezo1 mRNA 
expression in mice 4 weeks following surgery. There appeared to be no difference 
in Postn mRNA expression between sham-operated mice and mice which 
underwent MI (Figure 6.5A). There was also no correlation between Piezo1 






Figure 6.5 Postn and Piezo1 expression levels following MI-induced cardiac 
injury in mice with myofibroblast-specific deletion of Piezo1. RT-PCR 
analysis for (A) Postn and (B) Piezo1 mRNA expression 4 weeks after mice 
underwent surgery. Individual data and mean ± SEM are shown. Expression is 
measured as % of housekeeping control, Gapdh. Group sizes for Postn 
expression: sham, n=7; MI, n=13. Group sizes for Piezo1 expression: control MI, 
n=2; KO MI, n=11. Sham data were taken from Bageghni et al. (2019); all animals 
were male.  
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6.4.2.2.2 Effect of Piezo1 deletion on cardiac function 
A summary of physiological measurements of cardiac function 4 weeks after 
surgery for all three groups of mice (sham, Ctrl MI and KO MI) is shown in Table 
6.1. Measurements of stroke volume and ejection fraction showed a decrease 
from 17 µl in sham animals to 12 µl in Ctrl animals and 62 % in sham animals to 
41 % in Ctrl animals, respectively (Figure 1.6A,B). However, other cardiac 
parameters expected to be affected following MI induction, e.g. an increase in 
end systolic and diastolic volumes (Bageghni et al. 2019), were unchanged in Ctrl 
MI mice, in comparison with sham-operated mice (Figure 6.6C,D). Due to the lack 
of an induction of Postn mRNA expression and therefore, a lack of Piezo1 KO 
(Figure 6.5) in Cre+  mice, it was difficult to ascertain the impact of myofibroblast-
specific Piezo1 deletion. Very low sample numbers in the control group also make 





Table 6.1 Effect of myofibroblast-specific Piezo1 deletion on cardiac 
function 4 weeks after myocardial infarction. Cardiac parameters were 
assessed by Millar pressure-volume conductance catheter. Sham = from a 
previous study (Bageghni et al. 2019) (n=12); Ctrl MI = Cre- Postn-Cre-Piezo1flx/flx 
mice after MI (n=2); KO MI = Cre+ Postn-Cre-Piezo1flx/flx mice after MI (n=11). 














62.15 ± 3.61 41.13 ± 6.06 39.26 ± 4.37
End systolic volume (µl) 12.19 ± 1.78 16.82 ± 1.58 15.29 ± 2.65
End diastolic volume (µl) 26.94 ± 1.92 26.98 ± 7.06 24.25 ± 2.83
Cardiac output
(µl/min)
9800 ± 684 6836 ± 1566 5020 ± 585
Stroke volume
(µl)
16.72 ± 0.88 12.17 ± 3.7 8.85 ± 1.12
Heart rate
(bpm)
584.5 ± 21.9 575.6 ± 46.3 572.9 ± 14.1
End systolic pressure
(mmHg)
103.15 ± 4.23 102.26 ± 8.74 100.19 ± 2.65
End diastolic pressure
(mmHg)
10.66 ± 1.78 8.72 ± 2.84 7.59 ± 1.96
dPdtmax
(mmHg/sec)
11510 ± 802 9328 ± 2731 10620 ± 692
dPdtmin
(mmHg/sec)
-10285 ± 621 -9307 ± 3543 -8471 ± 728
Arterial blood pressure
(mmHg)





Figure 6.6 Effect of myofibroblast-specific Piezo1 KO on cardiac function 
and size following MI-induced cardiac injury. PV conductance catheter data 
from sham, control and myofibroblast-specific Piezo1 KO mice 4 weeks after 
surgery. Individual data and mean ± SEM are shown. Group sizes: sham (n=12), 
control MI (n=2), KO MI (n=11) for (A) SV, stroke volume; (B) EF, ejection 
fraction; (C) ESV, end systolic volume; (D) EDV, end diastolic volume; (E) ESP, 
end systolic pressure; (F) EDP, end diastolic pressure; (G) dP/dtmax, maximal rate 
of rise of left ventricular pressure and a measure of myocardial contractility. 
Group sizes: sham (n=8), control MI (n=2), KO MI (n=11) for (H) HW/TL, heart 
weight/tibia length and (I) HW/BW, height weight/body weight. Sham data were 
taken from Bageghni et al. (2019); all animals were male, **P<0.01, ***P<0.001 
following an ANOVA with Tukey’s post-hoc test.  
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6.4.2.2.3 Effect of Piezo1 deletion on cardiac gene expression 
Messenger RNA expression of various ECM regulatory genes (Mmp3, Tnc, 
Col1a1, Col3a1), hypertrophy markers (Mhy7, Nppa), an inflammatory gene (Il6) 
and a myofibroblast marker (Acta2) were analysed in MI hearts and compared to 
sham hearts. Despite data indicating that mice which underwent surgery to 
induce MI had reduced stroke volume and ejection fraction (Figure 6.6B), there 
were no obvious differences in the mRNA expression levels of these genes 
between sham and Ctrl MI mice 4 weeks after surgery (Figure 6.7). Although 
expression levels of all the genes appeared to be increased in KO MI mice, 
compared to both sham and Ctrl MI animals (Figure 6.7), this could not be fully 
elaborated on due to a lack of an induction of Postn mRNA expression and a lack 





Figure 6.7 Effect of myofibroblast-specific Piezo1 KO on markers of 
hypertrophy and cardiac dysfunction following MI-induced cardiac injury. 
Real-time RT-PCR analysis of cardiac mRNA levels in hearts from sham, control 
and Piezo1 KO mice 4 weeks after MI for (A) Col1a1, (B) Col1a3, (C) Mmp3, (D) 
Tnc, (E) Myh7, (F) Nppa, (G) Il6 and (H) Acta2. Individual data and mean 
± SEM are shown. Expression is measured as % of housekeeping control, 
Gapdh. Group sizes: sham (n=8), control (n=2), KO (n=11). Sham data were 
taken from Bageghni et al. (2019); all animals were male.  
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6.4.2.3 TAC-induced cardiac injury 
When the load on the heart is excessive, a number of compensatory mechanisms 
maintain circulatory function. TAC causes pressure overload which leads to 
cardiac remodelling within 7 days (Herum et al. 2015) and was chosen as the 
second technique for inducing cardiac injury. This procedure often leads to 
cardiac hypertrophy, a physiological, compensatory response to pressure or 
volume overload which results in increased cardiac myocyte size. When the 
increased work exceeds the reserve of the compensatory mechanisms, the heart 
is incapable to meet the demands imposed and overt congestive heart failure 
ensues (Spann 1969). The murine TAC model was first validated by Rockman et 
al. (1991) and is now a useful tool to mimic cardiac hypertrophy and heart failure 
development. Cre- animals are referred to as “Ctrl TAC” and Cre+ animals as “KO 
TAC” throughout; these animals were compared to animals undergoing a sham 
procedure (surgery without banding of the aorta). 
 
6.4.2.3.1 Validation of TAC-induced Piezo1 deletion 
RNA was isolated from the apex of the heart from sham and TAC-operated 
animals and analysed for Postn and Piezo1 mRNA expression. There was a 
clear, but somewhat variable, increase in Postn mRNA expression in hearts 
following TAC surgery, compared to sham-operated hearts, as has been reported 
previously, but this was not statistically significant with the small number of 
animals used (Figure 6.8A). There was also decreased Piezo1 expression in all 
KO TAC mice, compared to those in the Ctrl TAC group but, again, this was not 






Figure 6.8 Postn and Piezo1 expression levels following TAC-induced 
cardiac injury in mice with myofibroblast-specific deletion of Piezo1. RT-
PCR analysis for (A) Postn and (B) Piezo1 mRNA expression 4 weeks after 
control and Piezo1 KO mice underwent TAC surgery, compared to sham animals. 
Individual data and mean ± SEM are shown. Expression is measured as % of 
housekeeping control, Gapdh. Group sizes for Postn expression: sham n=4, TAC 
n=6. Group sizes for Piezo1 expression: sham n=4, Ctrl TAC n=3, KO TAC n=3; 
all animals were female. 
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6.4.2.3.2 Effect of Piezo1 deletion on cardiac function 
The data discussed here are viewed as pilot data due to the small number of 
animals utilised. A summary of each parameter of cardiac function measured in 
all three groups of animals is summarised in Table 6.2. Physiological 
measurements of cardiac function 4 weeks after surgery revealed ejection 
fraction was reduced by almost half in TAC-operated mice, compared to sham 
animals (Figure 6.9B). As expected, Ctrl mice displayed decreased stroke volume 
(Figure 6.9A) and raised end systolic and diastolic pressures (Figure 6.9C,D) 4 
weeks after TAC surgery, in comparison with sham-operated animals. There was 
no difference in the ratios of HW/TL or HW/BW between sham-operated and mice 
which underwent TAC (Figure 6.9E,F). This indicates that cardiac dysfunction, 
but not overt hypertrophy, was achieved following TAC surgery. The most 
obvious difference between control (Ctrl TAC) and experimental (KO TAC) 
animals was in end diastolic pressure. This parameter was markedly increased 
in Ctrl TAC mice, in comparison with sham-operated mice; this increase was not 
evident in KO TAC mice (Figure 6.9D). This result may indicate that a deletion in 
Piezo1 is beneficial as mice lacking Piezo1 exhibit lower end diastolic pressure 






Table 6.2 Effect of cardiac fibroblast-specific Piezo1 deletion on cardiac 
function 4 weeks after thoracic aortic constriction. Cardiac parameters were 
assessed by Millar pressure-volume conductance catheter. Sham = Cre+ Postn-
Cre-Piezo1flx/flx mice (n=3); Ctrl TAC = Cre- Postn-Cre-Piezo1flx/flx mice after TAC 
(n=3); KO TAC = Cre+ Postn-Cre-Piezo1flx/flx mice after TAC (n=3). Data are mean 









61.95 ± 7.68 34.11 ± 1.97 37.91 ± 5.21
End systolic volume (µl) 10.49 ± 3.76 16.98 ± 2.97 17.51 ± 1.18
End diastolic volume (µl) 25.43 ± 3.85 24.82 ± 3.92 27.97 ± 3.48
Cardiac output
(µl/min)
8672 ± 1289 4770 ± 850 6062 ± 1351
Stroke volume
(µl)
15.74 ± 2.22 8.19 ± 1.12 10.59 ± 2.40
Heart rate
(bpm)
550.0 ± 7.1 575.7 ± 24.2 578.1 ± 29.7
End systolic pressure
(mmHg)
96.91 ± 2.70 125.06 ± 10.80 130.43 ± 7.33
End diastolic pressure
(mmHg)
8.68 ± 2.84 17.04 ± 3.07 5.979 ± 1.23
dPdtmax
(mmHg/sec)
10753 ± 265 10479 ± 1802 13756 ± 1141
dPdtmin
(mmHg/sec)
-8090 ± 737 -10215 ± 2490 -12706 ± 972
Arterial blood pressure
(mmHg)





Figure 6.9 Effect of myofibroblast-specific Piezo1 KO on cardiac function 
and size following TAC-induced cardiac injury.  PV conductance catheter 
data from sham, control and myofibroblast-specific Piezo1 KO mice 4 weeks after 
TAC. Individual data and mean ± SEM are shown. (A) SV, stroke volume; (B) EF, 
ejection fraction; (C) ESP, end systolic pressure; (D) EDP, end diastolic pressure; 
(E) HW/TL, heart weight/tibia length and (F) HW/BW, height weight/body weight. 
Group sizes: sham (n=3), Ctrl TAC (n=3), KO TAC (n=3). All animals were female, 
*P<0.05 following an ANOVA with Tukey’s post-hoc test. 
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6.4.2.3.3 Effect of Piezo1 deletion on cardiac gene expression 
Assessment of gene expression by RT-PCR revealed that, although not 
statistically significant, Acta2 and Il6 mRNA expression were increased in Ctrl 
TAC mice compared to sham-operated animals; these increases were absent in 
KO TAC mice (Figure 6.10A,B). Increased expression levels of markers of 
cardiomyocyte hypertrophy (β-MHC; Myh7, ANF; Nppa) were observed in Ctrl 
TAC mice compared to sham-operated animals (Figure 6.10C,D), indicating TAC 
caused molecular changes at a cellular level suggesting cardiomyocyte 
hypertrophy. These increases were again lost in KO TAC mice (Figure 6.10C,D). 
These data  imply reduced numbers of myofibroblasts and diminished levels of 
inflammation and cardiac hypertrophy following TAC in myofibroblast-specific 
Piezo1 KO mice, compared to Ctrl mice. These data, similarly to the data on 
cardiac parameters, may signify that myofibroblast Piezo1 plays a detrimental 





Figure 6.10 Effect of myofibroblast-specific Piezo1 KO on markers of 
hypertrophy and cardiac dysfunction following TAC-induced cardiac injury. 
Real-time RT-PCR analysis of cardiac mRNA levels in hearts from sham, control 
and Piezo1 KO mice 4 weeks after TAC surgery for (A) Acta2, (B) Il6, (C) Myh7 
and (D) Nppa. Individual data and mean ± SEM are shown. Expression is 
measured as % of housekeeping control, Gapdh. Group sizes: sham (n=4), Ctrl 
TAC (n=3), KO TAC (n=3); all animals were female, *P<0.05 following an ANOVA 

































































































The final aim of this project was to investigate the role of Piezo1 in vivo in 
modulating cardiac remodelling using a mouse model. Two cell-specific KO 
mouse models were utilised to investigate the role of Piezo1 in cardiac function. 
Fibroblast-specific Piezo1 KO 
The model used in this study, a tamoxifen-inducible fibroblast-specific KO murine 
model based on use of a Cre-lox system involving Col1a2 promoter-driven 
Cre(ERT), has been frequently used to delete certain genes in fibroblasts prior to 
investigation into the role of a protein in a specific tissue (Swonger et al. 2016). 
Following tamoxifen injections administered at 3 weeks of age, RT-PCR analysis 
and Ca2+ measurements revealed a 20 % reduction in Piezo1 mRNA expression 
and a lessening of 10 % in the Yoda1-evoked Ca2+ influx in cultured cardiac 
fibroblasts from tamoxifen-treated Cre+ (Piezo1 KO) mice, compared to those 
from Cre- (Ctrl) mice. Group sizes were relatively large but these data did not 
reach statistical significance. The most commonly utilised method for 
administering tamoxifen is intraperitoneal injection, as performed here, because 
the amount of administered compound can be more easily controlled (Whitfield, 
Littlewood and Soucek 2015). However, to assess if the KO was incomplete due 
to a lack of technical expertise whilst injecting tamoxifen, tamoxifen citrate-
containing mouse chow at a treatment dosage of 400 mg/kg (Harlan laboratories) 
was used as an alternative. Andersson et al. (2010) have previously had success 
using this protocol. Treatment was planned to be given to 5 week-old mice for 2 
weeks. Mice were given access to tamoxifen-containing chow and weighed daily; 
however, mice lost over 10 % body weight within the first few days so had to be 
culled according to HO project licence guidelines. 
Tamoxifen-inducible fibroblast-specific KO models have been previously been 
developed in our group for a number of genes, including p38α and the IL-1 
receptor, IL-1R1  (Bageghni et al. 2018; Bageghni et al. 2019). It has previously 
been shown that, using this genetic approach, a 50 % reduction in both Mapk14 
mRNA expression and p38α protein expression could be achieved in cultured 
cardiac fibroblasts from p38 KO mice, compared to control mice (Bageghni et al. 
2018). However, Bageghni et al. (2019) found that this method was ineffective at 
diminishing IL1R1 expression in cardiac fibroblasts, despite their previous 




was adopted to generate a hemizygous mouse line with global deletion of one 
Il1r1 allele, with the remaining allele being floxed (Bageghni et al. 2019). This is 
a suitable tactic for targeting genes whose heterozygous (+/-) KO does not cause 
a phenotype (Feil, Valtcheva and Feil 2009). However, as previously discussed, 
this was not feasible in the case of Piezo1 as the global Piezo1 heterozygous KO 
mouse has a cardiovascular phenotype (Li et al. 2014). Therefore, in comparison 
with previous data of a similar nature, it was judged that the level of Piezo1 KO 
achieved in the Col1a2 promoter-driven Cre(ERT) mouse was not sufficient to 
observe functional effects in vivo. Thus, a second strategy was adopted using a 
more potent version of Cre. 
Myofibroblast-specific Piezo1 KO 
There are other benefits to the subsequent model other than a more potent 
version of Cre as, whilst the Col1a2 promoter-driven model is useful for studying 
the role of specific fibroblast proteins, it has drawbacks. It targets all fibroblasts 
(not only those in the heart) and the KO is usually induced at 2-3 weeks of age, 
long before cardiac remodelling is induced. For therapeutic relevance, the KO 
should be performed after the injury, but the Col1a2 promoter is less active in 
adult mice (Ponticos et al. 2004). To avoid these issues, a transgenic mouse line 
exploiting the periostin (Postn) promoter was utilised to direct expression of Cre 
recombinase exclusively in cardiac myofibroblasts (Kanisicak et al. 2016; Meng 
et al. 2018). Periostin is not expressed in the heart under normal physiological 
conditions but is highly expressed by resident fibroblasts when they adopt a 
myofibroblast phenotype (Dixon, Landry and Rattan 2019). Therefore, this 
method provides a highly selective, targeted system enabling the investigation of 
the specific role of Piezo1 in modulating fibroblast phenotype and cardiac 
remodelling after injury. Cre activation exclusively in cardiac myofibroblasts in the 
injured heart has been generated following both MI and TAC induction in these 
mice previously so these were the techniques chosen to evoke myocardial injury 
(Kanisicak et al. 2016; Khalil et al. 2017). 
Myocardial infarction 
Following surgery to induce MI, there was no difference observed between Postn 
and Piezo1 mRNA expression in Ctrl MI and KO MI mice. It is well established 
that low reliability and reproducibility are problems in MI models. The coronary 




inconsistent MI sizes post ligation (Chen et al. 2017). Therefore, caution was 
taken when analysing the data. An ejection fraction of 62 % in sham animals was 
reduced to 41 % in Ctrl MI animals. It must be kept in mind that a small number 
of replicates in the control group make the results difficult to interpret but these 
data were in keeping with previous studies which utilised LAD coronary artery 
ligation to induce MI and suggested a heart failure phenotype (Bageghni et al. 
2018). However, the other cardiac parameters measured were unaffected by 
surgery to induce MI. This was in agreement with RT-PCR analysis which showed 
that there were no significant increases in any of the remodelling genes 
investigated following MI induction, in comparison with sham animals. Increases 
in all of the genes studied have previously been shown to be increased following 
LAD coronary artery ligation (Bageghni et al. 2019). Therefore, as this model 
could not be validated by an increase in Postn mRNA expression in MI animals 
and a subsequent decrease in Piezo1 mRNA expression in KO MI animals, the 
role of myofibroblast Piezo1 could not be evaluated using this model. It is worth 
noting for any future work that a permanent LAD ligation model of MI was utilised 
in the present study; investigations with an ischemia-reperfusion model of MI 
more closely resembles the clinical scenario in which the majority of patients 
undergo revascularisation (van Zuylen et al. 2015). However, the permanent 
ligation model is useful for understanding direct mechanisms without the 
confounding element of reperfusion.  
Thoracic aortic constriction 
The average expression of Postn mRNA was tripled in TAC-operated mice, 
compared to mice which underwent a sham procedure, indicating that cardiac 
injury had been induced in these animals. Piezo1 mRNA expression in control 
and experimental mice following TAC was not statistically significantly different, 
presumably due to variation and the low number of replicates. However, all values 
for Piezo1 mRNA expression in the KO animals were reduced compared to Ctrl 
animals, hinting that the induction of cardiac injury by performing TAC, followed 
by tamoxifen administration generated a deletion of Piezo1. Mice which 
underwent TAC displayed reduced cardiac function, as shown by an ejection 
fraction which was reduced by almost half and a doubling in end diastolic 
pressure. There was no difference observed in the ratios between HW/TL or 




cardiac dysfunction had not yet manifested into overt hypertrophy. However, 
increased expression levels of markers of cardiomyocyte hypertrophy (β-MHC; 
Myh7, ANF; Nppa) were observed in Ctrl TAC mice compared to sham-operated 
animals. Piezo1 deletion in mice resulted in a loss of the TAC-induced increase 
in end diastolic pressure and increased expression of markers of hypertrophy 
observed in Ctrl TAC mice. This may signify that a deletion in myofibroblast 
Piezo1 is beneficial in cardiac remodelling following pressure overload and, 
therefore, the ion channel may be a therapeutic target. 
The most promising data for inducing cardiac injury and observing a KO of Piezo1 
was performing TAC on mice. This is a more apt method to use to study the 
mechanosensitive ion channel, Piezo1, due to TAC inducing pressure overload, 
rather than MI. This study has provided preliminary data on the role of Piezo1 in 
cardiac function. Data suggest that a lack of Piezo1 may be beneficial in pressure 
overload-induced cardiac remodelling. However, a limitation is the numbers of 
animals used; larger data sets are essential in order to deduce more accurate 
conclusions. Future work would include studying specific features of remodelling 
using histological staining to strengthen the conclusions drawn here. It is also 
important to consider that transgene integration of Cre can cause unanticipated 
side effects. Cre toxicity can occur when expression is high or when Cre 
recognises genomic sequences resembling loxP sites; Cre has also been shown 
to cause damage to DNA in the absence of a floxed sequence (Loonstra et al. 
2001). Cardiomyocyte-specific Cre mice have displayed molecular signs of 
cardiac toxicity by 3 months of age and exhibit decreased cardiac function by 6 
months of age compared to WT littermates (Pugach et al. 2015). This highlights 
the importance of using Cre mice as controls in conditional KO studies. 
In summary, the lack of Piezo1 KO in experimental animals, compared to control 
animals following the induction of MI and the very low number of replicates in the 
control group made it difficult to ascertain the impact of myofibroblast-specific 
Piezo1 deletion using this model. However, following TAC-induced pressure 
overload, a KO of Piezo1 appeared to be achieved. The induction of TAC caused 
cardiac dysfunction and, in terms of the effect of Piezo1 KO, there was a 
significant difference in end diastolic pressure between control and Piezo1 KO 
mice; the increase in end diastolic pressure observed in control mice following 




animals. There were trends for and significant increases in Acta2, Il6, Myh7 and 
Nppa mRNA expression in Ctrl TAC mice compared to sham-operated animals; 
these changes were also absent in KO TAC mice. These data indicate that 
cardiac fibroblast Piezo1 has a detrimental effect in cardiac hypertrophy and that 
its deletion may be beneficial under these conditions. However, care must be 
taken when interpreting the data due to the small number of replicates. Further 





Chapter 7 Final discussion, future directions and conclusion 
7.1 Summary of results 
Using a combination of mouse and human cardiac fibroblasts cultured in vitro, it 
has been demonstrated that: 
Chapter 3 
 Cardiac fibroblasts express Piezo1 mRNA and protein 
 Yoda1, the chemical activator of Piezo1, rapidly and potently activates 
Ca2+ entry 
 Dooku1, a Yoda1 analogue, can inhibit Yoda1-evoked Ca2+ in both 
Piezo1-overpressing cells and cardiac fibroblasts 
 Acute pharmacological inhibition, genetically modified mouse models and 
siRNA knockdown of Piezo1 mRNA expression verifies that Yoda1-
mediated Ca2+ entry occurs via activation of endogenous Piezo1 
 Mechanical force applied using cell-attached patch clamp 
electrophysiology activates Piezo1 channels 
Chapter 4 
 Yoda1-mediated activation of Piezo1 alters the expression of genes 
associated with cardiac remodelling 
 Yoda1 increases Il6 and Tnc mRNA expression in a Piezo1-dependent 
manner; an inactive analogue of Yoda1, 2e, has no effect 
 Activation of Piezo1 stimulates IL-6 secretion 
 Piezo1 is important for basal levels of IL6 mRNA expression; this is 
dependent on substrate stiffness or composition 
Chapter 5 
 Yoda1 triggers MAPK signalling 
 Piezo1 activation induces the concentration-dependent phosphorylation 
of p38 MAPK and ERK1/2 after 10 min of treatment; 2e has no effect 
 Compound 159, an analogue with better ADME properties then Yoda1, 




 Yoda1-mediated p38α MAPK and ERK1/2 phosphorylation is dependent 
upon extracellular Ca2+ 
 P38 MAPK, rather than ERK1/2, is responsible for Yoda1-evoked IL-6 
expression and secretion 
 SFKs are also activated by Yoda1 and this precedes p38 MAPK 
phosphorylation; of the SFKs, Fyn, Src and Yes kinases are expressed 
Chapter 6 
Genetic manipulation using Cre-loxP technology to generate Piezo1 KO mice and 
experimental models of cardiac injury revealed: 
 A myofibroblast-specific Piezo1 KO mouse model could be successfully 
generated 
 TAC is effective at inducing pressure overload and cardiac dysfunction in 
mice 
 TAC, followed by tamoxifen administration, induces a deletion of 
myofibroblast Piezo1  
 A deletion of myofibroblast Piezo1 may be beneficial in pressure 
overload-induced cardiac dysfunction 
 
7.2 Final discussion 
Prior to this study, there was a lack of knowledge on Piezo1 in cardiac fibroblasts, 
despite confirmation that Piezo1 mRNA is expressed in the murine heart (Coste 
et al. 2010) and that cardiac fibroblasts express other mechanically-activated ion 
channels (Yue, Xie and Nattel 2011). In the present study, it was established for 
the first time that Piezo1 mRNA is expressed in cardiac fibroblasts. Piezo1 mRNA 
expression was higher than the expression of its family member, Piezo2, and 
higher in cardiac fibroblasts than in cardiomyocytes. Piezo1 protein could also be 
detected in cardiac fibroblasts; this protein formed a Ca2+-permeable channel 
which could be activated by a chemical agonist of Piezo1, Yoda1, and mechanical 
stimuli. Piezo1 could be activated by pressure induced by cell-attached patch 
clamp electrophysiology but not by hypotonic stress in cardiac fibroblasts, 





Following cardiac injury, cardiac fibroblasts secrete ECM proteins and cytokines, 
which contribute to healing and cardiac remodelling (Humeres and Frangogiannis 
2019). Piezo1 activation using Yoda1 induced the expression of two key cardiac 
remodelling genes, TNC and IL-6, which are both upregulated following cardiac 
injury (Imanaka-Yoshida et al. 2001; Nian et al. 2004). Both proteins are initially 
cardioprotective after insult but subsequently promote adverse cardiac 
remodelling and become detrimental (Midwood et al. 2011; Fontes, Rose and 
Čiháková 2015). This implies that reduced Piezo1 activity may be beneficial post-
cardiac injury. This links to a study by Bae, Sachs and Gottlieb (2015) which 
demonstrated that low pH, as observed in pathological conditions such as 
ischemia, can stabilise the inactivated state of Piezo1; this may be an attempt by 
the body to attenuate unfavourable Piezo1 activity when necessary. 
The mechanism for Piezo1-mediated IL-6 secretion was uncovered in this study. 
It was verified that Ca2+ influx through the activated Piezo1 channel led to 
activation of SFKs, which preceded the activation of p38 MAPK and culminated 
in the secretion of IL-6. Extensive data have demonstrated a critical role of 
inflammation in the fibrotic response. Persistently elevated IL-6 levels lead to 
chronic inflammation; this is associated with hypertrophy, fibrosis and ultimately 
heart failure (Fontes, Rose and Čiháková 2015). Notably, Piezo1 has recently 
been identified to initiate an inflammatory response in myeloid cells by sensing 
cyclical hydrostatic pressure (Solis et al. 2019). 
The gene expression data correlates with the preliminary data gathered on the 
role of Piezo1 in vivo following cardiac injury using a novel myofibroblast-specific 
Piezo1 KO murine model. These data hinted that a lack of myofibroblast Piezo1 
may be beneficial in pressure overload-induced cardiac remodelling, as mice with 
a deletion of myofibroblast Piezo1 had improved end diastolic pressure and 
reduced inflammation and cardiac hypertrophy following TAC-induced cardiac 
dysfunction, compared to control mice. Other studies have suggested that 
inhibiting Piezo1 may be beneficial in disease states. Mechanical strain leads to 
Piezo1-mediated Ca2+ influx in chondrocytes and inhibition of the channel 
protects articular chondrocytes from mechanically induced cell death, which may 
be relevant in arthritis following traumatic joint injury (Lee et al. 2014). In addition, 
blockade of Piezo1 channels and deletion of pancreatic acinar cell Piezo1 has 




due to the inhibition of the excessive cytoplasmic calcium signals (Romac et al. 
2018).  
The present study has revealed that Ca2+ signals through Piezo1 are important 
for inducing IL-6 expression and secretion through a novel signalling pathway in 
cardiac fibroblasts. Early studies indicate that this inflammatory signal may be 
important in pressure overload-induced cardiac remodelling. It is conceivable 
that, within the context of cardiac pathophysiology, dampening Piezo1 activity 
could offer a novel target in the search for therapeutic interventions for cardiac 
hypertrophy and fibrosis, and therefore, heart failure. 
 
7.3 Clinical relevance 
The British Heart Foundation state that, in the UK today, over 7 million people are 
living with cardiovascular disease and this is the cause of a quarter of all deaths 
(www.bhf.org.uk). Half a million people in the UK have been officially diagnosed 
with the devastating disorder that is heart failure; a rise in cardiovascular risk 
factors, improved survival from ischaemic heart disease and population ageing 
have contributed to a sustained increase in prevalence (Taylor et al. 2019). 
Current treatment options for heart failure patients include angiotensin-converting 
enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, 
mineralocorticoid receptor antagonists and diuretics. Cardiac fibrosis is a 
hallmark of the majority of cardiac pathologies, therefore anti-fibrotic strategies 
are acknowledged as hopeful approaches in the treatment of cardiac dysfunction. 
While not approved for the treatment of cardiac fibrosis specifically, several of 
these therapeutic agents, including ACE inhibitors and ARBs, have been 
revealed to exert pleiotropic effects on fibroblasts that underlie some of their 
potential benefits in cardiac fibrosis (Porter and Turner 2009; Yue et al. 2013). 
This implies that improved therapeutics for cardiac fibrosis are imperative in the 
treatment of heart failure. 
As the preliminary in vivo data in this study hints that a lack of myofibroblast 
Piezo1 may be beneficial following pressure overload-induced cardiac injury, it 
would be useful to assess whether a Piezo1 blocker had a comparable effect. 
Unfortunately current inhibitors of Piezo1 are non-specific inhibitors of many 




molecules, as described in Chapter 3, is currently ongoing, with the aim of 
discovering a more specific antagonist of Piezo1. It would be essential to ensure 
a potential therapeutic drug had good ADME properties (e.g. solubility, half-life 
and clearance rate) and would need to be utilised successfully in vivo first. 
However, due to Piezo1 being expressed in a diverse number of tissues, having 
many different roles and being activated my numerous types of mechanical 
stimuli (Coste et al. 2010), an attempt to target the ion channel therapeutically 
may present difficulties. It would require drugs to act in a tissue-specific manner. 
It has been established that global or endothelial-specific deletion of mouse 
Piezo1 profoundly disturbs the developing vasculature and is embryonic lethal 
within days of the heart beating (Li et al. 2014). Targeting Piezo1 later in life may 
have a less disastrous effect as adult mice are able to survive following 
conditional disruption of Piezo1 in the endothelium but were established to 
display disadvantageous effects in the cardiovascular system, in terms of their 
physical performance (Rode et al. 2017). It would need to be carefully considered 
when was the optimum time to target Piezo1. As previously discussed, both loss- 
and gain-of-function mutations in Piezo1 have been attributed to diseases in 
humans (Martin-Almedina, Mansour and Ostergaard 2018) which implies that 
tight regulation of Piezo1 is vital. It may be necessary to modulate the gating 
rather than completely inhibit the channel; this may become more realistic with 
the current increase in knowledge surrounding residues important for Piezo1 
gating (Zheng, Gracheva and Bagriantsev 2019). In order to entirely comprehend 
conformational changes associated with Piezo1 activation, it will be critical to 
capture Piezo1 and Piezo2 structures in activated and inactivated states. 
 
7.4 Future work 
7.4.1 Is substrate stiffness and/or composition important for Yoda1-
mediated IL-6 levels? 
Piezo1-specific siRNA was established to reduce basal levels of IL-6 mRNA 
expression and secretion. This appeared to be dependent on the mechanical 
and/or chemical environment which the cells are grown on as Piezo1-specific 




plated on collagen-coated silicon membranes (930 kPa); there was no effect 
when cells were plated on tissue culture plastic (106 kPa) or on very soft 
fibronectin-coated membranes (10/30 kPa). As previously discussed, substrate 
compliance has been demonstrated to modulate Ca2+ signalling in fibroblasts 
(Godbout et al. 2013; Lembong et al. 2015). To confirm these findings, it could 
be investigated whether pressure-induced ionic currents or Yoda1-induced Ca2+ 
oscillations were reduced when cardiac fibroblasts were cultured on soft 
hydrogels, compared to on stiffer substrates by patch clamp recording and single 
cell imaging, respectively, or whether altering the coating of the membranes had 
an impact. This could be executed using control and Piezo1-specific siRNA to 
confirm that it is the nature of the substrate which is important for the magnitude 
of Ca2+ entry through Piezo1. 
 
7.4.2 What is the mechanism responsible for the effect of Yoda1 on 
myofibroblast phenotype? 
It appears that the effects of Yoda1 on cardiac fibroblast differentiation are non-
specific. However, it is possible that the outcome observed here is due to 
incomplete knockdown of Piezo1 not being sufficient to abolish the response. 
Future work could involve using cardiac fibroblasts with a complete KO of Piezo1 
to verify this, e.g. in cells isolated from the myofibroblast-specific Piezo1 KO 
mouse. In this study, it was hinted at that the ERK pathway may be involved in 
the Yoda1-mediated increase in collagen gel contraction. The ERK pathway has 
previously been demonstrated to be involved in TGF-β1-stimulated fibroblast to 
myofibroblast differentiation (Midgley et al. 2013). 
 
7.4.3 What is the mechanism leading to Yoda1-evoked TNC 
expression? 
This study demonstrated that Yoda1-evoked Piezo1 activation upregulated TNC 
expression in both mouse and human cardiac fibroblasts. It is believed that the 
mechanism responsible for this is not similar to that for Yoda1-induced IL-6 
secretion as a p38 inhibitor had no effect on Yoda1-induced TNC expression 




expression was affected by the other pharmacological inhibitors used in this 
thesis. Correlating with data obtained in this study, antagonists of the ERK and 
p38 MAPK pathways had no effect on cyclic strain-induced tenascin-C induction 
in chick embryo fibroblasts (Chiquet, Sarasa-Renedo and Tunç-Civelek 2004). 
However, a specific inhibitor of Rho-dependent kinase strongly attenuated this 
response, indicating that the regulation of TNC in fibroblasts by cyclic strain 
requires Rho/ROCK signalling (Chiquet, Sarasa-Renedo and Tunç-Civelek 
2004). Future work could be to use alternative inhibitors, including Y-27632, a 
highly potent and selective ROCK inhibitor, to ascertain the molecular 
mechanisms occurring which lead to this change in TNC expression. 
 
7.4.4 Which specific Src-family kinases are activated by Piezo1 
activation and are important for p38 signalling and altered 
gene expression? 
PamChip multiplex tyrosine kinase activity profiling in mouse cardiac fibroblasts 
revealed that Piezo1 activation induced the activation of multiple SFKs. Follow-
up expression studies revealed that human cardiac fibroblasts express Src, Fyn 
and Yes kinases, but none of the other family members. Further work would 
involve investigating specifically which of the kinases are activated by Yoda1. To 
do this, cardiac fibroblasts would be treated with Yoda1 and then activated SFKs 
would be immunoprecipitated using a phospho-Src family antibody, followed by 
western blot with expression antibodies for Src, Fyn and Yes. The role of Piezo1 
could be confirmed using cells transfected with Piezo1-specific or control siRNA 
and similar experiments could be undertaken using cyclical stretch (Flexcell, 10% 
strain, 1 Hz) to compare SFK activation in response to chemical and mechanical 
stimulation of Piezo1, in addition to in response to being plated on altered ECM 
substrates. It is currently unknown which specific family members are responsible 
for Yoda1-induced p38 activation and IL-6 expression. To determine this, siRNA 
gene silencing could be used to knockdown the individual kinases. IL-6 mRNA 
expression (qRT-PCR) and protein secretion (ELISA) would be analysed in 






7.4.5 Do Src-family kinases bind to Piezo1? 
One limitation of studying Piezo1 at the protein level is the lack of an antibody 
able to specifically and strongly detect endogenous Piezo1. BEEC4 was 
developed for the lab by Cambridge Bioscience but is restricted to detecting 
overexpressed Piezo1 by western blotting; no endogenous Piezo1 band could be 
detected in murine cardiac fibroblasts (data not shown). The generation of 
Piezo1-HA mice, using CRISPR technology, has been used in this thesis to 
confirm that endogenous Piezo1 is expressed in murine cardiac fibroblasts using 
an anti-HA antibody and western blotting. The development of these mice 
facilitates further experiments. Piezo1-HA immunoprecipitation experiments 
could be performed to allow investigation into endogenous Piezo1 interactions, 
such as whether SFK directly interact with the Piezo1 channel following activation 
using Yoda1. The influence of chemical or mechanical Piezo1 activation (Yoda1 
or cell-stretching respectively) and the influence of the ECM substrate on 
Piezo1/SFK interactions could also be investigated. 
 
7.4.6 What is the functional role of Piezo1 in cardiac fibroblasts? 
Cardiac fibroblasts undergo increased proliferation and migration post cardiac 
injury (Porter and Turner 2009) and Piezo1 has been demonstrated to have a 
role in these functions in other cell types (McHugh et al. 2012; Gudipaty et al. 
2017). In addition to assessing myofibroblast differentiation using the collagen 
gel contraction assay, proliferation could be assessed using the IncuCyte-FLR 
live cell imaging system and migration using the scratch wound or Boyden 
chamber assays (Riches et al. 2009). Utilising control and Piezo1-specific siRNA 
would aid in elucidating if Piezo1 has a role in important cardiac fibroblast 
functions. Yoda1 could also be used to treat cells to see if activating the Piezo1 
channel had any effect on these cell functions. The suggestions for future work 







Figure 7.1 Schematic of the proposed mechanism linking Yoda1-mediated 
Piezo1 activation to IL-6 secretion in cardiac fibroblasts, with proposed 
questions for future in vitro study. Q1 - Is substrate stiffness and/or 
composition important for Yoda1-mediated IL-6 levels? Q2 - What is the 
mechanism responsible for the effect of Yoda1 on myofibroblast phenotype? Q3 
- What is the mechanism leading to Yoda1-evoked TNC expression? Q4 - Which 
specific Src-family kinases are activated by Piezo1 activation and are important 
for p38 signalling and altered gene expression? Q5 - Do Src-family kinases bind 
to Piezo1? Q6 - What is the functional role of Piezo1 in cardiac fibroblasts? 
 
7.4.7 Further investigation into the role of Piezo1 in vivo 
Preliminary data were gathered on the role of Piezo1 following myocardial injury 
using a novel myofibroblast-specific Piezo1 KO murine model; it was implied that 
a lack of myofibroblast Piezo1 may be beneficial following pressure overload-
induced cardiac injury. Further work to add replicates to these data sets would 
allow more accurate conclusions to be drawn. It would also be necessary to 
confirm that the deletion of Piezo1 was confined to the myofibroblast population, 
with no effect on other cell types; this could be done using the MACS magnetic 




investigating gene expression of markers of hypertrophy, it would be useful to 
examine histological sections for fibrosis, cardiomyocyte hypertrophy and the 
accumulation of inflammatory cells and myofibroblasts. Doppler 
echocardiography could also be utilised to assess myocardial function (e.g. 
ejection fraction, fractional shortening, ventricle wall thickness) every fortnight 
following cardiac injury to evaluate the progression to heart failure. It would be 
appealing to induce hypertrophy and cardiac fibrosis using an alternative method, 
to investigate whether there are similarities with the TAC data. Systemic infusion 
of the β-adrenergic agonist, isoproterenol, is known to promote overt hypertrophy 
(Murray, Prabhu and Chandrasekar 2000; Jaffré et al. 2009). Mini-osmotic pumps 
could be implanted in mice subcutaneously and either saline or isoproterenol 






Modulation of Piezo1 channel activity is implicated in a growing number of human 
diseases, including cardiovascular disease. The overall aim of this study was to 
gain an understanding of the role of Piezo1 in cardiac fibroblasts. Investigation 
revealed expression of Piezo1 in mouse and human cardiac fibroblasts and it was 
demonstrated that the channel could be activated using chemical and mechanical 
stimuli. Activation of Piezo1 using its agonist, Yoda1, led to changes in the 
expression of key cardiac remodelling genes, including TNC and IL-6. IL-6 is a 
cytokine with considerable importance in cardiac hypertrophy and fibrosis. 
Exploration into the mechanism by which Yoda1 induces IL-6 secretion revealed 
a downstream pathway linking Ca2+ entry through the Piezo1 channel and 
activation of both SFK and p38 MAPK to IL-6 secretion. It was also demonstrated 
that Piezo1 was a regulator of basal levels of IL-6; this was dependent on the 
surrounding mechanical and chemical environment. In vivo investigation into the 
role of Piezo1 revealed that the protein may have a role in pressure overload-
induced cardiac dysfunction but more exploration is warranted to confirm the role 
of Piezo1 in cardiac remodelling. These novel findings may improve 
understanding of how cardiac fibroblasts sense mechanical stimuli in order to 
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